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Abstract 
]n this study, the effects of the sPLA] enzymes isolated from the snake venoms of Naja 
naja venom (sPLA2-r) and Crotalus altrox venom (sPLA2-n) on mast cell reactivity 
were examined. Mast cells isolated from the rat peritoneal cavity were chosen as a 
model to examine the effects of these sPLAj enzymes. -
Mast cells derived from the rat differed in their response to these sPLA2 enzymes. 
Histamine was released in a dose dependent manner by sPLAj-I up to a maximum of 
68% of the total histamine content. This was dependent on extracellular Ca^ ,^ 
metabolic energy and the native structure of sPLA2-L This histamine release was 
significantly reduced by the PLA2 inhibitors, p-BPB and 12-epi-scalaradial and was 
unaffected by the cyclo-oxygenase inhibitor, flurbiprofen and the lipoxygenase 
inhibitor, zileuton. hi contrast, the maximum % histamine release observed with 
sPLA2-II was generally not greater than 10%. This low level of histamine release was 
blocked by the PLA! inhibitors and was unaffected by flurbiprofen and zileuton 
pretreatment. Li addition, PGD! was produced dose dependently with sPLA2-n, 
whereas with sPLA2-I production was only observed with a high concentration of 1 U 
ml'i. It is proposed that the enzymatic nature of the sPLA2 enzymes was involved in 
mediating the effects observed here. In addition a receptor mediated response is also 
possible as binding sites for these sPLA2 enzymes have recently been identified. 
Further studies are required to establish the exact mechanism (s) involved in these 
cellular responses. 
Rat mast cells activated by different stimuli (anti-IgE, compound 48/80 and A23187) 
differed in their response to the sPLAj enzymes. Lnmunologically induced histamine 
release was enhanced in the presence of the sPLAj enzymes. This enhancement was 
reduced by the PLAj inhibitors and was unaffected by flurbiprofen and zileuton. 
Lnmunologically induced PGDj production was enhanced with sPLAj-II, but not with 
sPLA2-I. The sPLA2 enzymes did not enhance histamine release when mast cells were 
activated with compound 48/80 or the calcium ionophore A23187. 
The mechanism of this enhancement was further investigated using intracellular 
calcium measurements. Both sPLA2 enzymes led to a slow increase in the [Ca^ ]^j. 
The net increase in the [Ca^ ]^j was higher with sPLA2-I when compared with sPLAj-
II. However, sPLA2-II produced a significant increase in the [Ca^ ]^j following 
activation with anti-rat IgE. This enhancement was specific for the late phase of the 
biphasic calcium response. No enhancement of the Ca�+ signal was observed with 
sPLA2-I. It is proposed that the sPLA2-II plays a role in the calcium influx pathway 
required for the immunological activation of mast cells. Further studies are required 
to establish the exact mechanism(s) of action of sPLA2-II. 
This study also demonstrated the heterogeneity of mast cells isolated from the rat 
peritoneum, human lung and guinea pig lung tissues, in their responsivity to the sPLA2 
enzymes. Histamine release was observed with mast cells from the rat and guinea pig 
(high concentrations of sPLAj-D, whereas human lung mast cells were generally 
unresponsive. Mast cells isolated from all three sources were generally unresponsive 
to sPLA2-II (the maximum % histamine release was about 10%). komunologically 
induced histamine release from rat mast cells was enhanced in the presence of these 
sPLA2 enzymes. In contrast, inhibition was observed with mast cells isolated from 
human and guinea pig lung tissues. 
The present study indicates two potential roles for sPLA2 enzymes in immunological 
reactions. Studies with rat peritoneal mast cells have suggested a pro-inflammatory 
role whereas the human studies would suggest an anti-inflammatory role. This 
highlights the importance of studying precise mast cell populations in relation to 
inflammatory conditions and in the development of agents to inhibit the effects of these 
sPLA2 enzymes. 
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1.1 Historical background / General information 
I 
Mast cells were originally defined by Ehrlich as mononuclear cells containing 
metachromatic granules, due to the presence of proteoglycans such as heparin. The 
granules of these cells took up blue dyes and changed colour to a pinkishy'purple 
colour. They were first seen in unstained frog mesentery preparations by Von 
Recklinghausen in the latter half of the nineteenth century. Ehrlich named the cell 
"Mastzelle" from the German word "masten", which means to fatten or feed, as he 
thought these cells represented over-nourished connective tissue cells. He also 
described the mast cell's circulating blood counterpart, the basophil. Mast cells and 
basophils share two basic properties: secretory granules and high affinity receptors for 
immunoglobulin E (IgE) (for review see Bloom, 1984; Wasserman, 1990; Marone, 
1995). It was recognised in 1953, that these cells contained histamine in their 
secretory granules (Riley & West, 1953). At the same time, histamine was shown to 
be one of the mediators of acute allergic reactions. 
It is now clear that the mast cell plays a major role in mediating the symptoms of 
immediate hypersensitivity reactions (White & Kaliner, 1988; Dale & Foreman, 1989; 
White, 1990; Pearce, 1991; Longlet et al., 1995). The mast cell is uniquely placed 
to participate in allergic responses and populates tissues which come into frequent 
contact with the external environment such as the skin, the respiratory and 
gastrointestinal tract (Lichtenstein, 1993). More recently mast cells have also been 
found associated with the brain (for review see Silver et al.，1996). 
2 
Mast cells are now known to exist as many different types and display marked 
heterogeneity in their morphological, histochemical and functional properties (for 
review see Barrett & Pearce，1993; Irani & Schwartz, 1994; see chapter 4). 
Morphologically mature mast cells are large (9 to 13 jum), have a single nucleus and 
a cytoplasm packed with large membrane bound granules. Human mast cells also 
contain numerous cytoplasmic lipid bodies OBehrendt et al., 1978; Dvorak et al., 1983; 
Galli et aL, 1984). 
Mast cells are thought to originate from multipotential stem cells in the bone marrow 
(for review see Kitamura et al.，1993a & b). These undifferentiated mast cell 
precursors leave the bone marrow, migrate in the blood and invade connective and 
mucosal tissues where differentiation and proliferation is completed. Mast cell 
development is regulated by T cell and fibroblast derived growth factors, interleukin-3 
(IL-3) together with stem cell factor (SCF) possibly being the most important (Galli 
et al.’ 1993; Kitamura et al., 1993a & b). 
1.2 Mast cell mediators 
The activation of mast cells causes the release of a wide range of biologically active 
compounds. These mediators are either preformed and stored within the secretory 
granule, or are rapidly synthesised following cell activation. The former includes 
histamine, proteoglycan and proteinases. The latter includes arachidonic acid (AA) 
metabolites such as the prostaglandins (PG) and leukotrienes (LT), platelet-activating 
factor (PAF), and a variety of cytokines (for review see Harvima & Schwartz, 1993). 
3 
1.2.1 Pre-formed mediators 
Histamine, the dominant amine stored in mast cells and basophils, is synthesised from 
histidine by L-histidine decarboxylase (Bauza & Lagunoff, 1981). It is stored in the 
cytoplasmic secretory granules (acidic pH), where it is positively charged and appears 
to bind to negatively charged groups in the proteoglycan-protein matrix. Upon cellular 
activation, histamine rapidly dissociates from the proteoglycan-protein matrix by cation 
exchange with extracellular sodium at neutral pH (Uvnas, 1970). Histamine released 
following cellular degranulation rapidly diffuses into the surrounding tissues where it 
exerts its biological effects by binding to Hi, H2 and H3 receptors on cell surfaces 
(White & Kaliner, 1988; White,1990; Leurs et al., 1995). The effects mediated via 
the Hi receptor include bronchial and gastro-intestinal smooth muscle contraction and 
increased permeability of the venular endothelium. Li contrast, the effects mediated 
via the H2 receptor are more anti-inflammatory and include the suppression of T-
lymphocyte cytotoxicity, suppression of lymphocyte proliferation, stimulation of 
gastric acid secretion and enhanced epithelial permeability in human airways. H3 
receptors regulate histamine formation and release in the brain. Rat peritoneal mast 
cells have high histamine levels of 10-30 pg/cell whereas human mast cells, basophils 
and rat mucosal mast cells have low levels of 1-3 pg/ceU OHarvima & Schwartz, 1993). 
Connective tissue mast cells of the rat, but not of man, also contain the amine 
serotonin (5-hydroxytryptamine) (Weitzman et al., 1985). 
The presence of highly sulphated negatively charged proteoglycans in the 
secretory mast cell granules remains the principal method of visualizing mast cells. 
4 
Histochemical staining of these cells with basic dyes results in metachromasia as seen 
under the light microscope. Two major sub-classes of proteoglycans have been 
identified in mast-cells: heparin and chondroitin sulphate. Heparin is the principal 
proteoglycan of human mast cells, as well as rat and mouse connective tissue mast 
cells. Rat mucosal mast cells contain chondroitin sulphate. These mast cell 
proteoglycans bind to histamine, neutral proteases and acyl hydrolases at the acidic pH 
within the secretory granules and are thought to facilitate the uptake and packaging of 
preformed mediators into the secretory granules, in addition to regulating their stability 
and enzymatic activity (Harvima & Schwartz, 1993). 
Mast cell granules also contain a number of enzymes such as exoglycosidases, 
arysulphatases and neutral proteases. The former are found loosely bound to the 
structural matrices and are released in parallel with histamine upon cell activation. 
Neutral proteases catalyse peptide bond cleavage and comprise about a third of the total 
protein of mast cell granules and serve as markers for distinguishing different cell 
types (Harvima & Schwartz，1993). 
1.2.2 Newly synthesised lipid mediators 
Some mediators are only formed on activation of the mast cell. Endogenous AA is the 
most important precursor of these mediators (Sullivan & Parker, 1979). This 
unsaturated fatty acid is released from the membrane glycerolphospholipids by the 
action of the enzyme phospholipase Aj (PLA2), or phospholipase G (PLC) together 
with diacylglycerol lipase and/or other lipases. Once liberated, AA is oxidatively 
5 
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metabolised by several pathways to produce thromboxanes, prostaglandins and 
leukotrienes collectively known as the eicosanoids. The cyclo-oxygenase pathway, 
which gives rise to prostaglandins and thromboxanes, starts with the action of 
prostaglandin endoperoxide synthase (Smith, 1989). Li both human and rat mast cells 
the major product released is prostaglandin D] (PGD2) (Lewis et al., 1982; Ennis et 
al.，1984). PGD2 is a short lived constrictor ofbronchial smooth muscle ^Iardy et al.， 
1984) and is a potent inhibitor of platelet aggregation (Mills & MacFarlane, 1974). 
The lipoxygenase pathway first generates the unstable compound 5-
hydroperoxyeicosatetraeonic acid (5-HPETE), which is rapidly metabolised to 5-
hydroxyeicosatetraenoic acid (5-HETE) and LTA4. LTA4 can be metabolised to yield 
LTB4 or LTC4(Smith, 1989). LTC4and LTB4are generated by human lung mast cells 
(Peters et al, 1982b; Freeland et al.’ 1988). LTB4 is a potent chemotaxin for 
neutrophils and eosinophils (Ford-Hutchinson et al., 1980; Goetzl & Pickett, 1981). 
The mixture of leukotrienes LTC4, LTD4 and LTE4 have many physiological effects 
such as enhanced vascular permeability, constriction of bronchial smooth muscle and 
enhanced mucus secretion (Lewis et al., 1990). Li rodents LTC4 and LTB4 are 
generated by mucosal mast cells rather than by connective tissue type mast cells 
(Schwartz, 1987). 
Platelet-activating factor (PAF) is another lipid mediator generated during 
inflammatory reactions. Activated human lung mast cells generate PAF whereas 
basophils do not. PAF activates neutrophils to release mediators involved in 
chemotaxis, causes smooth muscle contraction, enhances vasopermeability and is 
chemotactic for eosinophils (Schwartz, 1987). 
6 
]n addition, mast cells can synthesise and release a variety of functional cytokines such 
as IL-3, IL-4, IL-5, IL-6, granulocyte-macrophage colony stimulating factor (GM-
CSF), tumour necrosis factor (TNF)-a and interferon (IFN)-y (Galli et al., 1991; 
Galli, 1993; Marshall & Bienenstock，1994; Galli & Costa，1995). Cytokine synthesis 
occurs hours after activation in contrast with the rapid generation of AA metabolites. 
The functions of these cytokines have not yet been established, but are thought to be 
involved in mast cell differentiation. 
1.3 Mast Cell Activation 
Two pathways ofmast cell activation have been extensively characterised: the antigenic 
pathway and the non-antigenic pathway (for review see Landry et al., 1992; Sagi-
Eisenberg 1993; Foreman, 1993). Following activation, mediators such as histamine 
and PGD2 are released into the extracellular environment. 
1.3.1 The antigenic pathway of mast cell activation 
The classical pathway of activation involves IgE, produced by B lymphocytes. Contact 
of a foreign allergen with a susceptible individual, stimulates B-cell differentiation into 
IgE antibody secreting cells and a population of B-memory cells. The allergen also 
interacts with T-lymphqcytes which augment or inhibit IgE production via T-helper or 
T-suppresser cells respectively O^ercelli & Geha, 1989). 
The IgE molecules produced bind to high affinity IgE receptors (Fc^Rl) found on mast 
7 
cell membranes (Ishizaka & Ishizaka, 1974). Early classical studies demonstrated that 
bridging of specific receptors of the IgE type by the corresponding allergen triggered 
mediator release. Other agents are also able to cross-link IgE receptors such as 
dimerised IgE, anti-IgE and con A (a lectin which cross-links IgE carbohydrate 
moieties) and can cause mediator release (Keller, 1973; Langunoff & Martin, 1983; 
Foreman, 1993; Razin et aL，1995). 
Molecular characterisation of the high affinity IgE receptor revealed a tetrameric 
complex made up of an a and p sub-unit, and two 丫 sub-units linked by disulphide 
bonds. The extracellular domain of the a sub-unit is necessary for IgE binding. The 
carboxyl-terminal cytoplasmic tails of both the P and y sub-units, buried in the cell 
membrane, are important in FcJRl mediated signal transduction (Metzger, 1992; Alber 
& Metzger, 1993). These sub-units do not display any enzymatic activity by 
themselves but are quickly and transiently phosphorylated following receptor 
crosslinkage (for review see Hamawy et al., 1995). 
Aggregation of the high affinity IgE receptor molecules on the mast cell membrane, 
with allergen, initiates an intracellular signalling pathway, that results in mast cell 
degranulation and the release of inflammatory mediators. The exact sequence of 
events which occurs following receptor aggregation and subsequent mediator release 
has yet to be determined. At present many enzyme systems and cell components are 
thought to be involved (for reviews see Sagi-Eisenberg, 1993; Beaven & Metzger, 
1993; Razin et al.’ 1995; Scharenberg & Kinet，1995). 
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The phosphatidylinositol system appears to be one of the major pathways activated 
upon IgE receptor aggregation. Hydrolysis of phosphatidylinositol 4,5-bisphosphate 
by PLC in the cell membrane, leads to the concomitant release of diacylglycerol 
(DAG) and inositol 1,4,5-trisphosphate (IP3). EP3 itself acts as an intracellular second 
messenger and releases calcium from intracellular stores, resulting in an increase in 
the intracellular calcium ion concentration ([Ca】+])，which is usually transient (for 
review see Berridge, 1993). 
An increase in the [Ca^ ]^j is required for histamine secretion. The direct 
microinjection of Ca�+ into mast cells (Kanno et al., 1973)，together with the use of 
Ca2+ ionophores (Foreman et al., 1973) both provide evidence for the key role of Ca 2+ 
in mast cell degranulation. Liposomes containing calcium, but not magnesium or 
potassium ions were also shown to induce histamine release from rat peritoneal mast 
cells (Theoharides & Douglas, 1978). 
Jn order to maintain an elevated [Ca^ ]^；, a Ca�+ influx from the extracellular 
environment is required. Foreman et al. (1977) showed that IgE-mediated histamine 
release from rat peritoneal mast cells was accompanied by an influx of ^^ Ca^ ^ from the 
extemal medium. White et al. (1984) used the fluorescent probe quin-2 to directly 
demonstrate a rise in the cytosolic [Ca�+] in mast cell IgE induced histamine release. 
r 
Recent patch clamp studies and single cell Ca^ ^ measurements have demonstrated the 
existence of two calcium influx pathways in mast cells; a calcium specific pathway 
activated by the depletion of calcium from intracellular stores (Hoth & Penner, 1992 
9 
& 1993; Fasolato et al” 1994) and nonspecific cation channels which are permeable 
to divalent cations (Penner et al.’ 1988; Matthews et al.，1989; Kudo & Kimura, 1992; 
Fasolato et al.，1993a; Obukhov et al., 1995). 
The calcium specific pathway was termed IcRAc (for calcium release-activated calcium 
current). IcRAc is highly selective for Ca�+，over Ba!+，Sr^ + andMn!+. IcRAc is 
activated following depletion of the intracellular calcium stores, either by IP3, 
ionomycin or EGTA. It is voltage independent and inhibited by high cytosolic [Ca�+] 
(Hoth & Penner, 1992 & 1993; Fasolato et al., 1994). The capacitance model 
described by Putney (1990) links the depletion of internal calcium stores with the 
activation of a calcium influx pathway. Depletion of the intracellular calcium stores 
are believed to release a signal which activates this calcium influx. Randriamampita 
& Tsien (1993)，and Parekh et al. (1993) have isolated a molecule thought to be 
involved in the activation of this calcium influx. Fasolato et al. (1993b) reported that 
the signal for this calcium influx involved a GTP-dependent step. More recently, 
Parekh & Penner (1995) reported that IcRAc in the rat basophilic leukemia cell line 
(RBL-2H3) can be inactivated following treatment with the protein kinase C (PKC) 
activator, phorbol 12-myristate 13-acetate. The PKC inhibitors staurosporine and 
bisindolylmaleimide prevented inactivation of IcRAc suggesting a role for PKC in its 
regulation. Zhang & McCloskey (1995) have reported activation of ^^ R^ c ^ RBL-2H3 
cells following IgE receptor crosslinkage. 
The nonspecific cation channels are known as the large conductance 50-pS channels 
(Penner et al., 1988; Matthews et aL, 1989; Kudo & Kimura, 1992; Fasolato et al” 
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1993a). The 50pS channel is thought to be regulated by a guanine nucleotide binding 
protein (G protein), as it was activated by internal guanosine 5‘-0-(3-thiotriphosphate) 
(GTP-Y-S) and inhibited by internal guanosine 5 ‘ -0-(2-thiodiphosphate) (GTP_P_S). 
The activity of this channel is inhibited by elevated [Ca�+]” More recently, Obukhov 
et al. (1995) have reported on a large conductance (250 pS) nonselective cation channel 
in RBL-2H3 cells. This channel was activated by ATP and carbachol and activation 
was independent of intemal calcium. 
The efflux of calcium is thought to be mediated by a sodium calcium antiporter system. 
The immunological activation of mast cells causes a temporary cessation of this efflux 
pathway and enhances the [Ca^ ]^j produced by the release of calcium from intemal 
stores and the influx from the extracellular medium (Pearce & White, 1984). 
The second product of phosphatidyl inositol breakdown catalysed by PLC is 
diacylglycerol (DAG). DAG is the endogenous activator of protein kinase C (PKC). 
Although protein phosphorylation is the role of this calcium dependent enzyme, its role 
in mast cell activation is yet to be determined (Chakravarty, 1990; White et al., 
1990b). Recent studies, have suggested that a phosphatidylcholine (PC) cycle may be 
a better source of DAG, involving phospholipase D (PLD) (Kennedy, 1990; Exon, 
1994). 
r 
IgE receptor cross linking appears to initiate a series of protein, phosphorylation 
reactions (for review see Hamawy et al., 1995). Phosphorylation of the P and y sub-
units, by non-receptor tyrosine kinases is rapid and requires aggregated receptors. The 
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^rc-family protein-tyrosine kinase (PTK) p53/56^ (Eiseman & Bolen, 1992; Field et 
aL, 1995) and the PTK p72^ ^^  (Takanobu et al., 1991; Benhamou et al., 1993) are 
thought to participate in these reactions. Lni addition the PLC isoenzyme PLCyKPark 
et al” 1991; Li et al” 1992) and the 6 isoform of PKC (Germano et al.，1994; 
Haleem-Smith et al.，1995) are also rapidly tyrosine phosphorylated following receptor 
aggregation. 
The involvement of G proteins in mast cell degranulation was demonstrated by 
Gomperts (1983). The introduction of the nonhydrolysable analogues of GTP, GTP-y-
S or GppNHp, into the cytosol of ATP^ permeabilized mast cells resulted in their 
degranulation in the presence of external calcium. Aridor et al. (1990) reported that 
GTP-y-S also resulted in DAG formation and was inhibited by neomycin (an 
aminoglycoside antibiotic known to inhibit PI breakdown). GTP-y-S had a biphasic 
effect and at high concentrations (> 100 |jM) inhibited DAG formation. However, 
Saito et al. (1987) observed that pretreatment of rat peritoneal mast cells with islet-
activating protein pertussis toxin (IAP), had no significant effect on mediator release 
induced by anti-IgE. Ali et al. (1989) also observed that the introduction GTP-y-S 
resulted in PIP2 breakdown in RBL-2H3 cells. Wilson et al (1989) reported that 
mycophenoloic acid an inhibitor of inosine monophosphate dehydrogenase inhibited 
IgE mediated histamine secretion and calcium influx in RBL-2H3 cells, whereas 
cholera toxin enhanced secretion (Knoop & Thomas, 1984; McCloskey et al” 1988). 
Based on these observations two mechanisms were proposed to be involved in PLC 
activation in rat mast cells and RBL-2H3 cells. One mechanism involves tyrosine 
kinase activation and subsequent phosphorylation of PLC. The second pathway 
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involves G-proteins as coupling entities intervening between the IgE receptor and the 
PLC enzyme. 
IgE receptor crosslinkage also appears to initiate phospholipid methylation. Two 
methyltransferases are involved in converting phosphatidylethanolamine (PE) to PC. 
PC is then further metabolised by PLA] to yield lysophosphatidylcholine 0-ysoPC) and 
free AA (Ishizaka et al., 1980; Ishizaka et al., 1983; Axlerod & Hirata, 1982). 
However, several workers have been unable to confirm these reports of an increase in 
phospholipid methylation, following activation of mast cells or basophils (Moore et al., 
1984; Holgate et al.’ 1985; Benyon et al., 1988). The origin of this discrepancy is 
unclear but the involvement of PE methylation in histamine secretion is questionable. 
It has also been suggested that a transient monophasic rise in cyclic adenosine 
monophosphate (cAMP) may play an important role in mast cell degranulation. The 
immunological activation of mast cells produces a transient increase in the intracellular 
level of cAMP. Bridging of the IgE receptor molecules on the mast cell membrane are 
thought to activate adenylate cyclase through a GTP dependent regulatory protein. 
This rise in cAMP also corresponds with an increase in phospholipid methylation. 
However, the relationship between these two events is unclear. It has been proposed 
that lipid methylation may be required for the activation of adenylate cyclase or it may 
enhance the coupling of the IgE receptor to adenylate cyclase through an increase in 
membrane fluidity (for review see Pearce, 1987). The role of cAMP in histamine 
secretion is also controversial as it has been reported both to inhibit and induce 
histamine release ^Iolgate et al.，1980). 
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PLAj activation has also been reported to play a role in the release of histamine from 
activated mast cells. Early studies demonstrated that exogenous AA potentiated 
immunologically induced histamine release from rat peritoneal mast cells and human 
basophils (Sullivan & Parker, 1979; Marone et al., 1979). This potentiation was not 
seen with other fatty acids such as linoleic acid and linolenic acid. Purified PLA! 
isolated from porcine pancreas was shown to cause mast cell degranulation and this 
was blocked by the PLA! inhibitor p-Bromophenacyl bromide (p-BPB) suggesting that 
PLA2 was involved in the generation of this free AA in mast cells (Chi et al., 1982). 
Eicosa-5,8,11,14-tetraynoic acid (ETYA), a cyclo-oxygenase and lipoxygenase 
inhibitor, inhibited histamine release from rat mast cells and human basophils (Sullivan 
& Parker, 1979; Marone etal., 1979). Non-steroidal anti-inflammatory drugs, which 
block the cyclo-oxygenase pathway of AA metabolism yielded controversial results. 
Histamine release was unaffected by aspirin or indomethacin (Sullivan & Parker, 1979) 
and enhanced by indomethacin, meclofenamic acid and aspirin (Marone et al,, 1979). 
Miibitors of the lipoxygenase pathway 5,8,11,14-henicosatetraynoic acid (HTYA), 
4,7,10,13-icosatetraynoic acid (ITYA) and 5,8,11-eicosatriynoic acid (ETYA), blocked 
immunologically induced histamine secretion from rat mast cells and human basophils 
OVIarone et al., 1981; Nemeth & Douglas, 1982). Magro (1982) tested a wide variety 
of AA inhibitors on their ability to inhibit immunologically induced histamine release 
from human basophils. Agents specific for the lipoxygenase pathway were effective 
in blocking histamine release, whereas agents inhibitory to cyclo-oxygenase, 
isomerases and thromboxane synthetases were ineffective. However, Morita et al. 
(1985) reported that the 5-lipoxygenase inhibitor AA-861 did not inhibit 
immunologically induced histamine release from human basophils. More recently, 
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Kuno et al. (1993) reported that p-BPB and the lipoxygenase inhibitor 
nordihydroguaiaretic acid (NDGA) inhibited compound 48/80 induced histamine 
release from rat mast cells; indomethacin was without effect. These observations led 
to the proposal that one or more products of the lipoxygenase pathway played a role 
in histamine release from mast cells. Three candidates have been proposed: 12-
hydroxyeicosatetraenoic acid, 5-HETE and 5-HPETE. All these compounds have been 
reported to significantly enhance immunologically induced histamine release from rat 
mast cells and human basophils (Stenson et al.，1980; Peters et al., 1981 & 1982a). 
1.3.2 The non-antigenic pathway of mast cell activation 
This pathway of mast cell activation can be selective or cytotoxic. The cytotoxic group 
of agents (e.g. the detergent Triton X 100) act by disrupting the plasma membrane, 
causing irreversible damage and expulsion of the intracellular contents. The non-
cytotoxic compounds include polybasic agents (compound 48/80)，neuropeptides 
(substance P), peptide hormones (bradykinin), venom peptides (mastoparan), 
anaphylatoxins (C3a, C5a) and calcium ionophores (A23187, ionomycin). Although 
little is known about their receptors or secretory mechanisms, several observations 
suggest that these stimuli utilise a secretory pathway different from IgE dependent 
stimuli (for review see Landry et al., 1992; Langunoff & Martin 1983: Foreman, 
1993).， 
• \ 
The first known intracellular event of this pathway is the activation of pertussis toxin-
sensitive G-proteins distal to PLC (Saito et al., 1987; Aridor et al” 1990; Aridor & 
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Sagi-Eisenberg, 1990). PLC activation results in the generation of IP3 and DAG. 
PLA2 is also activated (for review see Landry et al., 1992; Foreman, 1993). 
G-proteins are also involved in the non-immunological pathway of secretion in mast 
cells. Pretreatment of rat peritoneal mast cells with islet-activating protein pertussis 
toxin (IAP), results in a marked inhibition of receptor mediated histamine secretion 
when challenged with the polyamine compound 48/80 (Nakamura & Ui, 1984 & 1985; 
Saito et al, 1987; Bronner et al., 1990). Penner et aL (1987) and Aridor et al (1990) 
observed that depletion of intracellular GTP levels inhibited compound 48/80 induced 
histamine release. The venom peptide mastoparan directly activates purified G-
proteins, as do substance P and compound 48/80 (Higashijima et aL, 1990; Mousli et 
aL, 1990 a, b & c; Tomita et al.，1991). Further work with bradykinin and 
anaphylatoxin C3a extended this hypothesis of G-protein activation via a receptor 
independent mechanism (Bueb et aL, 1990). The compounds described above are 
thought to induce histamine release through a direct interaction with a G-protein. 
However, these agents cannot penetrate the surface of the plasma membrane and reach 
the G-proteins. It appears that the hydrophobic portion of these compounds are 
involved in membrane insertion, allowing the basic portion to interact and activate the 
G-protein. Their ability to rapidly induce mediator release indicates the importance 
of cell surface events in initiating the response. 
y 
A role for sialic acid residues (negatively charged endings of membrane glycolipids 
and glycoproteins) of the cell surface has been proposed. Removal of these residues 
by neuraminidase treatment inhibits the response to peptides without altering IgE 
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dependent stimulation (Landry et al., 1992). The authors proposed that binding ofthe 
secretory stimulus to sialic residues would facilitate the passage of the agents into the 
plasma membrane. 
Although, the exact biochemistry between membrane signalling and granule release is 
still unclear, the fmal stage is the fusion of the membrane surrounding the granule with 
the membrane surrounding the whole cell, which results in histamine secretion (Lindau 
& Gomperts, 1991). 
1.4 Phospholipase enzymes 
Phospholipases are a group of enzymes that hydrolyse phospholipids, which are 
abundant in biological membranes, to generate free fatty acids and lysophospholipids. 
Phosphoglycerides are a class of phospholipids derived from glycerol and contain a 
glycerol backbone, two fatty acyl chains and a phosphorylated alcohol. The hydroxyl 
groups located at the first (sn-l) and second (sn-2) carbon atoms of the glycerol 
molecule are esterified to the carboxyl groups of the fatty acid chain. Normally 
saturated and unsaturated fatty acids occupy these sn-l and sn-2 positions respectively. 
The hydroxyl group of the third carbon atom (sn-3) is esterified to phosphoric acid. 
This phosphate group can be esterified to the hydroxyl group of serine, ethanolamine, 
choline, glycerol or inositol (Dennis, 1983). 
Although phospholipases OPL) share the same basic function of phospholipid hydrolysis 
they can be broadly classified into two categories (a) the acyl hydrolyases and (b) the 
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phosphodiesterases. The acyl hydrolyases (PLAi and PLA2) cleave the ester bonds at 
the sn-l and sn-2 position of the phospholipid molecule, respectively. The 
phosphodiesterases cleave at the sn-3 position on the glycerol side (PLC) or on the 
polar side (PLD) of the phospholipid molecule (Dennis, 1983). 
1.4.1 Phospholipase Aj 
Phospholipase A2 (PLA2) was the first phospholipase to be identified, bi the early 
1900,s it was observed that the incubation of phosphatidylcholine with pancreatic juice 
or cobra venom resulted in the formation of free fatty acids (for historical review see 
Wittcoff, 1951). PLA2 enzymes were subsequently found to occur in pancreatic juices 
and a large variety of snake venoms. 
AA is usually found at the sn-2 position of membrane phospholipids (PE and PC) and 
can be released by PLAj. This free AA serves as a precursor for the biosynthesis of 
the pro-inflammatory lipid mediators (eicosanoids), (Dennis, 1987; Smith, 1989). 
Phospholipids, the building blocks of biological membranes are constantly metabolised 
and PLA2 plays a role in this. PLAj is also involved in membrane remodelling through 
a series of deacylation>^reacylation reactions (Van Den Bosch, 1980). PLA: also has 
a membrane protecting role, preventing oxidative damage by preferentially removing 
peroxidised fatty acids from membrane phospholipids fVan Kuijk et al.，1987). 
Characterization has focused mainly on the extracellular PLA2 enzymes due to their 
ubiquitous nature and high concentrations found in pancreatic juices and snake venoms 
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O^erheij etal., 1984; Waite, 1987; Glaser etal., 1993; Dennis, 1994). Traditionally, 
these extracellular enzymes were divided into three main groups based on their primary 
amino acid sequence and the positioning of disulphide bridges. The PLA2 enzymes 
isolated from the snake venoms of the Elapidae and Hydrophidae species are classified 
as group I enzymes. Group H includes those PLA2 enzymes isolated from the venoms 
of the Viperidae and Crotalidae species and those isolated from bee venom belong to 
group m (Heinrikson et al, 1977; Davidson & Dennis, 1990; Dennis, 1994). 
All of these PLA2 enzymes have been isolated as extracellular enzymes and they share 
many common traits such as a striking homology in both their amino acid sequence 
(Verheij et al., 1981; Dennis, 1983) and X-ray crystal structures (Renetseder et al., 
1988; Scott et al., 1990 & 1991; White et al., 1990a). These enzymes are small, have 
a molecular mass of about 14 kDa and differ in their states of aggregation. They are 
optimally active in the neutral to alkaline pH range. Ca�+ is required in the mM range 
both for catalysis and substrate binding. They are unusually stable due in part to their 
high disulphide bond content (seven). The catalytic mechanism by which these 
enzymes hydrolyse the phospholipid substrate has been well studied (Scott et al., 1990 
& 1991; Verheij & Dijkstra, 1994). It involves the positioning of His-48 and Asp-99 
to form an active Asp-His couple. This couple polarises a bound water molecule 
which then attacks the carbonyl group and the Ca!+ ion stabilises this transition. These 
extracellular PLA2 enzymes are optimally active when the phospholipid substrate is 
part of an interface such as a membrane. Generally these enzymes do not display any 
selectivity for the fatty acid present in the sn-2 position of the phospholipid substrate. 
Li the past few years numerous PLA2 enzymes have been identified, all essentially 
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have the same function but do not fit into this traditional categorization. Di many cases 
several of these enzymes are present in the same cell (Marshall & Roshak, 1993). 
Recently a Ca]+ independent, 85 kDa cytosolic phospholipase A! (cPLA!) was purified 
and cloned from human monocytic U937 cells (Kramer et al., 1991; Sharp et al., 
1991; for review see Clark et al., 1995). This cPLA2 bears no sequence homology 
with the extracellular PLA2S. It appears to be highly selective for phospholipid 
substrates containing AA at the sn-2 position of phospholipids. Another group of 
calcium independent phospholipase A2 enzymes (iPLA2) have recently been identified. 
They have been shown to exist in the brush-border membranes of the small intestine, 
lysosomes and a wide variety of animal tissues such as the lung, mycoardium and 
alveolar macrophages (for review see Ackermann & Dennis, 1995) The difficulty of 
purifying these iPLA2 has hampered their characterization. 
1.4.2 The type I secretory PLA2 (sPLA2-I) 
The mammalian pancreatic PLA2 belongs to the type I PLA2 class and has been well 
characterised (for review see Waite, 1987). This enzyme is unique in that it is 
synthesised and stored as a soluble zymogen or proenzyme in pancreatic acinar cells. 
Upon stimulation this proenzyme is secreted into the duodenum and converted into its 
active form through tryptic proteolysis of the N-terminal extra peptide (Nishijima et 
al., 1983). Once activated it plays a central role in the digestion of dietary 
phospholipids. 
This pancreatic type I PLAj enzyme has also been located in a variety of tissues with 
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no digestive function such as the rat lung, spleen and stomach (Tojo et al.，1988; 
Sakata et al” 1989; Yasuda et aL，1990) and also in human lung (Seilhamer et al., 
1986). The exact function of this extrapancreatic type I PLA] enzyme is unclear. 
There have been reports suggesting that it may function in a similar manner as a 
cytokine/growth factor. The type I PLA2 enzyme can regulate cell proliferation in the 
Swiss 3T3 fibroblast cell line (Arita et al, 1991). Cell proliferation has also been 
reported in rat cells such as vascular smooth muscle cells, vascular endothelial cells, 
synovial cells and chondrocytes (Hanasaki & Arita，1992) The type I PLAj also 
exhibits a contractile effect in isolated guinea pig lung parenchyma (Sommers et al.， 
1992; Kanemasa et al., 1992). These physiological effects are thought to be mediated 
in part through the existence of high affinity type I PLA2 binding sites. 
To date two types of high affinity receptors for these type I PLA2 enzymes have been 
characterised. The first type of receptor was initially identified in rat brain (Lambeau 
et al,, 1989). It recognised both the neurotoxic PLA2 isolated from the Taipan snake 
venom and the bee venom PLA2with high affmity. The porcine pancreatic type I PLAj 
displayed very low affinity for this receptor. A second type of receptor was initially 
identified in rabbit skeletal muscle by Lambeau et aL (1990). This receptor binds both 
porcine pancreatic type I PLA: and the human inflammatory type II PLA: with K^  
values of 10 and 0.8 nM respectively (Lambeau et al., 1994). A receptor for the type 
I PLA2 was also characterised in the Swiss 3T3 fibroblast cell line (Arita et al, 1991). 
The porcine pancreatic type I PLAj displayed high affmity (Kj value of 1.58 nM) 
whereas the type II PLAj isolated from rat and rabbit platelets displayed much lower 
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affinity. Similar observations were made by Hanasaki & Arita (1992) in rat vascular 
smooth muscle. The characterised receptor displayed high affinity for the porcine 
pancreatic type I PLAj whereas the type II PLA2 displayed much lower affinity. 
The type I PLAj receptors in rabbit (Lambeau et al., 1994)，bovine (Ishizaki et al., 
1994) and human (Ancian et aL, 1995) species have recently been cloned. These 
cloned receptors are homologous to the macrophage mannose receptor (Taylor et al.， 
1990) and the DEC-205 receptor recently cloned in dendritic cells (Jiang et al., 1995). 
All of these receptors share the same structural organisation composed of several 
distinct domains. These sPLA2 180-kDa receptors consist of a type I transmembrane 
protein, which has a large extracellular region composed of an N-terminal cysteine-rich 
region and a fibronectin type II domain with eight or ten repeats of a carbohydrate 
recognition domain, followed by a transmembrane domain and a short intracellular C-
teraiinal region. These proteins mediate adsorptive endocytosis. 
1.4.3 The type II secretory PLA2 (sPLA2-II) 
t i contrast to the type I PLAj the intracellular and extracellular type II PLA: enzymes 
have not been as well characterised. They have been found associated with several 
cells and tissues. Their presence in inflammatory fluids, tissue exudates or serum have 
implicated a putative role in inflammation (for review see Wong & Dennis，1990; 
Pruzanski et al.，1993). 
The type H PLA� purified from human platelets and human synovial fluid has been 
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cloned and the complete amino acid sequence determined (Kramer et al., 1989; 
Seilhamer et al., 1989). Unlike the type I PLA】，these enzymes contain a 20 amino 
acid extension preceding the N-terminus resembling a signal sequence. These enzymes 
appear to be highly conserved between human, porcine and rat displaying an overall 
homology of 79%. Complete homology was observed for both catalytic site and 
disulphide bond content. There was no substrate selectivity for fatty acids at the sn-2 
position of the phospholipid, but preference was displayed for the phospholipid class 
containing ethanolamine or serine (Kudo et al., 1993). 
High levels of the soluble type II PLA! have been detected in animal models of 
inflammation. Vadas & Hay (1982) reported elevated levels of a circulating PLAj in 
rabbits with endotoxin shock. Chang et al. (1987a) observed that the PLA2 purified 
from the peritoneal exudate of caseinate treated rats was similar to that secreted from 
rat platelets. Similarly, local and circulating levels of PLA2 are elevated during 
infections, inflammatory diseases and injury in humans (Vadas & Pruzanski, 1986). 
Pruzanski et al. (1985) observed high levels of soluble PLAj activity both in the sera 
and synovial fluids isolated from patients with rheumatoid arthritis or osteoarthritis. 
Purification of this enzyme revealed a dissimilarity with the porcine pancreatic type I 
PLA2 (Stefanski et al.，1986). Green et al. (1991) also found elevated levels of 
circulating PLA� in patients with sepsis. This inflammatory enzyme was both 
immunologically and chemically indistinguishable from that associated with rheumatoid 
arthritis. The source of this PLA2 is thought to include a number of inflammatory cell 
types such as neutrophils (Wright et al., 1990)，platelets (Kramer et aL, 1989) and 
mast cells (Murakami et al., 1992a). 
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This type II PLAj is an inducible enzyme and arises in response to inflammatory 
stimuli. Nakano et al. (1990) reported that the inflammatory mediators, IL-1 and 
tumor necrosis factor (TNF) as well as the bacterial lipopolysaccharide (LPS), 
increased type II PLA� mRNA levels in cultured rat vascular smooth muscle cells. 
This in tum led to an enhanced enzyme secretion from the cells. They also observed 
that agents which increase cAMP levels (forskolin, isobutylmethylxanthine and 
dibutyryl cAMP) resulted in increased type II PLA! mRNA levels. IL-1, TNF and 
LPS, had no effect on the cAMP levels. These observations demonstrated that 
induction of the type II PLA! involved a cytokine response element and/or a cAMP 
response element. Crowl et al. (1991) also reported that type II PLAj was expressed 
and secreted from human hepatoma cells in response to the inflammatory mediators JL-
6, IL-1 and TNF. IL-6 was the most potent inducer and a synergistic effect was 
observed both with IL-1 or TNF. Recombinant IL-1 beta (rIL-ip) was found to 
increase type II PLA2 mRNA levels in rabbit articular chondrocytes (Kerr et aL, 
1989). These increased mRNA levels correlated with an increase both in enzyme 
activity and LTB4 production over a 20 hour period. Jn rat cultured astrocytes IL-1, 
TNF and LPS enhanced type II PLAj gene expression and secretion (Oka & Arita, 
1991). Dexamethasone suppressed this PLA2 gene expression induced by LPS but not 
that of TNF. The time course of PGE2 formation was similar to that of PLA2 
production when cells were stimulated with LPS. Treatment of rat glomerular 
mesangial cells with IL-ip, TNF or forskolin stimulated both the synthesis and 
/ 
secretion of type II PLA2 and PGE2 (Schalkwijk et al.，1991). Pretreatment of these 
cells with dexamethasone suppressed the IL-lp, TNF and forskolin induced effects. 
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The exogenous addition of type IIPLA2 failed to elicit any response in intact cells such 
as HL-60 granuloctes, mast cells and endothelial cells. However, if cells were 
activated in the presence of the type II PLA2 enzyme an enhancement of eicosanoid 
production was usually observed. Hara et al. (1991) reported that both rat and human 
type II PLA2augmented PGE2 production from A23187 activated HL-60 granuloctes. 
There was no significant increase observed in PGE� production in unstimulated cells. 
Murakami et al. (1991a) also observed that exogenously added type II PLA2 
augmented PGDj production in IgE-antigen-primed rat peritoneal mast cells. Similar 
observations were made with human umbilical endothelial cells (HUVEC) (Murakami 
et al., 1993b) where exogenously added type H PLAj augmented PGI2 production from 
TNF activated cells. These observations would suggest that inflammatory conditions 
are required for the type II PLA2 to exhibit any effect on the inflammatory response 
through the generation of AA metabolites. The exact mechanism(s) involved in the 
action of the type II PLA2 have yet to be determined, 
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1.5 Aims of the Study 
The type II sPLA2 is present in inflammatory fluids and in inflammatory tissue 
exudates. Mast cells, in addition to platelets, neutrophils and macrophages, rapidly 
release this sPLA2 when activated. This extracellular sPLA2 may provide free AA for 
eicosanoid synthesis by the range of cells associated with the inflammatory condition. 
In addition, sPLAj-II may provide some phospholipid metabolite which may in tum 
augment the inflammatory response. The association of elevated levels of the type II 
sPLA2 enzyme with inflammatory conditions suggested that it may also exert an affect 
on mast cells. Therefore, one of the aims of this study was to investigate the effect of 
the type II sPLA2 on mast cell reactivity. Studies in the early 80's showed the 
involvement of PLA2 in mast cell degranulation and AA metabolites were proposed to 
be responsible. These reports were controversial and the recent development of more 
specific inhibitors for the enzymes involved in the AA metabolic pathway will help 
clarify this. The effect of these newly developed agents on histamine release from 
mast cells were also investigated. In addition, the type I sPLA2 was also included in 
this study as these early observations employed the type I sPLAj isolated from the 
porcine pancreas. The responsiveness of mast cells isolated from the rat peritoneum, 
human lung and guinea pig lung to the sPLAj enzymes was also examined in view of 









Common chemicals, solvents and buffer components were supplied by Sigma Chemical 
Co., U.S.A.; BDH Chemicals Ltd., Poole, UK; Mallinckrodt, Kentucky, U.S.A. and 
Merck, Germany. All aqueous solutions were made up in water prepared with a 
Millipore milli-Q system. 
Phospholipase A! enzymes 
Phospholipase Aj (PLA2) enzymes with defined specific activities, purified from Naja 
naja venom (sPLAj-I) (lot no. 14H7030) and Crotalus altrox venom (sPLA2-ED (lot 
no. 14H9544) were obtained from Sigma. Stock solutions (1,000 U ml]) were 
prepared with sterile water, stored in aliquots at -20°C and subsequent dilutions made 
with Hepes buffer. 
Phospholipase A! inhibitors 
p-Bromophenacyl bromide (^-BPB) (lot no. 102H2626), aristolochic acid (lot no. 
128F0446) and mepacrine (quinacrine) (lot no. 62H3279) were obtained from Sigma. 
Stock solutions (10 mM) for p-BPB and aristolochic acid were prepared daily with 
dimethyl sulfoxide (DMSO) and subsequent dilutions made with Hepes buffer. The 
stock solution (10 mM) for quinacrine was prepared daily with Hepes buffer. 12-
deacetyl-12-epi-scalaradial (12-epi-scalaradial), (lot no. M6278) was obtained from 
BIOMOL Research Laboratories, U.S.A. The stock solution (1 mM) was prepared in 
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ethanol, stored at -20°C and subsequent dilutions made with Hepes buffer. The 
cytosolic PLA2 (cPLA2) inhibitor methyl arachidonyl fluorophosphonate (MAFP), (lot 
no. 22451913) was obtained from Cayman Chemical Company, U.S.A. The stock 
solution (5 mg ml"^ ) was supplied in methyl acetate and stored at -70°C. Dilutions 
were made with Hepes buffer. 
Cyclo-oxygenase inhibitor 
Flurbiprofen (lot no. 821885f) was obtained from Cayman Chemical Company. The 
stock solution (10 mM) was prepared daily with ethanol and subsequent dilutions made 
with Hepes buffer. 
Lipoxygenase inhibitor 
Zileuton (A64077) was a generous gift from Abbott Laboratories, UK. The stock 
solution (10 mM) was made up with DMSO and subsequent dilutions made with Hepes 
buffer. 
Antimycin A 
Antimycin A (lot no. 102H4029) was obtained from Sigma. The stock solution (2 




Except where otherwise stated all experiments were performed using Hepes buffered 
Tyrode's solution pH 7.4, (Hepes buffer) of the following composition: NaCl (137 
mM), glucose (5.6 mM), N-2-hydroxyethyl piperazine-N‘-2-ethane sulphonic acid 
OHepes) (10 mM), KC1 (2.7 mM), NaH2PO4 (0.4 mM). CaCl2 (1 mM) and MgCl2 (1 
mM). 
The following buffers were also used throughout this study: 
Hepes buffer supplemented with 1 mg ml"^  of bovine serum albumin (BSA). (Hepes 
buffer + BSA). 
Hepes buffer supplemented with 10% foetal calf serum (FCS) (Gibco). (Hepes buffer 
+ FCS). 
Percoll stock solution: 9 parts of Percoll and 1 part of 10x calcium free Hepes buffer. 
Percoll discontinuous gradients were prepared by layering 100%, 80%, 70%，60%, 
50% and 40% Percoll solutions (1 ml) consecutively. Percoll solutions were prepared 
by dilution with calcium free Hepes buffer. 
Isotonic shock solution pH 7.4 consisting 0fNH4Cl (0.155 M) and KHCO3 (0.01 M). 
Buffers for investigating the requirement of metabolic energy: 
Glucose free Hepes buffer (GF Hepes buffer). 
GF Hepes buffer supplemented with 2x glucose (11.2 mM) (2x Glucose). 
GF Hepes buffer supplemented with 2x antimycin A (0.002 mM) (2x antimycin A). 
30 
Buffers for investigating the effects of extracellular calcium: 
Calcium and magnesium free Hepes buffered Tyrode,s (CMF Hepes buffer). 
CMF Hepes buffer supplemented with 2x calcium (2 mM CaCy (2x calcium). 
CMF Hepes buffer supplemented with 2x EDTA (0.2 mM EDTA) (2x EDTA). 
Buffers for the prostaglandin D] assay: 
Assay buffer: 0.1 M phosphate, pH 7.4 containing NaCl (0.4 M), EDTA (1 mM), 
BSA (0.1%) and sodium azide (0.01%) (Cayman Chemical Company. U.S.A.). 
Packet contents were dissolved in 500 ml of Millipore water and stored at 4°C. 
Wash buffer: 0.01 M phosphate, pH 7.4 containing Tween-20 (0.05%) (Cayman 
Chemical Company. U.S.A.). Packet contents were dissolved in 500 ml of Millipore 
water and stored at 4°C. 
Buffer for animal sensitization: 
0.01 M phosphate buffered saline (PBS), pH 7.2 containing KC1 (2.86 mM), KH2PO4 
(1.47 mM), NaCl (137 mM) and Na2HPO3 (8.09 mM). 
2.3 Secretory stimuli 
Sheep anti-rat IgE serum, (anti-rat IgE) (product no. 64-352) was obtained from ICN, 
Costa Mesa, California. Goat anti-human IgE serum, (anti-human IgE) (product no. 
I-0632) was obtained from Sigma. The lyophilized powder was reconstituted with 
sterile water (2 ml) and aliquots stored at -20°C. 
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Chicken egg albumin, (OVA) (grade V，ovalbumin) (lot no. 14H7035) was obtained 
from Sigma. The powder was stored at 4°C. Stock solutions (1 mg ml]) were 
prepared daily with Hepes buffer. 
Compound 48/80, (lot no. 53H0006) was obtained from Sigma. The powder was 
stored at -20�C. Stock solutions (1 mg ml]) were prepared daily with Hepes buffer 
and stored at 4°C. 
The calcium ionophore A23187 (lot no. 114H4025) was obtained from Sigma. Stock 
solutions (10 mM) were prepared with DMSO, stored in aliquots at -20°C and 
subsequent dilutions made with Hepes buffer. 
2.4 Source of mast cells 
Rat peritoneal mast cells were obtained from male Sprague Dawley rats (body weight 
250-350 g). Guinea pig lung mast cells were obtained from male and female Dunkin 
Hartley guinea pigs O^ ody weight 300-500 g). These animals were obtained from the 
animal house located in the Basic Medical Science Building, The Chinese University 
of Hong Kong. 
Human lung mast cells were isolated from human lung tissue obtained from cancer 
y 
patients undergoing resection of the lung at the Prince of Wales Hospital, Shatin. 
Macroscopically healthy areas of a lung lobe, judged normal by a pathologist, were 
placed in Hepes buffer at 4-10°C for transport to the laboratory. Human lung mast 
32 
cells were isolated from the tissue within 24 hours. 
2.4.1 Sensitization of animals 
For studies on immunologically induced histamine release, cells were isolated from 
animals that had previously been exposed to allergen (ovalbumin). Both rat and guinea 
pig were sensitized according to the following procedures. 
Rat sensitization: Male rats (body weight 200-250g) were given an intraperitoneal 
injection of PBS (0.5 ml) containing OVA (1 mg) and Al(OH)3 (100 mg). The 
adjuvant was added to the allergen solution, with constant stirring 30 min before 
injection. Animals were sacrificed 3 weeks later. 
Guinea pig sensitization: Male and female guinea pigs were sensitized using an 
emulsified solution of OVA and Freund's complete adjuvant. The solution of allergen 
and adjuvant was expelled repeatedly through two Leur Lock syringes connected via 
a double hubbed needle to form an emulsion. 1 ml of the emulsion (50 mg OVA in 
0.5 ml of saline and 0.5 ml of Freund's complete adjuvant) was injected 
intraperitoneally into each guinea pig. Animals were sacrificed 3 weeks later. 
2.4.2 Isolation of rat peritoneal mast cells 
The rat was first anaesthetized with ether and sacrificed by cervical dislocation 
followed by exsanguination. Hepes buffer (20 ml) containing heparin (5 units ml]) 
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was injected intraperitoneally. The abdomen was gently massaged for 2 min and cut 
open along the midline. Peritoneal cells were recovered using a plastic Pasteur pipette 
and collected into polystyrene tubes chilled on ice. The cells were pelleted by 
centrifugation (180xg, 4°C，5 min). Non-purified cells were washed twice in Hepes 
buffer and used for functional studies without further treatment. Samples heavily 
contaminated with blood were discarded. The cell pellet usually contained 7.6 士 
0.6% mast cells. 
2.4.3 Purification of rat peritoneal mast cells 
Cells to be purified were isolated as before (section 2.4.2). The cells were washed 
once in Hepes buffer + BSA, and the pellet resuspended in 1 ml of Hepes buffer + 
BSA (Mackay & Pearce, 1992). The cells were mixed with 4 ml of a Percoll stock 
solution and Hepes buffer + BSA (1 ml) was layered on top to produce an interface. 
This was centrifuged at 140xg for 25 min at 4°C. The resulting cell pellet usually 
contained 91.9 士 0.8% mast cells. This was washed twice in Hepes buffer + BSA 
and twice in Hepes buffer before use for functional studies. 
2.4.4 Isolation of human lung mast cells 
Human lung tissue was dissected free of pleura, large bronchi and blood vessels. The 
tissue was washed twice in Hepes buffer and minced finely with scissors into 
approximately 1 mm^ fragments. These fragments were washed extensively with 
Hepes buffer + BSA to remove blood and mucus. The chopped tissue was then 
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incubated at 37°C for 60 min with gentle agitation in a solution of collagenase (Sigma 
type lA, 80 Units ml]) in Hepes buffer + BSA. At the end of the incubation, the 
mixture was filtered through gauze, to remove undisrupted tissue. The isolated cells 
were recovered by centrifugation (200xg, 25°C，5 min). Cells were washed twice in 
Hepes buffer + BSA and once in Hepes buffer. Cells were finally resuspended in 
Hepes buffer + FCS and stored temporarily at 4°C. The remaining undisrupted tissue 
was subjected to a second incubation as described above. At the end of this incubation, 
the tissue was disrupted by expression through a syringe. The resulting suspension 
was filtered and the cells recovered, were washed as before. Cells from both 
incubations were pooled and kept at 4°C in Hepes buffer + FCS. The cell suspension 
was washed twice in Hepes buffer before use for functional studies. The % mast cells 
present was usually 4.7 士 0.7% of the total nucleated cells. 
2.4.5 Partial purification of human lung mast cells 
The method employed was an adaptation of the procedure described by Schulman et 
al. (1988) for the purification of human lung mast cells. Cells to be purified were 
washed once with Hepes buffer. The pellet was resuspended in 3 ml of an isotonic 
shock solution and kept on ice for 5 min. The reaction was stopped by the addition of 
Hepes buffer + BSA (20 ml). Cells were pelleted by centrifugation (200xg, 5 min, 
4°C), and resuspended in 1 ml of Hepes buffer + BSA. The cell suspension was 
layered on top of a Percoll discontinuous gradient and centrifuged at 400xg for 20 min 
at 4°C. Cells from each interface were collected and mast cells were generally found 
at the 50%, 60% and 70% interfaces. Fractions rich in mast cells were pooled 
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together and washed twice in Hepes buffer to remove any remaining Percoll. Cells 
were stored in Hepes buffer + BSA and kept at 4°C until use for functional studies. 
2.4.6 Isolation of guinea pig lung mast cells 
Animals were sacrificed by cervical dislocation followed by exsanguination. Lungs 
were removed from the thoracic cavity. Lung mast cells were recovered as described 
previously (2.4.4). The incubation buffer contained collagenase at a concentration of 
160 Units ml-i. The % mast cells present was usually 3.9 士 0.8% of the total 
nucleated cells. 
2.5 General procedure for studying histamine release from isolated mast cells 
Both purified and non-purified cells were prewarmed for 5 min at 37°C in a shaking 
water bath. Aliquots of cells (500 jitL for rat peritoneal mast cells (RPMC), 360 fjtL 
for human (HLMC) and guinea pig lung mast cells (GPLMC)) were added to prepared 
polystyrene tubes containing either the buffer alone (500 fjL for RPMC, 40 fjiL for 
HLMC and GPLMC) or buffer and stimulus. All experiments using RPMC included 
duplicate tubes for each sample. The histamine release reaction was allowed to 
proceed for 10 min for RPMC and HLMC, and 20 min for GPLMC. The reaction was 
stopped by placing the tubes in an ice cold water bath, followed by the addition of ice 
cold Hepes buffer (2 ml for RPMC, 600 fjiL for HLMC and GPLMC). Cells were 
immediately separated from the supematants by centrifugation (180xg, 4°C, 5 min). 
The remaining cell pellets were resuspended in Hepes buffer (3 ml for RPMC, 1 ml 
36 
for HLMC and GPLMC) and boiled for 15 min to release the residual histamine. 
Samples were either assayed immediately or stored at -20°C. The following 
modifications of this procedure were adapted throughout this study. 
2.5.1 Procedure for investigating the effect of the sPLAj enzymes on the 
spontaneous histamine release from isolated mast cells 
Aliquots of cells were added to prepared tubes containing the sPLA2 enzymes (50 /xL 
for RPMC, 40 ptL for HLMC and GPLMC). Cells were incubated with the sPLAj 
enzymes for various time periods: RPMC (10, 20 and 30 min), HLMC_(10 and 20 
min) and GPLMC (20 and 30 min). The reaction was stopped by the addition of 
appropriate volumes of ice cold Hepes buffer. Thereafter the procedure was as 
described above (section 2.5). The kinetics of the spontaneous histamine release 
induced by sPLAj-I (0.1 and 1.0 U ml"^ ), on purified RPMC over a time period of 1 
to 40 min were also examined. 
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2.5.2 Procedure for inyestigating the effect of heat treated sPLA2-I on histamine 
release from isolated RPMC 
The sPLA2-I stock solution was boiled for 30 min and allowed to cool at room 
temperature. This was then incubated with RPMC for 10 min and the procedure 
described before was followed (section 2.5). Unheated sPLAj-I was used as the 
control. 
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2.5.3 Procedure for investigating the effect of antimycin A on histamine release 
induced by sPLA2-I on isolated RPMC 
RPMC were recovered as described previously (section 2.4.2). Non-purified cells 
were washed and resuspended in GF Hepes buffer. Aliquots of cells (500 fiL) were 
added to prepared tubes containing 500 fiL of the following buffers; 2x Glucose, GF 
Hepes buffer and 2x antimycin A. Cells were incubated for 20 min before the addition 
of sPLA2-I or compound 48/80 (25 jnL). The histamine release reaction was allowed 
to proceed for 10 min. The reaction was stopped by the addition of ice cold GF Hepes 
buffer and the procedure described in section 2.5 was followed. 
2.5.4 Procedure for investigating the effect of extracellular calcium on histamine 
release induced by sPLAj-I on isolated RPMC 
Purified RPMC were recovered as described previously (2.4.2), and resuspended in 
CMF Hepes buffer. Aliquots of cells (500 ptL) were added to prepared tubes 
containing 500 jjL of the following buffers; 2x calcium, CMF Hepes buffer and 2x 
EDTA. Cells were incubated for 10 min in the appropriate tubes at 37°C. Aliquots 
of sPLA2-I (25 |xL) were added and the reaction was terminated by the addition of ice 
cold CMF Hepes buffer. Thereafter, the procedure described in section 2.5 was 
followed. 
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2.5.5 Procedure for investigating the effects of the sPLAj enzymes on activated 
mast cells 
Aliquots of cells were added to prepared tubes containing the sPLA2 enzymes. Cells 
were preincubated with the sPLA2 enzymes for 10 min at 37°C. Mast cell 
secretagogues (anti-IgE, ovalbumin, compound 48/80 and A23187) (25 fiL) were 
added to activate histamine secretion and the reaction allowed to proceed, for 10 min 
for RMPC or HLMC and 20 min for GPLMC. The reaction was stopped as described 
in section 2.5. Controls containing cells with the sPLA� enzymes or secretagogue 
alone were also included. 
2.5.6 Procedure for investigating the effect of preincubation time on sPLAj 
induced histamine release from immunologically activated RPMC 
Aliquots of RPMC were added to prepared tubes containing the sPLA2 enzymes and 
preincubated for 1，5 and 10 min at 37°C. Anti-rat IgE (25 juL) was then added to 
activate histamine secretion and the reaction allowed to proceed for 5 and 10 min. The 
reaction was stopped as described in section 2.5. Controls containing cells with the 
sPLA2 enzymes or secretagogue alone were also included. 
2.5.7 Procedure for investigating the effects of the PLA2 inhibitors 
The sPLA2 enzymes were preincubated with the various PLA2 inhibitors for 30 min at 
37°C. Cells were then added and incubated for a further 20 min. Thereafter the 
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procedure described in section 2.5 was followed. Controls containing cells with the 
inhibitors or the sPLA] enzymes were also included. The inhibitors were dissolved in 
Hepes buffer, DMSO, ethanol or methyl acetate and controls for these vehicles were 
included in all experiments. When studying the effect of these inhibitors on 
immunologically activated mast cells, the sPLAj enzymes were preincubated with the 
inhibitors for 30 min at 37°C. Aliquots of cells were then added and incubated for 10 
min. Anti-IgE (25 |xL) were then added to stimulate secretion for a further 10 min. 
The reaction was terminated as before (2.5). Controls containing cells with the 
inhibitors, sPLAj enzymes or secretagogue alone were also included. 
2.5.8 Procedure for investigating the effects of the cyclo-oxygenase and 
lipoxygenase inhibitor 
Aliquots of purified RPMC were preincubated with flurbiprofen or zileuton for 15 min 
at 37°C. The sPLA2 enzymes (25 f/L) were then added and incubated for a further 20 
min. Thereafter the procedure described in section 2.5 was followed. Controls 
containing cells with the inhibitors or sPLA: enzymes alone were also included. When 
studying the effect of these inhibitors on immunologically activated mast cells, cells 
were preincubated for 15 min. The sPLA! enzymes (25 jttL) were then added and 
incubated for 10 min. Anti-rat IgE (25 ptL) was then added to stimulate secretion for 
a further 10 min. The reaction was terminated as before (2.5). Controls containing 
cells with the inhibitors, sPLA2 enzymes or secretagogue alone were also included. 
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2.6 Histamine assay 
The histamine assay was first described by Shore et al. (1959) and is based on the 
reaction between histamine and o-phthaldialdehyde (OPT) under alkaline conditions. 
The resultant condensation product is highly fluorescent and can be measured using a 
spectrofluorimeter. 
Samples from RPMC were measured for histamine using the simple condensation assay 
without any extraction steps (Loeffler et al,，1971). Briefly, samples (3 ml) were 
treated with NaOH (lM, 400 jLtL), followed by the addition of OPT (100 f/L，lmg mi"^  
in methanol) and samples immediately mixed. The reaction was stopped 4 min later 
by the addition of HC1 (3M, 200 (jL). Fluorescence measurements were obtained at 
an excitation wavelength of 360 nm with an emission wavelength of 450 nm. 
Bandwidths were set at 5 and 10 nm respectively. Measurements were performed 
using a Hitachi Fluorescence Spectrophotometer F-4010 at room temperature. 
Samples from HLMC and GPLMC were measured for histamine using an automated 
fluorometric method (Ennis, 1991). Samples were treated with perchloric acid (0.4N) 
to precipitate out any protein present and centrifuged (250xg, 25°C, 25 min). 
Following introduction into the autoanalyzer, samples were made alkaline and 
histamine was extracted into butanol. The organic phase was separated and washed 
r 
once in a less alkaline medium, made less polar by the addition of heptane and the 
histamine back-extracted into dilute sulphuric acid. The amine was allowed to react 
with OPT under alkaline conditions and the adduct generated was stabilized by 
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acidification. Fluorescence was detected with a fluorometer and recorded on a chart 
recorder. The automated analyzer was a BRAN + LUEBBE AutoAnalyzer II and was 
used in conjunction with the AACE evaluation software which provided comprehensive 
tools to process and evaluate the data collected. 
Histamine was measured in both the supernatant and cell pellet fractions. Histamine 
release was expressed as a percentage of the total cellular histamine content: 
% Histamine release ( H^ ) = 100 x ( Hg / ( Hs + Hc ) ) 
where Hg represents the amount of histamine in the supernatant and Hc the 
corresponding amount remaining in the cell pellet. The percentage inhibition of 
histamine release was calculated as follows: 
% Histamine inhibition = 100 x 0¾ - 0¾ + P - Hp)) / Hg 
where Hg represents the amount of histamine released with the secretagogue alone, Hg 
+ p represents the amount of histamine released by the secretagogue in the presence of 
the sPLA2 enzymes and Hp represents amount of histamine released by the sPLA2 
enzyme alone. Li each experiment all values were corrected for the spontaneous 
release of histamine occurring in the absence of any stimulus. 
2.7 Measurement of Prostaglandin Dj 
2.7.1 Prostaglandin Dj methoxime enzyme immunoassay kit 
Prostaglandin Dj (PGD�was measured with a pr0staglandinD2 methoxime (PGD : 
MOX) enzyme immunoassay kit which was obtained from Cayman Chemical 
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Company. U.S.A. and stored at -20�C. Procedures were carried out according to the 
instructions in the assay kit. 
2.7.2 The Prostaglandin Dj assay 
PGD2 itself is a relatively unstable eicosanoid and in this assay is chemically converted 
to a more stable compound. Briefly, samples were treated with methoxamine 
hydrochloride which converts the unstable PGDj into a stable methoxime derivative 
PGD2-MOX. The assay is based on the competition between free PGD^-MOX and a 
fixed amount of acetylcholinesterase labelled PGDj-MOX, for a limited number of 
binding sites on a PGDj-MOX specific antibody. Thus, with fixed amounts of 
antibody and enzyme linked PGD2-MOX, the amount of acetylcholinesterase labelled 
PGD2-MOX bound by the antibody will be inversely proportional to the amount of free 
PGD2-MOX. The antibody PGD2-MOX (free or acetylcholinesterase labelled) 
complex binds to a second antibody bound to the plate well. Any unbound compounds 
are washed away. The amount of acetylcholinesterase labelled PGD2-MOX bound by 
the antibody can be determined by adding Elhnan's reagent (contains the substrate for 
acetylcholinesterase) to the well. The intensity of the product has a distinct yellow 
coloured product and can be determined spectrometrically. This is proportional to the 
amount of labelled PGDj-MOX bound to the well. 
2.7.3 PGD2 release from purified rat peritoneal mast cells 
Samples were removed from the supernatant fraction of the histamine release reaction 
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as described in section 2.5. These samples were immediately frozen by immersion in 
liquid nitrogen, stored at -70°C and assayed within 2 weeks. 
2.7.4 Derivatization of PGD2-MOX 
All samples and the PGD� standard (dissolved in assay buffer) were converted to the 
stable methoxime derivative. 100 fxL of the oximating reagent (methoxylamine HC1 
mixed with sodium acetate in a 10% ethanol solution) was added to all polystyrene 
tubes containing 100 fxL of sample or standard. All tubes were heated at 60°C for 30 
min. Sample tubes were centrifuged (lOOxg, 25°C, 5 min) and the supernatant 
fraction diluted with assay buffer. PGD2 standards (8 to 1000 pg ml]) were prepared 
with assay buffer from the PGDj-MOX standard. A typical standard curve for PGDj-
MOX is shown in fig 2.1. 
2.7.5 PGD2 assay procedure 
100 /xL of assay buffer was pipetted into the non-specific binding (NSB) wells and 50 
/xL into the maximun binding wells (Bo) in duplicate. 50 fj,L aliquots from each 
standard and sample were pipetted into appropriate wells in duplicate. 50 fiL of the 
acetylcholinesterase labelled PGDj-MOX was added into all wells except the blank, 
followed by 50 ptL of antiserum (containing the PGDj-MOX specific antibody) to all 
wells except the blank and NSB wells. The plate was covered and incubated overnight 
at room temperature. After the incubation any unbound reagents were removed by 
washing (5 times) with wash buffer. The plate was blotted onto tissue paper to ensure 
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complete removal of any remaining residual liquid. 200 jttL of Ellman's reagent was 
immediately dispensed into all wells. The plate was covered, mixed gently and 
incubated at room temperature for 90 min in the dark. The absorbance (optical 
density) was determined in an MR5000/7000 Microplate Reader (Dynatech 
Laboratories) at 405 nm. 
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Figure 2.1 Typical standard curve for the PGD2-MOX enzyme immunoassay 
The assay procedure was described in the text (2.7.5). Average optical density (OD) readings 
for each standard in duplicate was calculated. A standard curve was generated by plotting the 
percent bound/maximum bound (%B/Bo) as a log function of the PGD2-MOX concentration. 
The %B/Bo for each standard and sample was calculated as follows; 
%B/Bo = 100 X (standard OD - NSB OD / zero standard OD - NSB OD) 
where Bo represents the amount of acetylcholinesterase labelled PGD2-MOX bound to the 
antibody in the absence of any standard (zero standard), B represents the amount of 
acetylcholinesterase labelled PGD2-MOX bound to the antibody in the presence of a known 
standard and NSB represents the amount of acetylcholinesterase labelled PGDj-MOX non 
specifically bound to the well. All OD readings were corrected for background (blank). 
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2.8 Measurement of intracellular calcium 
2.8.1 Fluorescent calcium indicator fura-2 
The fluorescent probe fura-2 was packaged as a 1 mg aliquot of the unstable 
acetoxymethyl ester form. This aliquot was reconstituted in DMSO to a concentration 
of 1 mM. This was then aliquoted and stored in tightly sealed micro centrifuge tubes 
at -20�C. 
2.8.2 Cell loading of the calcium indicator 
Purified rat peritoneal mast cells were obtained as described in section 2.4.3. Mast 
cell suspensions were incubated with the acetoxymethyl ester of fura-2 (1 fjM) in 
Hepes buffer + BSA at 37°C for 15 min (Kuno et aL，1993). Jn all experiments, a 
control sample of the cell suspension was not incubated with the calcium indicator. 
These cells were treated similarly and used to measure autofluorescence. Cells were 
washed twice to remove any extracellular calcium indicator and resuspended in Hepes 
buffer at a cell density of 1 x 10^  cells ml ^ This was then transferred to a quartz 
cuvette, which contained a magnetic stirrer. 
2.8.3 Measurement of fura-2 fluorescence 
• \ 
Measurements of intracellular calcium were performed using a Perkin Ehner 
Luminescence Spectrometer LS 50B. The cuvette was maintained in a temperature 
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controlled waterjacket at 37�C. Samples were cyclically excited by wavelengths of 
340 and 380 nm, with switching at an interval of 0.25 sec. The resulting fluorescence 
was measured at the emission wavelength of 510 nm and data processed using the LS 
50B software package. The bandwidth of the excitation pathway was set at 10 nm, 
whereas the emission pathway bandwidth was 20 nm. At predetermined time points, 
with the aid of a Hamilton syringe, the stimulating agent (sPLA2 or anti-rat IgE) was 
applied to the mast cell suspension. Histamine release for each sample was directly 
determined by removing 250 fiL of the supernatant from the cuvette after the 
observation period was complete. This was immediately centrifuged and the 
procedure described in section 2.5 was followed. 
The following calibration procedure was used: cells were lysed with digitonin (100 fig 
ml_i) to generate the maximum fluorescence value (Smax) followed by Ca^ ^ chelation 
with EGTA/Tris (4 mM EGTA), to generate the minimum fluorescence value (S^J 
(Thomas & Delaville，1991). Calcium levels were calculated from the ratio of the 
fluorescence by using the following equation described by Grynkiewicz et al. (1985); 
[Ca2+]i (nM) = K, (S-S,J/(S_-S) x F ^ A o - b 。 -
where K^  is the dissociation constant for the ftira-2 Ca�+ complex and is equivalent to 
224 nM at 37°C. S^^ and S^^ are the ratios of the fluorescence when fura-2 is in the 
absence of Ca�+ and saturated with Ca:+ respectively. S is the experimental ratio and 
F380. free 丨 3^80. bound is thc mtio of fluoresccnce excited at 380 nm between free and 
saturating Ca^ ^ conditions. Autofluorescence values were obtained from cells not 
loaded with the dye by measuring the signal at 340 and 380 nm. Calibrations and 
autofluorescence measurements were performed daily. 
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Fluorescence measurements for all samples were made for 1 min before the addition 
of stimulus. Any increase in the fluorescence intensity following stimulus addition 
were related to this 1 min basal reference level. In all experiments fluorescence was 
measured for a sample of cells in the absence of any stimulus. It was observed that the 
fluorescence intensity increased with the passage of time. Therefore all measurements 
were corrected for this spontaneous increase in calcium. 
2.9 Cell counts 
Mast cell number and cell viability was determined for all mast cell populations with 
a haemocytometer. For an estimation of the percentage viability, 1 part of the cell 
suspension was stained with 1 part of Trypan blue (0.4 %) for 5 min at 37°C. Dead 
cells retain this dye and appear dark blue in colour. With regard to mast cell number, 
9 parts of the cell suspension were stained with 1 part of Alcian blue. The alcian blue 
dye contained 1 % Alcian blue, 1 % tween 20 and 0.9% NaCl in 0.5 M HC1. Staining 
was allowed to proceed for 5 min at 37°C. Mast cells retain this dye and appear bright 
blue in colour. Cell counting was performed within 15 min after staining. 
2.10 Data analysis 
All values are given as the means 士 standard error of the mean (SEM) for the number 
y 
(n) of experiments performed. Differences between groups of data were compared 
using Student's t tests (SIGMA plot). Significance was claimed when p < 0.05. 
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CHAPTER 3 




Mast cells and their derived mediators are known to play a central role in allergic 
reactions. Mediators such as histamine, PGDj and a variety of cytokines are released 
following cell activation. These mediators are known to cause many biological effects 
such as vasodilation, increased vascular permeability and cellular recruitment. Mast 
cells are associated with many chronic inflammatory conditions such as inflammatory 
bowel disease and rheumatoid arthritis. Besides mast cells, increased levels of the type 
n sPLA2 enzyme have also been detected in the synovial fluid and plasma of patients 
with these inflammatory diseases. The source of this enzyme is thought to include 
many inflammatory cells such as neutrophils, macrophages and mast cells. The 
association of elevated levels of the type II sPLA2 enzyme with inflammatory 
conditions suggested that it may also affect mast cells. Previous studies in the early 
1980's, showed that the sPLA2 purified from the porcine pancreas (classified as a type 
I sPLA2), caused mast cell secretion and this was blocked by PLAj inhibitors. It was 
proposed that PLA2 activation was involved in mast cell secretion. Therefore, the aim 
of this study was to investigate the effects of a type I and type II sPLA2 on mast cell 
reactivity. The sPLA2 purified from Naja naja venom and Crotalus altrox venom were 
chosen as examples of the type I and type II sPLA2 enzymes respectively. Rat 
peritoneal mast cells were chosen as a model due to their abundance and ease of 
isolation and purification. Histamine is immediately released from mast cells after 




The procedures described in chapter two were applied here 
PART 1: Effects of sPLA2-I on unstimulated rat peritoneal mast cells 
3.3 Results 
3.3.1 Effects of sPLAj-I on the spontaneous histamine release from RPMC 
Rat peritoneal mast cells were incubated with sPLAj-I for 10，20 and 30 min. 
Histamine release was induced by sPLAj-I (0.5 to 10 U ml'^ ) in a dose dependent 
manner (Fig 3.1). Cells incubated for 30 min released significantly more histamine 
than those incubated for 10 min (0.5 to 5 U ml'\ p < 0.05). sPLA2-I (5 U ml]) 
induced histamine release was 74.72 土 1.49% for the 30 min incubation compared to 
62.79 士 6.33% for the 10 min incubation. Concentrations between 0.5 and 1 U ml], 
incubated for 20 min, released significantly more histamine than the 10 min incubation 
(p ^ 0.05). 0.05 and 0.01 U ml'^  of sPLAj-I did not have any effect on the 
spontaneous histamine release. 
To eliminate the chance that any remaining functional cells such as macrophages or 
neutrophils were influencing the results, mast cells were purified. Similar results were 
obtained when purified mast cells were incubated with sPLA2-I (0.01 to 10 U ml'^ ). 
Histamine release was again observed dose dependently at all three time incubations 
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(Fig 3.2). Cells incubated for 20 and 30 min significantly released more histamine 
than those cells incubated for 10 min (1 to 10 U ml"\ p < 0.01). The maximum 
histamine release observed was 67.91 士 2.31% following a 30 min incubation 
compared with 48.32 士 3.92% for the 10 min incubation. Lower concentrations of 
sPLA2-I did not have any effect on the spontaneous histamine release. 
3.3.2 Time course of sPLA2-I induced histamine release 
Fig 3.3 illustrates the time course of sPLA2-I induced histamine release (1 and 0.1 U 
ml'^ ). With an sPLAj-I concentration of 1 U ml], histamine release was rapid within 
the first 5 minutes and plateaued after 10 minutes. The maximum histamine release 
observed was 79.85 士 2.69%. Whereas with 0.01 U ml"^  histamine release was slow 
and plateaued after 30 minutes of incubation, with a maximum release of 60.13 士 
4.83%. 
3.3.3 Effects of heat treated sPLA2-I on the spontaneous histamine release 
To further characterise the histamine releasing activity of sPLA2-I, the enzyme 
preparation was heated at 100°C for 30 min. When cells were incubated with this 
heated enzyme there was no histamine release observed (Fig 3.4). Lndeed the activity 
of the enzyme was significantly reduced when compared to the unheated enzyme (1 to 
y 
10Uml- i ,p -0 .05) . 
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3.3.4 Effects of antimycin A on sPLAj-I induced histamine release 
The removal of glucose from the incubation buffer did not reduce the histamine release 
induced by sPLA2-I or the classical mast cell secretagogue compound 48/80 (Table 
3.1). However substitution with the metabolic inhibitor antimycin A did significantly 
reduce histamine secretion at all sPLA2-I concentrations tested (p ^ 0.01). Antimycin 
A is an inhibitor of electron transfer between cytochrome b and c in the oxidative 
phosphorylation pathway (Ahmed et al., 1951). The spontaneous histamine release 
was comparable in all the incubation media. 
3.3.5 Effects of extracellular calcium on sPLAj-I induced histamine release 
Histamine release induced by sPLA2-I was significantly reduced in the absence of 
extracellular calcium (Fig 3.5) (0.01 to 1 U ml'\ p < 0.01). However, between 1 and 
10 U ml]，histamine release was observed in the absence of extracellular calcium, 
although it was significantly lower than the corresponding control. The maximum 
histamine release observed was 66.69 士 4.36% (control) compared with 14.55 土 
1.19% without calcium (10 U ml"^ ). Histamine release was totally abolished by 
pretreatment of the cells with the chelating agent EDTA. The spontaneous histamine 
release was unaffected by all these conditions. 
3.3.6 Effects of PLA】 inhibitors on sPLA2-I induced histamine release 
The effects of p-Bromophenacyl bromide ^7-BPB), mepacrine and aristolochic acid on 
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the histamine releasing activity of sPLA2-I were also studied. p-BPB inactivates snake 
venom PLA2 by alkylation of the histidine residue found in the catalytic site fVolwerk 
et aL, 1974; Roberts et al” 1977). The anti-malarial agent mepacrine is thought to 
inhibit PLA� hydrolysis by disrupting the lipid water interface required for optimal 
enzyme activity (Chang et aL, 1987b). Aristolochic acid derived from Aristolochia 
plant species inhibits snake venom PLA2 and human synovial fluid PLA2 in 
vitro (Vishwanath et aL, 1988). 
Table 3.2 shows the effect of different pretreatment times withp-BPB, mepacrine and 
aristolochic acid on sPLA2-I induced histamine release. sPLAj-I induced histamine 
release was significantly reduced by p-BPB at all pretreatment times investigated. A 
significant reduction was also observed with mepacrine and aristolochic acid. These 
inhibitors caused no significant alteration to the spontaneous histamine release. /7-BPB 
was the most potent of the inhibitors tested and this inhibitory effect was further 
investigated with 30 min being chosen as a suitable pretreatment time. 
Pretreatment of sPLAj-I (1 U ml]) with p-BPB, significantly decreased the induced 
histamine release in a dose dependent manner, at all concentrations examined, except 
at 0.1 fxM (Fig 3.6a). However, with an sPLA2-I concentration of 0.01 U ml'^ 
histamine release was only significantly reduced with 10 fjiM of;7-BPB (Fig 3.6b). 
y 
The effects of p-BPB on sPLA2-I induced histamine release from purified rat peritoneal 
mast cells were also examined. A 30 min pretreatment of sPLA2-I (0.1 U ml ) with 
p-BPB, significantly reduced the induced histamine release at concentrations of 1 and 
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10 |xM (Fig 3.7a). With an sPLA2-I concentration of 0.01 U ml \ histamine release 
was only significantly reduced with p-BPB concentrations of 1 and 10 ^M (Fig 3.7b). 
One of the hydrolysis products ofheteronemin (a scalarane found in many hido-Pacific 
sponges), 12-deacetyl-12-epi-scalaradial (12-epi-scalaradial) has been shown to inhibit 
the bee venom PLA� with an IQo of 0.2 />tM (Potts et al” 1992). Pretreatment of 
sPLA2-I (0.1 U ml_i) with 12-epi-scalaradial significantly decreased the induced 
histamine release dose dependently (Fig 3.8a). With the lower concentration of 
sPLA2-I of 0.01 U ml_i the reduction was dose dependent between 0.3 and 1.0 fjM (Fig 
3.8b). 
Methyl arachidonyl fluorophosphonate (MAFP) has been reported to be a potent 
irreversible inhibitor of cPLAj ^Iuang et al., 1994). It was shown to inhibit A23187 
induced LTB4 production in human neutrophils with an IC50 of 0.1 fiM. This cPLA2 
inhibitor did not have any inhibitory effect on the sPLA2-I induced histamine release 
from purified rat peritoneal mast cells (Fig 3.9a + b). 
3.3.7 Effects of sPLA2-I on PGD2 production 
Li a limited series of experiments (n = 3), the effects of sPLAj-I on PGD] production 
from purified rat peritoneal mast cells were also examined. Fig 3.10 shows that at the 
highest concentration tested, 1 U ml"\ there was an appreciable amount of PGD2 
produced (112.25 士 31.75 ng/10^ cells). Lower concentrations of sPLA2-I did not 
seem to have any effect on PGDj production. 
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3.3.8 Effects of sPLAj-II on the spontaneous histamine release from RPMC 
t i contrast to the type I sPLA2, when purified rat peritoneal mast cells were incubated 
with sPLA2-II (20 min), there was generally less than 10% of the total cellular 
histamine release observed (Fig 3.11). The highest release of about 10% was observed 
with 1 U ml'i. Similar results were obtained with both mixed and purified rat 
peritoneal mast cells (Fig 3.12). However, sPLA2-II concentrations greater than 1 U 
ml'i seemed to have an inhibitory effect on the spontaneous histamine release. 
3.3.9 Effects0fPLA2 inhibitors on sPLA2-II induced histamine release from 
purified RPMC 
Fig 3.13a illustrates the effects of a 30 min, p-BPB pretreatment on sPLA2-II (1 U ml_ 
1) induced histamine release. 1 and 10 fiM of p-BPB significantly reduced the low 
histamine release induced by sPLA2-II itself (10.09 土 0.97%). Fig 3.13b illustrates 
the effects of a 30 min, 12-epi-scalaradial pretreatment on sPLAj-n (1 U ml'^ ) induced 
histamine release. 0.6 and 1 fjM significantly reduced the low sPLA2-n induced 
histamine release. 
3.3.10 Effects of sPLA2-II on PGD! production 
y 
Fig 3.14 illustrates the effects of sPLA2-n on PGD2 production from purified rat 
peritoneal mast cells. PGD2 was generated in a concentration dependent manner from 
|
cells incubated with sPLAj-II for 20 min. The maximum PGD! produced was 41.19 
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Figure 3.1 Effects of sPLA2-I on the spontaneous histamine release from rat 
peritoneal mast cells. Cells were incubated with sPLAj-I (0.05 to 10 U mI'^ ) for 10 
(•)，20 ( • ) and 30 min ( • ) . The spontaneous histamine release was 7.13 士 0.69% 
(10 min), 8.42 士 0.54% (20 min) and 11.75 士 0.87% (30 min). Results are given 
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Figure 3.2 Effects of sPLA2-I on the spontaneous histamine release from purified rat 
peritoneal mast cells. Cells were incubated with sPLA2-I (0.01 to 10 U ml"^ ) for 10 
(•)，20 ( • ) and 30 min (•)• The spontaneous histamine release was 10.01 土 0.81 % 
(10 min), 13.32 士 1.38% (20 min) and 16.18 士 1.58% (30 min). Results are given 
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Figure 3.3 Time course of histamine release induced by sPLAj-I (0.1 ( • ) and 1 ( • ) 
U ml"^ ), from purified rat peritoneal mast cells. The spontaneous histamine release 
was 11.46 土 1.16% for the 1 min incubation and 13.39 士1.86% for the 40 min 
incubation. Results are given as the means 士 SEM for n = 4. 
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Figure 3.4 Effect of heat treated sPLAj-I (100�C，30 min) on the spontaneous 
histamine release from rat peritoneal mast cells. Cells were incubated with the heat 
treated enzyme ( • ) and the nonheat treated enzyme ( • ) for 10 min (0.05 to 10 U ml" 
1). The spontaneous histamine release was 6.92 士 1.20%. Results are given as the 
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Figure 3.5 Effects of extracellular calcium on sPLA2-I (0.001 to 10 U ml"^ ) induced 
histamine release from purified rat peritoneal mast cells. Cells were preincubated for 
5 min in Hepes buffer ( • ) , CMF Hepes buffer ( • ) and EDTA buffer ( • ) and then 
incubated with sPLA2-I for 10 min. The spontaneous histamine release was 10.48 土 
1.40%. Results are given as the means 士 SEM for n = 4-6. 
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Figure 3.6 (a + b) Effects of p-BPB on sPLAj-I induced histamine release from rat 
peritoneal mast cells. sPLAj-I (1 U ml'^  (a) and 0.01 U ml"^  (b)) was incubated with 
p-BPB for 30 min at 37°C before the addition of cells. ** = p ^ 0.01 when compared 
with control. The spontaneous histamine release was 10.56 土 0.38%. Values are 
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Figure 3.7 (a + b) Effects of p-BPB on sPLAj-I induced histamine release from 
purified rat peritoneal mast cells. sPLA2-I (0.1 U ml ^ (a) and 0.01 U ml'^  (b)) was 
incubated withp-BPB for 30 min at 37°C before the addition of cells. ** = p ^ 0.01 
when compared with control. The spontaneous histamine release was 10.21 士 0.85%. 
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Figure 3.8 (a + b) Effects of 12-epi-scalaradial on sPLA2-I induced histamine release from 
purified rat peritoneal mast cells. sPLAj-I (0.1 U ml'' (a) and 0.01 U ml'' (b)) was incubated 
with 12-epi-scalaradial for 30 min at 37°C before the addition of cells. ** = p < 0.01 and * 
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Figure 3.9 (a + b) Effects of MAFP on sPLA2-I induced histamine release from 
purified rat peritoneal mast cells. sPLAj-I (0.1 U ml'^  (a) and 0.01 U mt^  0?)) was 
incubated with MAFP for 30 min at 37°C before the addition of cells. The 
spontaneous histamine release was 11.33 土 0.79%. Results are given as the means 
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Figure 3.10 Effects of sPLAj-I on PGDj production from purified rat peritoneal mast 
cells. Cells were incubated with sPLA2-I for 20 min. As a positive control for PGDj 
production, cells were stimulated with anti-rat IgE for 10 min. Values are means 士 






L o - , 
I / 
r — I 
I 30 _ / 
I y . 
“ 1 5 - _ _ _ _ c r ^ 
• • m ^ 
• • » ^ i r ^ ^ k 
0 � ^ * 
I 1 1 1 1 
0.001 0.01 0.1 1 10 
Phospholipase A ! (Units ml'^) 
Figure 3.11 Effects of sPLAj-I and sPLAj-II on the spontaneous histamine release 
from purified rat peritoneal mast cells. Cells were incubated with sPLAj-I ( • ) and 
sPLA2-n ( • ) for 20 min (0.001 to 10 U mTi). The spontaneous histamine release was 
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Figure 3.12 Effects of sPLAj-H on the spontaneous histamine release from rat 
peritoneal mast cells. Cells were incubated with sPLA2-II (0.05 to 10 U ml"^ ) for 10 
( • ) ’ 20 ( • ) and 30 min ( • ) . The spontaneous histamine release was 7.31 土 1.15% 
(10 min), 8.67 土 0.73% (20 min) and 9.08 土 0.80% (30 min). Results are given as 
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Figure 3.13 (a + b) Effects of p-BPB (a) and 12-epi-scalaradial (b) on sPLA2-II 
induced histamine release from purified rat peritoneal mast cells. sPLAj-II (1 U ml"^ ) 
was incubated withp-BPB or 12-epi-scalaradial for 30 min at 37°C before the addition 
of cells. The spontaneous histamine release was 11.37 士 0.63%. ** = p ^ 0.01 when 
compared with control. Results are given as the means 士 SEM for n = 5-6. 
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Figure 3.14 Effects of sPLAj-H on PGDj production from purified rat peritoneal mast 
cells. Cells were incubated with sPLAj-H for 20 min. As a positive control for PGDj 
production, cells were stimulated with anti-rat IgE for 10 min. Values are means 士 
SEM for n = 4-5. 
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Table 3.1 Effects of glucose and antimycin A on the histamine release induced by 
sPLA2-I from rat peritoneal mast cells. Cells were preincubated in the various media 
for 20 min before the addition of sPLA2-I or Compound 48/80 (48/80). Values are 
means 士 SEM for n = 3-4. ** = p < 0.01 as compared to the appropriate control. 
Histamine release (% of total) 
Control Glucose free Antimycin A 
sPLA2-I 
10 Units mTi 73.0 士 1.4 70.9 士 1.7 15.0 士 2.2** 
5.0 Units mTi 72.2 士 1.3 67.7 士 2.4 14.4 士 1.7** 
2.5 Units ml-i 58.3 士 6.3 57.4 土 6.8 14.7 士 1.3** 
1.0 Unit ml-i 41.8 士 6.6 35.0 士 7.7 14.5 土 1.6** 
48/80 
1.0 fig mr^  61.3 士 2.0 60.6 ± 1 . 6 5 . 8 ± 4 . 3 * * 
0.25 fjLg ml-i 20.4 士 3.5 20.6 士 3.0 1.6 土 1.0* 
I 
73 
Table 3.2 Effects of p-BPB, mepacrine and aristolochic acid on sPLAj-I induced 
histamine release from rat peritoneal mast cells. sPLA2-I (1 U ml_i) was pretreated 
with 10 |jM of/7-BPB, mepacrine and aristolochic acid for 5, 15, 30 and 60 min at 
37°C. Cells were incubated for 20 min with inhibitor pretreated sPLAj-I. sPLAj-I 
induced histamine release was 45.96 土 3.79%. The spontaneous histamine release 
was 9.59 士 1.07%. ** = p < 0.01 and * = p ^ 0.05 as compared with control 
(45.96 土 3.79%). Values are means 士 SEM for n = 4-5. 
Histamine release (% of total) 
Time /7-BPB Mepacrine Aristolochic acid 
5 min 17.34 士 1.15** 34.29 士 3.55* 42.87 土 3.47 
15 min 16.04 士 1.23** 32.94 土 3.90* 38.39 土 4.57** 
30 min 15.91 士 2.12** 31.57 士 2.80** 35.41 土 2.52** 





3.4.1 Effects of sPLA2-I on RPMC 
The type I sPLA2 enzyme isolated from Naja naja venom caused the release of 
histamine from rat peritoneal mast cells dose dependently. These results are in 
agreement with previous observations where the sPLA2 enzyme isolated from Naja 
naja venom caused histamine release from rat peritoneal mast cells in a dose related 
manner (Choi etal., 1989; Nagai etal., 1991; Moreno etal” 1992; Lloret & Moreno, 
1993). Chi et al, (1982) also reported that the porcine pancreas PLA2 caused the 
rapid release of histamine from rat peritoneal mast cells. Histamine release occurred 
within 5 min and plateaued after 10 min (2 U ml"^ ). The histamine release observed 
here with 1 U ml"^  was also rapid within the first 5 min. The lower concentration of 
0.1 U ml] released histamine slowly and plateaued after 30 min. This is consistent 
with Choi et al (1989) who also observed a slow release of histamine within 15 
minutes. However the enzyme concentration they tested was 100 fold greater. 
Li the present study, the removal of calciumfrom the extracellular medium reduced the 
histamine releasing activity of sPLA2-I. The requirement for extracellular calciumhere 
suggests that the enzymatic activity of sPLAj-I may be involved in causing histamine 
release. Millimolar concentrations of extemal Ca^ ^ are required for the optimal 
enzymatic activity of sPLAj (Dennis, 1983). sPLA2-I may exert its effect by 
hydrolysing the mast cell phospholipid plasma membrane and generate a lipid 
metabolite which may be involved in the process of histamine secretion. Alternatively, 
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sPLA2-I may alter the mast cell plasma membrane structure through phospholipid 
hydrolysis. This could lead to an increased permeability to extracellular calcium ions. 
This influx of extracellular Ca�+ would lead to mast cell degranulation as Ca�+ plays 
an important role in the process of histamine secretion following cell activation 
(Pearce, 1985). 
sPLA2-I lost at least 90% of its histamine releasing ability when heated for 30 min at 
100°C, suggesting that the natural structure of the enzyme is required, either for its 
enzymatic activity, or for some specific interactions with the plasma membrane. 
However, these results appear to differ from Chi et al. (1982) who observed that the 
porcine pancreas sPLA2 (2 U ml'^ ) retained its mast cell degranulatmg activity when 
heated for 1 hour at 100�C. De Haas et al (1968) also reported that about 45% ofthe 
lipolytic activity of porcine pancreas sPLAj was retained after heat treatment for 1 
hour at 98°C. The differences observed here may be due to the different source of 
enzymes or differences in the assay conditions used. 
I 
The removal of glucose together with the inhibition of the oxidative phosphorylation ‘ 
pathway with antimycin A, significantly reduced the histamine releasing activity of 
sPLA2-I. An intracellular supply of ATP, is required to maintain the cells in a 
phosphorylated state, as protein phosphorylation plays a role in the secretory process 
(Gomperts, 1991). The requirement for ATP here would suggest that sPLA2-I required 
a metabolically active cell in order to mediate its histamine releasing effect and also 
suggested that sPLAj-I was having a specifc effect on the mast cell plasma membrane. 
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sPLA2-I may exert its effect by hydrolysing the mast cell phospholipid plasma 
membrane. To further investigate this, the effects of some PLA! inhibitors on sPLA2-I 
induced histamine release were examined. Several types of compounds have been 
reported to have PLAj inhibitory activity (for review see Chang et al., 1987b; Gelb et 
aZ., 1994) and some of these inhibitors work by competing with the phospholipid 
substrate for binding to the active site of the enzyme. It was observed here that both 
inhibitors, p-BPB and 12-epi-scalaradial, reduced the histamine release induced by 
sPLA2-I. Chi et al. (1982) also reported that the porcine pancreas PLAj induced 
histamine release from rat peritoneal mast cells was reduced following ;7-BPB 
treatment (100 fjM). p-BPB inactivates PLAj by alkylation ofthe histidine residue 
found in the catalytic site (Volwerk et al., 1974; Roberts et al.，1977). p-BPB has 
been shown to inhibit the PLAj isolated from Vipera russelli with an IC5�of 9 ^M 
CVallee et al.’ 1979). 12-epi-scalaradial is thought to inhibit PLA2 by imine formation 
between its aldehyde group and lysine residues in the PLAj enzyme and has been 
'：.； 
shown to inhibit the bee venom PLA2 with an IC50 of 0.2 fjM (Potts et al., 1992). 
Mepacrine and aristolochic acid also reduced the histamine releasing activity of sPLA2-
I at a concentration of 10 fjM. This is in agreement with Moreno et al. (1992), who 
i 
I also observed inhibition of histamine release induced by the sPLA2 isolated from Naja 
h 1 




respectively. Mepacrine is thought to work by altering the natural phospholipid 
substrate structure. It has been reported that large amounts of these inhibitors are 
a 
/ f required to produce significant inhibition of PLAj activity (Chang et aL, 1987b). 
.¢: 
1 ： Mepacrine (conc. > 0.2 mM) was reported to interact directly with the membrane 
j 
I 
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phospholipid structure of human platelets and erythrocytes (Dise et al.’ 1982). 
Moreno (1993) also observed that aristolochic acid (1 mM) inhibited the 5-
lipoxygenase enzyme involved in AA metabolism, t i order to minimise any non 
specific membrane interactions, the highest inhibitor concentration employed in these 
studies was 10 fM. t i the present study, both 12-epi-scalaradial andpBPB were more 
potent than mepacrine or aristolochic acid in inhibiting sPLAj-I induced histamine 
release. 
The histamine releasing activity of sPLAj-I was unaffected following treatment with 
the cPLA2 inhibitor MAFP. MAFP has been reported to inhibit A23187 induced LTB4 
production in human neutrophils with an IC50 of 0.1 /j,M (Huang et al” 1994). This 
suggested that the histamine release observed here was mediated by sPLAj-I itself. 
These observations with the various PLA� inhibitors, together with the requirement for 
ATP, extracellular Ca!+ and the native structure of the enzyme, would suggest that the 
enzymatic activity of sPLAj-I was in some way responsible for the observed histamine 
release. As more selective/specific sPLA2-I inhibitors become available the exact 
mechanism of action of sPLA2-I can be further investigated, 
• 
Hydrolysis of the plasma membrane phospholipid, by sPLA2-I may generate a lipid 
substance(s), such as a free fatty acid, a lysophospholipid or related metabolites, which 
may be responsible for the induced histamine release. This unknown lipid substance 
may promote fusion of the mast cell plasma membrane with the secretory granules 
during exocytosis. Lysophosphatidylcholine (lysoPC) has been reported to cause 
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membrane fusion, but only at high concentrations of 300 jLtg/ml (Poole et al.，1970). 
However, recent findings have modified this observation since lysophospholipids were 
shown to inhibit membrane fusion (Chemomordik et al.，1993). Further work is 
needed to clarify the role of lysophospholipids in membrane ftision. 
In resting platelets the outer layer of the plasma membrane is predominately occupied 
with neutral phospholipid such as phosphatidylcholine (PC) and sphingomyelin. The 
inner layer contains the negatively charged phospholipid, phosphatidylethanolamine 
(PE) and phosphatidyserine (PS) (Bevers et al., 1983). It is possible that this 
asymmetric lipid distribution may also exist in the plasma membrane of mast cells. 
sPLA2-I enzymes tend to display a phospholipid substrate specificity for PC and PE 
CVerheij et al., 1981). PC on the outer layer of the plasma membrane could be 
hydrolysed by sPLA2-I to yield a lipid substance. This lipid substance could then 
facilitate fusion between the plasma membrane and the secretory granules during 
exocytosis. LysoPC has been reported to inhibit mouse mast cell degranulation 
(Chemomordik et al” 1993). However, Martin & Lagunoff (1979) reported that the 
lysophospholipids, lysoPC, lysoPE and lysoPS all caused histamine release from rat 
peritoneal mast cells. Lysophospholipids are single chain amphiphiles and are capable 
of forming detergent micelles in aqueous media when suspended at concentrations 
above their critical micelle concentration (CMC). At and above the CMC, detergent 
� micelles lyse cells. Concentrations above 10 jitM of all three lysophospholipids were 
i required to cause histamine release independent of the presence of the stimulating 
？ 
i： agent, concanavalin A (con A). However, lysoPS also caused con A dependent 
i': 
I 




obtained with lysoPS was the result of differential actions on the mast cell membrane 
above and below its CMC. Below the CMC lysoPS interacts with the mast cell 
membrane in a noncytotoxic manner and potentiated con A induced histamine release, 
whereas above the CMC histamine was released in a cytotoxic manner. Although all 
three lysophospholipids caused substantial con A independent histamine release, this 
release was mediated through a cytotoxic mechanism. These observations would 
suggest that lysoPC does not seem to be responsible for the effects observed in the 
present study, but some other unidentified lipid metabolite may be involved. 
Alternatively, sPLA2-I may mediate its effect by binding to a specific binding site on 
the mast cell surface and simply act as a signalling molecule. sPLA2-I has been shown 
to regulate cell proliferation (Arita et al., 1991; Hanasaki & Arita, 1992) and induce 
contraction in isolated guinea pig lung parenchyma strips (Sommers et al., 1992; 
Kanemasa et al” 1992). These physiological effects are thought to be mediated 
through sPLA2-I receptor sites. sPLAj-I receptors have been identified and cloned 
from a variety of tissues and cells (Lambeau et al., 1994; Ishizaki et aL, 1994; Ancian 
et aL, 1995). These cloned receptors are homologous to the macrophage mannose 
receptor (Taylor et al., 1990) and the recently cloned DEC-205 receptor in dendritic 
cells (Jiang et aL, 1995). One characteristic of these receptors is their ability to 
intemalise upon ligand binding. Intemalisation following ligand binding has been 
reported for a number of cell surface receptors such as epidermal growth factor 
(Gorden et al., 1978), insulin (Goldfme, 1981) and D -^1 (Matsushima et al.’ 1986). 
These intemalised receptor-ligand complexes are then degraded in intracellular 
lysosomal compartments, titemalisation here could direct the action of sPLAj-I into 
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the mast cell following receptor binding. 
Binding of sPLA2-I to a specific binding site may lead to an intracellular signalling 
event which eventually leads to histamine secretion. Kishino et al. (1995) reported that 
the porcine pancreatic sPLA: augmented PGE2 production in rat mesangial cells. This 
effect was receptor mediated and did not require the enzymatic action of sPLAj-I. 
They found that incubation of rat mesangial cells with an enzymatically inactive mutant 
G30S, induced PGEj synthesis with the same potency as the wild-type porcine sPLAj-
I. Other enzymatically inactive mutants without receptor binding afFmity were without 
effect on PGE2 synthesis. Xing et al. (1995) also reported that short term exposure of 
NIH 3T3 cells to the porcine pancreatic sPLA2 did not generate any significant AA 
release from intact cells. However, AA generation was significantly increased 
following a 6 hour exposure. This effect was unaffected by p-BPB treatment. They 
proposed that this AA release was a receptor mediated event, t i the present study 
prior to AA generation mast cell degranulation may be facilitated through a receptor 
mediated process. 
s 
Arita & Hanasaki (1993) reported that rat peritoneal mast cells as well as platelets and 
macrophages did not display any specific binding for the porcine pancreas sPLAj. 
I These observations suggested that mast cells do not have any binding site for the 
sPLA2-I. However, this porcine pancreas sPLA2 binding site did not recognise the 
snake venom sPLA2 isolated from Naja naja venom (Ohara et al., 1995). Further 
work is needed to determine if binding sites for the type I sPLAj isolated from Naja 
naja venom are present on the surface of the mast cell plasma membrane. 
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The type I sPLA2 not only caused the release of histamine from rat peritoneal mast 
cells, but it also generated a significant amount of PGD2. Fonteh et al. (1994) also 
reported that treatment of mouse mast cells (BMMC) with 1 fig/ml of the sPLAj 
isolated from Naja naja venom for 4 min resulted in the selective release of AA for 
PGD2 and TXB2 production. Li this study, PGDj production was observed with an 
sPLA2 concentration of 1 U ml.i within 20 min. This PGD2 could be produced by 
hydrolysis of the membrane phospholipid (PC) to yield free AA. This free AA on the 
outside ofthe cell, could be rapidly taken up by the cell itself or some other cells and 
would then be available to the enzymes involved in AA metabolism inside the cell. 
Alternatively, if sPLA2-I was acting as a signalling molecule and was activating an 
intracellular signal transduction pathway, then PGD� could be generated by activation 
of the intracellular cPLA2. The high molecular weight cPLA2 has been detected in rat 
and mouse mast cell lines (RBL-2H3 and BMMC) (Murakami et al.，1992b; Nakatani 
et al.’ 1994a & b). This cPLA2 is thought to be responsible for liberating the AA 1 
involved in eicosanoid production following cell activation. Li addition to an increase | 
in the [Ca^ ]^j, which is involved in translocating the cPLA2 to the cellular membrane, , 
protein phosphorylation is also required for full activation of the cPLAj (Glover et al., 
1995; Hirasawa et al.，1995; for review see Clark et al.，1995). It has been reported 
that the cPLAj in mast cells becomes phosphorylated following IgE receptor 
crossUnkage (Nakatani et al” 1994a; Currie et al, 1994). Xing et al. (1995) reported 
that following a 6 hour exposure of NIH 3T3 cells to the porcine pancreatic sPLAj, a 
significant amount of AA was produced. This AA release was receptor mediated. 
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hi the present study, significant histamine release was observed with sPLA2-I 
concentrations greater than 1 U ml'^  and PGD2 production was only observed with an 
sPLA2-I concentration of 1 U ml ^ These effects were observed over a short time 
period of 20 min. The observations reported by Kishino et al. (1995) and Xing et al. 
(1995) required a long time span of 24 and 6 hours respectively and were receptor 
mediated, ki the present study sPLAj-I may mediate its effects through its catalytic 
site by hydrolysis of the mast cell plasma membrane phospholipid. This hydrolysis 
could alter the membrane structure and lead to an influx of extracellular ions such as 
I 
calcium, which can induce histamine secretion. The free AA from this lipid hydrolysis 
I 
I 
may be quickly metabolised by the cyclo-oxygenase enzyme to produce PGD2 Further | 
‘ i 
work is needed to determine the exact mechanism(s) of action of sPLA2-I on the ！ 
f 




3.4.2 Effects of sPLA2-II on RPMC f 
t' f I丨 
• 11 
i 
While the type I sPLAj isolated from Naja naja venom caused the release of histamine j 
from rat peritoneal mast cells, it was interesting that the type H sPLA! enzyme purified ^ 
from Crotalus altrox venom did not seem to have any effect. Lideed the histamine 
release observed was generally not greater than 10%. Murakamai et aL (1993a) 
observed that rat peritoneal mast cells incubated with the type II PLA2 purified from 
rat platelets (10 and 40 />tg ml"^ ) released histamine in a dose dependent manner. These 
concentrations were within the range examined in this study (0.4 to 40 fxg ml"^ ). 
Similarly, histamine release was also observed when rat peritoneal mast cells were 
incubated with the type II PLA2 purified from Crotalus durissus terrificus (5 U ml"^ ) 
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(Lloret & Moreno，1993). These differences maybe due to the different enzymes 
employed in the studies and methods of induction. LysoPS was added as a cofactor 
for histamine release and cells were isolated from Wistar rats in the studies by 
Murakamai et al. (1993). Lloret & Moreno (1993) used BSA as a cofactor for 
histamine release. La the present study lysoPS and BSA were not employed in the 
histamine release reaction. These differences in the experimental procedure may 
explain the different observations reported. 
Although cells usually released only about 10% histamine when incubated with the 
type II sPLAj, this release was reduced following pretreatment with the PLAj 
inhibitors, p-BFB and 12-epi-scalaradial. This would suggest that the catalytic site of 
the enzyme may be involved in causing the low histamine release observed here. The 
type II sPLA2 enzymes do display a phospholipid substrate specificity for PE and PS 
(Kudo et al.，1993). These phospholipid substrates are usually found in the irnier layer 
of the plasma membrane of resting platelets (Bevers et al.’ 1983). This may explain 
I 
why there was no significant release of histamine observed here with sPLAj-II, if its 
. * 
1 
effect is mediated through the hydrolysis of membrane phospholipid. < 
While sPLA2-II did not seem to produce any significant histamine release, PGDj was 
produced in a dose dependent manner. Murakami et al. (1991a & 1993a), observed 
that incubation of rat peritoneal mast cells with the type II sPLAj (0 to 20 jitg/ml) 
purified from rat platelets did not generate any significant amount of PGD2. The 
differences observed here, may again be due to the different experimental procedures 
employed in the various studies, as was discussed with the histamine results. The 
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observations here, would suggest that sPLA2-II may bind to a binding site on the mast 
cell plasma membrane, act as a signalling molecule and lead to the generation of 
PGD2. However no such sPLA2-II receptors have been identified on mast cells. 
It is possible that sPLA2-II may bind to the sPLA2-I receptor site with low affmity, 
Although Ca2+ is not required for receptor binding, the Ca 2+binding loop ofthe sPLAj 
enzyme which is essential for catalytic activity, is involved in interaction with the 
receptor site (Lambeau et al., 1995). The residues Gly-30 and Asp-49 which are 
conserved in all of the sPLAj enzymes sequenced so far (Davidson & Dennis, 1990)， 
are involved in the binding step (Lambeau et al., 1995). Li addition, Leu-31 is 
essential for receptor binding of the porcine pancreatic sPLA2 (Lambeau et al., 1995). 
Several different residues are found in position 31 in the other sPLAj sequences 
(Davidson & Dennis, 1990) and this may determine the binding affmity of the enzyme. 
Lambeau et al. (1994) reported that the cloned sPLA2-I receptor, like the native 
receptor in skeletal muscle membranes, binds the group II secreted PLA2, from ！ 
! 
platelets and synovial fluid with a K^  value of 0.8 士 0.2 nM where K^  represents the ！ 
！ 
equilibrium binding constant. This receptor also binds the group I porcine pancreas • 
sPLA2 with a higher K^  of 10 士 3 nM. Binding of sPLAj-II to such a site may lead 
to the activation of a signalling pathway or, upon binding sPLAj-H may undergo 
internalization. This could direct the action of sPLAj-II into the target cell. Lipid 
hydrolysis of the plasma membrane phospholipid could lead to a transient release and 
increase in free AA for the production of PGD2. Further work is needed to determine 
if binding sites for the group II sPLA2 exist on the surface of the mast cell plasma 
membrane. 
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Bevers et al (1983) reported that in activated platelets there appears to be a 
translocation of the inner phospholipid PE and PS to the outer layer of the plasma 
membrane. It is possible that in activated mast cells such a lipid translocation could 
also occur. This would make the phospholipid substrates PS and PE accessible to tiie 
sPLA2-n. The effect of the sPLA2 enzymes on stimulated mast cells was next 



















PART 2: Effects of sPLA2 on stimulated rat peritoneal mast cells 
3.5 Results 
3.5.1 Effects of sPLAj-I on histamine release from immunologically activated 
RPMC 
Preliminary experiments with a mixed population of rat peritoneal mast cells were • 
carried out to see if the sPLA2-I enzyme would have any effects on immunologically ! 
activated cells. Anti-rat IgE was used as the immunological stimulus at a 1/1,000 | 
»1 
dilution of the supplied stock. Cells were preincubated with sPLA2-I for 10 min •‘ 
！ 
subsequent to challenge with anti-rat IgE. Histamine release was then allowed to 
M 
proceed for a further 10 min. Non releasing concentrations of sPLA2-I between 0.05 !'： 
• i 
• ! 
and 0.5 U ml'^ significantly enhanced the anti-rat IgE induced histamine release dose ‘ 
f 
dependently (Fig 3.15). As illustrated in table 3.3 the experimentally observed j 
1 
histamine release induced by anti-rat IgE from sPLA2-I pretreated cells was far above j 
p 
the sum of the individual effects. Differences between the observed and additive 
effects were compared using paired Student's t tests. No significant enhancement was 
observed at concentrations higher than 0.5 U ml"^  as sPLAj-I itself was causing 
significant histamine release. 
r 
Experiments were repeated with purified rat peritoneal mast cells. Similarly cells were 
preincubated with sPLA2-I for 10 min before challenge with anti-IgE (1/100) for a 
further 10 min. Once again, concentrations of sPLAj-I between 0.005 and 1 U ml'\ 
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significantly enhanced the anti-IgE induced histamine release dose dependently (Fig 
3.16 and table 3.4). Concentrations greater than 1 U mTi caused significant histamine 
release alone, so enhancement was not observed. When purified cells were challenged 
with a non-releasing concentration of anti-IgE (1/10,000), a significant enhancement 
was again observed in a dose dependent manner (Fig 3.17 and table 3.5). 
3.5.2 Effects of preincubation time on sPLAj-I enhanced histamine release from 
immunologically activated RPMC 、 
• i 
I 
With an sPLA2-I concentration of 0.1 U ml"\ a significant enhancement was observed | 
with cells preincubated with the enzyme for 10 min, when compared with 1 and 5 min ‘ 
• 
t f 
(p ^ 0.05). The longer activation time (10 min) with anti-IgE also produced a more ‘ 




3.5.3 Effects of p-BPB on sPLAj-I enhanced histamine release from ‘ 
i 
1 
immunologically activated RPMC 1 
I 
In order to characterise the mechanism of the enhanced anti-IgE induced histamine 
release, the effects of ;7-BPB pretreatment on sPLA2-I were investigated. It was 
observed that p-BPB itself reduced the anti-rat IgE induced histamine release (Table 
‘3.6). Cells were incubated with p-BPB for 10 min and subsequently challenged with 
• \ 
anti-rat IgE for a further 10 min. These cells released less histamine than the 
corresponding controls. p-BPB reduced the histamine release induced both by sPLA2-I 
and anti-IgE. However a reduction of the enhanced histamine release was only 
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observed withp-BPB concentrations of 1 and 10 fjiM with 0.1 U ml"^  of sPLA2-I as 
illustrated in table 3.7a. Enhancement was 'determined by comparing the 
experimentally observed histamine release with the sum of the individual effects in the 
presence ofj^-BPB. The enhanced IgE induced histamine release was not reduced with 
the lower concentrations of p-BPB tested (0.01 and 0.1 pcM). With the lower sPLA^-I 
concentration of0.01 U ml"\ a significant reduction was again observed with 1 and 10 
|jM 0f/7-BPB (Table 3.7b). 
3.5.4 Effects of 12-epi-scalaradial on sPLAj-I enhanced histamine release from 
immunologically activated RPMC 
12-epi-scalaradial was similar to p-BPB in that the histamine release induced by anti-rat 
IgE was significantly reduced (Table 3.6). Table 3.8a & b shows the effect of 12-epi-
scalaradial on the enhancing activity of sPLA2-I. The sPLA2-I (0.1 U ml'^ ) enhanced 
: ！ 
histamine release was significantly reduced with 0.6 and 1 fiM of 12-epi-scalaradial. j 
: ‘ 
Similar reductions were also observed with 0.01 U ml"^  of sPLA2-I. | 
• 
i! j: ^ 
5, 
I 
3.5.5 Effects of MAFP on sPLA2-I enhanced histamine release from 
immunologically activated RPMC 
Fig 3.19a & b shows that the sPLAj-I enhanced histamine release was unaffected by 
pretreatment with the cPLA! inhibitor MAFP. Table 3.6 also shows that MAFP had 
no effect on anti-IgE induced histamine release from purified rat peritoneal mast cells. 
1' 
； , 
89 ;| i 
3.5.6 Effects of sPLA2-I on PGD^ production from immunologically activated 
RPMC 
Cells were preincubated for 10 min with sPLAj-I and subsequently challenged with 
anti-rat IgE (10 min). Both histamine and PGDj measurements were made. Fig 3.20a 
and table 3.9a show that histamine release was significantly enhanced with 0.1 and 1 
U ml_i of sPLA2-I. However this enhancement was not observed with the 
corresponding PGDj produced (Fig 3.20b and table 3.9b). Although a significant • 
I 
enhancement of PGD2 production was observed with an sPLA2-I concentration of 0.01 ^ 
U ml"\ it should be noted here that the number of observations is three and more | 
^ 




3.5.7 Effects of flurbiprofen and zileuton on sPLAj-I induced histamine release | 
|i 





Fig 3.21a & b shows that the cyclo-oxygenase inhibitor flurbiprofen had no inhibitory ！ 
effect on sPLAj-I induced histamine release. Flurbiprofen was also without effect on 
the enhanced histamine release induced by anti-IgE (Fig 3.22a & b). The effects of 
zileuton, a reversible inhibitor of 5-lipoxygenase, were also examined (Carter et al., 
1991). An IC50 value of 0.8 /xM was reported by Bell et al. (1993) in blocking 
ionophore induced LTB4 production from purified rat peritoneal mast cells. Zileuton 
was without effect on sPLAj-I induced histamine release OFig 3.23a). Zileuton also 
had no inhibitory effect on the enhancing activity of sPLAj-I (Fig 3.23b). 
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3.5.8 Effects of sPLAj-II on histamine release from immunologically activated 
RPMC 
Although sPLA2-II did not have any significant effect on the spontaneous histamine 
release, a significant enhancement of histamine release was observed in the presence 
of anti-IgE (Fig 3.24 and table 3.10). Concentrations of sPLAj-II between 0.005 and 
5 U ml'i showed a synergistic effect on the anti-rat IgE induced histamine release. 
However at the highest concentration of 10 U m l � t h e enhancing activity was 
diminished, tideed the histamine released in the presence of sPLA2-II was 
insignificantly different from that induced by anti-IgE alone. These preliminary 
experiments were performed with a mixed population of rat peritoneal mast cells. 
A similar enhancement was again observed with purified cells (Fig 3.25 and table 
3.11). This synergistic effect was observed at all sPLA2-II concentrations examined. 
However with an sPLA2-n concentration of 10 U ml"\ the enhanced histamine release 
was lower than that observed with 1 U ml'\ The histamine release observed was 52.96 
i 
士 3.68% (10 U mTi) compared with 63.38 士 4.03% at a concentration of 1 U ml ^ 
Similarly when a non releasing concentration of anti-IgE (1/10,000) was used to 
activate sPLAj-II preincubated cells, this synergistic effect was again observed (Fig 
3.26 and table 3.12). This enhanced histamine release was one fold lower with 10 U 





3.5.9 Effects of preincubation time on sPLAj-H enhanced histamine release from 
immunologically activated RPMC 
With an sPLA2-n concentration of 0.1 U ml'\ enhancement of anti-IgE induced release 
was observed at all preincubation times tested. There was no difference observed with 
the two activation times with anti-IgE (Fig 3.27a & b). 
3.5.10 Effects of p-BPB on sPLA2-II enhanced histamine release from • 








reduction of the enhanced histamine release was observed at p-BPB concentrations of � 
n 
1 and 10 f M with 1 U ml"^  of sPLA2-II (Table 3.13). | 
f 
3.5.11 Effects of 12-epi-scalaradial on sPLAj-U enhanced histamine release from . 
i 
immunologically activated RPMC \ 
I 
Table 3.14 shows the effect of 12-epi-scalaradial on the enhancing activity of sPLA2-n. 
The sPLAj-H (1 U mT) enhanced histamine release was significantly reduced with 0.6 
and 1 jLtM of 12-epi-scalaradial. 
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3.5.12 Effects of MAFP on sPLAj-II enhanced histamine release from 
immunologically activated RPMC 
Fig 3.28 shows that the sPLA2-II enhanced histamine release was unaffected by 
pretreatment with the cPLA2 inhibitor MAFP. 




Fig 3.29a & b shows the effect of sPLA2-II preincubated cells activated by anti-rat IgE j 
f 
on PGD2 production and histamine release. Although anti-rat IgE induced histamine ?' 
j 
ji 
release was significantly enhanced dose dependently, PGDj production was only 1 
n| 




3.5.14 Effects of flurbiprofen and zileuton on sPLA2-II induced histamine release , 
and enhanced histamine release from RPMC , 
1 * 
Fig 3.30a & b shows that flurbiprofen had no inhibitory effect on sPLAj-II induced 
histamine release and was also without effect on the enhanced histamine release from 
purified rat peritoneal mast cells. Zileuton was also without effect on sPLA2-II 
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Figure 3.15 Effects of sPLA2-I on anti-rat IgE induced histamine secretion from rat 
peritoneal mast cells. Control cells were incubated with sPLA2-I (0.01 to 10 U ml"^ ) 
for 20 min ( • ) . Anti-rat IgE stimulated cells were pretreated with sPLA2-I for 10 min 
and stimulated for a further 10 min with anti-rat IgE ( • ) . Anti-rat IgE (1/1,000) 
induced histamine release was 7.48 士 3.66% (—). The spontaneous histamine release 
was 5.89 士 0.52%. Results are given as the means 士 SEM for n = 3-5. 
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Figure 3.16 Effects of sPLAj-I on anti-rat IgE induced histamine secretion from 
purified rat peritoneal mast cells. Control cells were incubated with sPLAj-I (0.005 
to 10 U ml-i) for 20 min (•) . Anti-rat IgE stimulated cells were pretreated with 
sPLA2-I for 10 min and stimulated for a further 10 min (•)• Anti-rat IgE (1/100) 
r 
induced histamine release was 33.57 土 1.70% (—). The spontaneous histamine 
• \ 
release was 8.73 士 0.91%. Results are given as the means 土 SEM for n = 5-6. 
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Figure 3.17 Effects of sPLAj-I on anti-rat IgE induced histamine secretion from 
purified rat peritoneal mast cells. Control cells were incubated with sPLA2-I (0.005 
to 10 U ml"^ ) for 20 min (•)• Anti-rat IgE stimulated cells were pretreated with 
sPLA2-I for 10 min and stimulated for a ftoher 10 min ( • ) . Anti-rat IgE (1/10,000) 
induced histamine release was 5.85 士 0.76% (—)• The spontaneous histamine release 
was 8.73 士 0.91%. Results are given as the means 土 SEM for n = 4-7. 
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Figure 3.18 Effects of preincubation time with sPLAj-I (0.1 U ml'^ ) on anti-rat IgE 
(1/3,000) induced histamine secretion from purified rat peritoneal mast cells. Control 
cells were incubated with sPLAj-I (•)• Anti-rat IgE stimulated cells were pretreated 
with sPLA2-I for 1，5 and 10 min and subsequently challenged for 5 min (a) or 10 min 
0)) ( • ) . Anti-rat IgE induced histamine release was 3.05 士 1.36% (a) and 3.38 士 
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Figure 3.19 (a + b) Effects of MAFP on anti-rat IgE stimulated secretion from 
sPLA2-I pretreated purified rat peritoneal mast cells. sPLA2-I (0.1 (a) and 0.01 (b) U 
ml'^ ) was incubated with MAFP for 30 min at 37°C before the addition of cells. Anti-
IgE (1/3,000) induced histamine release was 9.99 士 2.68%. The spontaneous 
histamine release was 11.33 土 Q.79%, Results are given as the means 士 SEM for n 
= 5 . 
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Figure 3.20 (a + b) Effects of sPLA2-I on anti-IgE induced (a) histamine secretion 
and 0)) PGD2 production from purified rat peritoneal mast cells. Control cells were 
incubated with sPLA2-I (0.001 to 1 U mT) for 20 min ( • ) . Anti-IgE stimulated cells 
were pretreated with sPLAj-I for 10 min and stimulated for a further 10 min ( • ) . 
Anti-rat IgE (1/100) induced histamine release was 14.14 士 0.67% (—) and PGD2 
production was 17.67 士 5.12 ng/10^ cells. The spontaneous histamine release was 




^ 40 ~ T 
! i ^ J L 
0 T T 
e 30 - r n r n 
<3J 英 p^  
^ 




» 10 -w 
« 
0 PLA^ 0.01 0.1 1 10 I 
sPLA^-I + Flurbiprofen (jiM) ！ 
(b) 丨 
50 n !i 
J ！� 
,'I ” 
3 40 - 1 
2 |1 ^ � 
6 3 0 - 丨 
4^  V3 CS J|J 
13 I 
S 2 0 - 丁 T 
.S r ^ T r_I_i 丨 
S I 
CQ ( 
1 1 0 -
X 
0 PLA^ 0.01 0.1 1 10 
sPLA2-I + Flurbiprofen (^iM) 
y 
Figure 3.21 (a + b) Effects of flurbiprofen on sPLA2-I induced histamine release 
from sPLA2-I pretreated purified rat peritoneal mast cells. Cells were preincubated 
with flurbiprofen for 15 min at 37°C before incubation with sPLA2-I (0.1 U ml_i (a) 
and 0.01 ¢)) U ml'^ ) for 20 min. The spontaneous histamine release was 13.99 士 
1.76%. Results are given as the means 土 SEM for n = 4. 
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Figure 3.22 (a + b) Effects of flurbiprofen on anti-rat IgE stimulated secretion from 
sPLAj-I pretreated purified rat peritoneal mast cells. Cells were preincubated with 
flurbiprofen for 15 min at 37°C before incubation with sPLA2-I (0.1 U ml'^  (a) and 
0.01 (b) U ml-i) for 10 min. Cells were stimulated with anti-IgE (1/3,000) for a 
further 10 min. Anti-IgE induced histamine release was 10.61 士 1.12%. The 
spontaneous histamine release was 13.99 土 1.76%. Results are given as the means 士 
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Figure 3.23 (a + b) Effects of zileuton on (a) sPLAj-I induced histamine release and 
(b) anti-rat IgE stimulated secretion from sPLAj-I pretreated purified rat peritoneal 
mast cells. Cells were preincubated with zileuton for 15 min at 37°C before 
incubation with sPLAj-I (0.01 U mT). Cells were stimulated with anti-IgE (1/3,000) 
for a further 10 min. Anti-IgE induced histamine release was 13.58 土 4.77%. The 
spontaneous histamine release was 12.00 土 0.95%. Results are given as the means 士 
SEM for n =5. 
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Figure 3.24 Effects of sPLA2-II on anti-rat IgE induced histamine secretion from rat 
peritoneal mast cells. Control cells were incubated with sPLAj-H (0.001 to 10 Uml"^ ) 
for 20 min (•) . Anti-rat IgE stimulated cells were pretreated with sPLAj-H for 10 min 
and stimulated for a further 10 min with anti-rat IgE (•)• Anti-rat IgE (1/1,000) 
induced histamine release was 16.89 士 6.97% (—). The spontaneous histamine 
release was 7.55 士 0.84%. Results are given as the means 土 SEM for n = 5-6. 
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Figure 3.25 Effects of sPLA2-II on anti-rat IgE induced histamine secretion from 
purified rat peritoneal mast cells. Control cells were incubated with sPLA2-n (0.005 
to 10 U ml"^ ) for 20 min (•) . Anti-rat IgE stimulated cells were pretreated with 
sPLA2-II for 10 min and stimulated for a fUrther 10 min ( • ) . Anti-rat IgE (1/100) 
induced histamine release was 31.37 士 2.30% (—). The spontaneous histamine 
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Figure 3.26 Effects of sPLAj-H on anti-rat IgE induced histamine secretion from 
purified rat peritoneal mast cells. Control cells were incubated with sPLAj-H (0.005 
to 10 U ml"^ ) for 20 min (•) . Anti-rat IgE stimulated cells were pretreated with 
sPLA2-n for 10 min and stimulated for a further 10 min ( • ) . Anti-rat IgE (1/10,000) 
induced histamine release was 5.17 土 0.54% (—). The spontaneous histamine release 
was 7.73 士 0.48%. Results are given as the means 士 SEM for n = 4-7. 
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Figure 3.27 Effects ofpreincUbation time with sPLAj-U (0.1 U ml-丨）on anti-rat IgE (1/3,000) 
induced histamine secretion from purified rat peritoneal mast cells. Control cells were 
incubated with sPLAj-II ( • ) . Anti-rat IgE stimulated cells were pretreated with sPLA2 -I for 
1, 5 and 10 min and subsequently challenged for 5 min (a) or 10 min (b) ( • ) . Anti-rat IgE 
induced histamine release was (a) 3.05 土 1.36% and (b) 3.38 士 1.76% (—). Results are 
given as the means 土 SEM for n = 4. 
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Figure 3.28 Effects of MAFP on anti-rat IgE stimulated secretion from sPLAj-II 
pretreated purified rat peritoneal mast cells. sPLA2-II (1 U ml_i) was incubated with 
MAFP for 30 min at 37°C before the addition of cells. Anti-rat IgE (1/3,000) induced 
histamine release was 9.92 士 1.82%. The spontaneous histamine release was 10.77 
土 0.66%. Results are given as the means 士 SEM for n = 3-4 
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Figure 3.29 (a + b) Effects of sPLA2-II on anti-rat IgE induced (a) histamine secretion and 
¢0 PGD2 production from purified rat peritoneal mast cells. Control cells were incubated with 
sPLA2-n (0.001 to 1 U ml-i) for 20 min ( • ) . Anti-rat IgE stimulated cells were pretreated with 
sPLA2-II for 10 min and stimulated for a further 10 min ( • ) . Anti-rat IgE (1/100) induced 
histamine release was 27.33 土 1.29% (—) and PGDj production was 33.19 土 6.73 ng/10^ 
cells. The spontaneous histamine release was 10.70 土 1.77%. Results are given as the means 
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Figure 3.30 (a + b) Effects of flurbiprofen on (a) sPLA2-n induced histamine release 
and (b) anti-rat IgE stimulated secretion from sPLA2-n pretreated purified rat 
peritoneal mast cells. Cells were preincubated with flurbiprofen for 15 min at 37°C 
before incubation with sPLAj-II (0.01 U ml'^ ). Cells were stimulated with anti-IgE 
(1/3,000) for a further 10 min. Anti-IgE induced histamine release was 5.72 土 
1.30%. The spontaneous histamine release was 11.88 士 0.52%. Results are given 
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‘Figure 3.31 (a + b) Effects of zileuton on (a) sPLAj-H induced histamine release and 
0>) anti-rat IgE stimulated secretion from sPLAj-II pretreated purified rat peritoneal 
mast cells. Cells were preincubated with zileuton for 15 min at 37°C before 
incubation with sPLA2-II (0.01 U ml"^ ). CeUs were stimulated with anti-IgE (1/3,000) 
for a further 10 min. Anti-IgE induced histamine release was 8.05 士 1.36%. The 
spontaneous histamine release was 10.95 士 1.69%. Results are given as the means 
土 SEM forn = 3. 
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Table 3.3 Comparison between histamine release induced by anti-rat IgE from sPLAj-
I pretreated rat peritoneal mast cells with the calculated combined histamine release 
induced by sPLA -^I and anti-rat IgE. Anti-rat IgE induced histamine release was 7.48 
士 3.66%. * = p < 0.05 as compared with the calculated combined value. Values are 
means 士 SEM for n = 3-5. 
Histamine release (% of total) 
sPLA2-I [sPLA2-I + IgE] [sPLA2-q + PgE] 
10 Units ml-i 80.70 土 1.46 89.26 土 5.22 
5.0 Units ml-i 78.36 土 1.72 82.65 土 4.77 
1.0 Unit ml-i 62.95 士 4.45 46.29 士 7.40 
0.5 Units ml-i 54.18 士 6.29* 25.21 士 3.78 
0.25 Units ml'^  45.82 士 6.34* 16.49 士 2.59 
0.1 Units ml-i 37.51 士 8.62* 15.00 士 4.24 
0.05 Units ml-i 34.00 土 6.71* 13.02 士 3.70 
0.01 Units nU-i 21.63 士 8.00 6.35 士 1.96 
[sPLA2-I + IgE] = histamine release induced by anti-rat IgE from sPLA2-I pretreated 
cells as observed in the experiment. 
[sPLA2-I] + [IgE] = combined histamine release, calculated by adding the release 
induced by sPLAj-I alone to that induced by anti-rat IgE alone for each individual 
experiment. 
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Table 3.4 Comparison between histamine release induced by anti-rat IgE f rom sPLAj-
I pretreated pur i f ied rat peritoneal mast cells wi th the calculated combined histamine 
release induced by sPLA2-I and anti-rat IgE. Anti-rat IgE induced histamine release 
was 33.57 土 1 . 7 0 % . * * = p < 0.01 and * = p 么 0.05 as compared w i th the 
calculated combined value. Values are means 士 SEM for n = 5-6. 
Histamine release (% o f total) 
sPLA2-I [sPLA2-I + IgE ] [sPLA2-q + PgE] 
10 Units ml_i 81.08 士 0.66 101.27 士 2.40 
7.5 Units ml-i 81.39 士 0.93 99.57 士 3.45 
5.0 Units ml_i 81.02 士 0.68 99.49 士 3.14 
2.5 Units ml-i 80.65 士 0.86 89.36 士 2.11 
1.0 Uni t ml_i 75.88 士 0.90* 66.41 士 2.78 
0.5 Units ml-i 73.09 士 1.63** 52.83 土 2.64 
0.25 Units ml'^ 69.72 士 3 .16** 48.80 士 1.98 
0 .1 Units mTi 66.76 士 2 .76** 50.00 士 1.22 
0.05 Units ml-i 65.82 士 2 .54** 45.50 士 1..22 
0.025 Units ml"^ 61.17 土 3 .64** 43.14 士 2.02 
0.01 Units ml-i 56.58 士 2 .73** 41.74 士 2.51 
0.005 Units m l ] 53.94 士 2 .72** 40.96 士 2.91 
[sPLA2-I + IgE] = histamine release induced by anti-rat IgE f rom sPLAj - I pretreated 
cells as observed in the experiment. 
[sPLA2-I] + [IgE] = combined histamine release, calculated by adding the release 
induced by sPLAj - I alone to that induced by anti-rat IgE alone for each individual 
experiment. 
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Table 3.5 Comparison between histamine release induced by anti-rat IgE f rom sPLAj -
I pretreated pur i f ied rat peritoneal mast cells w i th the calculated combined histamine 
release induced by sPLA^-I and anti-rat IgE. Anti-rat IgE induced histamine release 
was 5.85 土 0.76%. * * = p < 0.01 and * = p ^ 0.05 as compared wi th the calculated 
combined value. Values are means 士 S E M for n = 4-7. 
Histamine release (% of total) 
sPLA2- I [sPLA2-I + I gE ] [sPLA2-q + PgE] 
10 Units ml_i 76.47 士 1.09 72.05 土 2.48 
7.5 Units mTi 77.96 士 1.09 71.61 士 2.28 
5.0 Units ml-i 77.62 士 1.05 70.84 士 2.54 
2.5 Units ml_i 67.70 士 4.64 60.69 士 2.76 
1.0 Uni t ml-i 52.76 士 6.04* 37.68 士 3.76 
0.5 Units ml_i 45.32 士 4 .96** 24.87 土 0.86 
0.25 Units ml_i 38.91 士 0.25* 21.71 士 0.80 
0.1 Units ml_i 40.69 士 5.56* 18.83 土 0.47 
0.05 Units mTi 36.45 土 6.43* 14.96 士 1.07 
0.025 Units ml"^ 33.04 土 5.18* 14.98 士 1.24 
I 
0.01 Units ml-i 27.26 士 4.56* 12.49 土 0.67 
0.005 Units m l ] 27.54 士 4 .87** 11.89 土 0.87 
[sPLAj - I + IgE] = histamine release induced by anti-rat IgE from sPLA2-I pretreated 
cells as observed in the experiment. 
[sPLA2-I] + [IgE] = combined histamine release, calculated by adding the release 
induced by sPLAj - I alone to that induced by anti-rat IgE alone for each individual 
experiment. 
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Tab le 3.6 Effects o f 12-epi-scalaradial, p-BFB and M A F P on histamine release 
induced by anti-rat IgE f rom pur i f ied rat peritoneal mast cells. Cells were 
preincubated w i th 12-epi-scalaradial，p-BPB and M A F P for 10 m in before activation 
w i th anti-rat IgE. * * = p ^ 0.01 as compared w i th the appropriate control. Values 
are means 士 SEM. 
His tamine release (% o f total) 
12-epi-scalaradial ptM (n = 13) 
C o n t r o l 0 .01 f i M 0 . 1 / ^ M 0.3 f j iM 0.6 f j iM I f M 
9 . 4 7 士 1.32 6.78 士 2.48 5 . 8 8 ± 1 . 4 6 * * 2 . 3 4士 0 . 8 5 * * 0 . 3 7士 0 . 2 1 * * 0 . 1土 0 . 0 7 * * 
/7-bromophenacyl bromide / iM (n = 9) 
C o n t r o l 0.01 ^tM 0.1 ^ M 1 f j iM 10 ^ M 
8 . 0 9 士 1.03 8.70 土 1.07 6 . 4 3 ± 1 . 2 4 * * 2 . 2 2土 0 . 6 8 * * 0 . 3 8 ± 0 . 1 5 * * 
M e t h y l arachidonyl fluorophosphonate | i M (n = 9) 
Con t ro l 0.001 ^ M 0.01 ^tM 0.1 /^M 1 p M 




Table 3 .7 (a + b) Comparison between histamine release induced by anti-rat IgE from 
sPLA2-I pretreated pur i f ied rat peritoneal mast cells w i t h the calculated combined 
histamine release induced by sPLA^-I and anti-IgE in the presence o f p-BPB. sPLA2-I 
concentrations tested were (a) 0.1 U ml"^ and (b) 0.01 U m i " ^ * * = p ^ 0.01 as 
compared w i t h the calculated combined value. Values are means 土 S E M for n = 3 A . 
Table 3.7 a Histamine release (% of total) 
P - B P B [sPLA2-I + I g E ] [sPLA2-q + P g E ] 
0 .01 /xM 52.06 士 2 .14 * * 28.20 ± 3 . 0 1 
0 .1 AtM 42.53 士 3 .09* * 22.24 士 2.92 
1.0 ^ M 17.35 士 2.33 12.47 士 2.87 
10 ^ M 5.21 士 2.13 3.48 土 1.90 
Table 3.7 b Histamine release (% of total) 
夕-BPB [sPLA2-I + I gE ] [sPLA2-q + PgE] 
0 .01 f j iM 29.47 士 2 .87* * 17.73 士 2.11 
0 .1 iLcM 26.29 士 3 .68** 14.53 士 2.53 
1.0 |xM 1 0 . 9 1 ± 1.93 7.70 士 2 . 4 6 
10 jLcM 3.33 士 1.32 1.89 士 0.87 
[sPLA2-I + IgE] = histamine release induced by anti-rat IgE from sPLA j - I pretreated 
cells i n the presence of p -BPB as observed in the experiment. 
[sPLA2-I] + [ IgE] = combined histamine release, calculated by adding the release 
induced by sPLA2-I alone to that induced by anti-rat IgE alone in the presence o f p-
BPB for each individual experiment. 
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Tab le 3.8 (a + b) Comparison between histamine release induced by anti-rat IgE 
from sPLA2-I pretreated purif ied rat peritoneal mast cells wi th the calculated combined 
histamine release induced by sPLA2-I and anti-rat IgE in the presence o f 12-epi-
scalaradial. sPLA2-I concentrations tested were (a) 0.1 U m l ^and G)) 0.01 U ml"^ 
* = p ^ 0.05 as compared wi th the calculated combined value. Values are means 士 
S E M for n = 3-7. 
Tab le 3.8 a Histamine release (% o f total) 
12-epi-scalaradial [sPLA2-I + IgE ] [sPLA^-q + PgE] ； 
0.1 fjM 35.13 士 3.70* 18.71 士 1.53 ‘ 
0 . 3 f M 2 1 . 4 1 土 3 . 3 8 * 1 0 . 6 2 土 2 . 7 0 
0.6jitM 5 . 2 1 士 1 . 6 0 1 . 7 3 土 0 . 8 7 
1.0 ixM 4 .10士 1.09 0.92 士 0 . 6 3 ‘ 
mm^m^^^^^^mmnm^^^^m^m^mm^mmmmm^m^mmm^^^^^^^^^^^^^^^mmmmm^mimmmmm^^mm^^^^^^^^^^mmmmmmmmmmm^mi^^^^^^^^^^m^^^^^^^mmm^^^^^^^mmtm^^^mmm^t^^^^^mmt^^^^^^^^^^ 
! 
Table 3.8 b Histamine release (% o f total) 
12-epi-scalaradial [sPLA2-I + IgE] [sPLA2-ri + PgE] 
0.1 ixM 21.87 士 2.45* 12.47 土 1.20 | 
• i 
0.3 fM 11.79 士 2.00* 4.90 土 2.13 
0 . 6 fxM 1.88 士 0 . 8 4 0 . 5 5 土 0 . 4 2 
1 . 0 fiM 1 . 3 6 土 0 . 5 1 0.13 士 0.13 
[sPLAj- I + IgE] = histamine release induced by anti-rat IgE from sPLA2-I pretreated 
cells in the presence of 12-epi-scalaradial as observed in the experiment. 
[sPLA2-I] + [IgE] = combined histamine release, calculated by adding the release 
induced by sPLA2-I alone to that induced by anti-rat IgE alone in the presence o f 12-
epi-scalaradial for each individual experiment. 
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Table 3.9 (a + b) Comparison between (a) histamine release and (b) PGDj 
production, induced by anti-rat IgE f rom sPLA2-I pretreated purif ied rat peritoneal 
mast cells w i th the calculated combined values f rom sPLA2-I and anti-rat IgE. Anti-rat 
IgE induced histamine release was 14.14 士 0.67% and PGD! production was 17.67 
土 5.12 ng/106 ceUs. * * = p < 0.01 and * = p < 0.05 as compared with the calculated 
combined value. Values are means 土 SEM for n = 3. 
Table 3.9 a Histamine release (% of total) 
sPLA2-I [sPLA2-I + IgE] [sPLA2_q + PgE] 
1 Uni t ml-i 64.99 士 2 .00** 29.55 士 5.10 
0.1 Units ml-i 36.39 士 6.79* 15.94 士 1.88 
0.01 Units ml-i 20.25 士 5.30 14.37 土 0.48 
0.001 Units ml-i 16.20 士 1.59 14.38 士 0.50 
Table 3.9 b PGDj production (ng/W cells) 
I 
1 — I 
sPLA2-I [sPLA2-I + IgE] [sPLA2-q + PgE] 
1 Uni t ml_i 166.00 土 16.69 129.91 土 27.20 
0.1 Units ml-i 45.00 士 14.98 21.41 士 8.57 
0.01 Units ml-i 34.75 士 2.61* 17.67 士 5.12 
0.001 Units ml-i 13.50 士 8.43 17.67 士 5.12 
[sPLA2-I + IgE] = histamine release and PGDj production induced by anti-rat IgE 
f rom sPLA2-I pretreated cells as observed in the experiment. 
[sPLA2-r| + [IgE] = combined histamine release and PGDj production, calculated by 
adding the release/production induced by sPLAj-I alone to that induced by anti-rat IgE 
alone for each individual experiment. 
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Table 3.10 Comparison between histamine release induced by anti-rat IgE f rom 
sPLA2-II pretreated rat peritoneal mast cells w i th the combined histamine release 
induced by sPLA2-II and anti-rat IgE. Anti-rat IgE induced histamine release was 
16.89 士 6.97%. * * = p < 0.01 and * = p ^ 0.05 as compared w i th the calculated 
combined value. Values are means 士 SEM for n = 5-6. 
Histamine release (% of total) 
sPLA2-II [sPLA2-II + IgE] [sPLA2-iq + PgE] 
10 Units ml-i 33.56 土 11.18 21.23 士 8.59 
5.0 Units ml-i 44.26 士 9 .81** 18.29 士 7.12 
1.0 Un i t ml_i 49.01 士 9 .49** 22.92 士 6.40 
0.5 Units ml-i 46.94 土 9 .82** 21.77 士 6.23 
0.25 Units ml_i 44.89 士 9 .50** 19.93 士 6.41 
0.1 Units ml-i 44.00 士 9 .45** 21.21 士 7.49 
0.05 Units mTi 42.32 士 10.43** 15.53 士 7.22 
0.025 Units ml"^ 36.20 士 8.32* 13.88 士 6.03 | , 
0.01 Units ml-i 38.22 土 9 .26** 18.56 士 6.97 
0.005 Units ml"^ 31.23 士 9 .09** 19.58 土 8.89 
0.001 Units ml_i 33.20 士 9.85 18.50 士 8.46 
[ sPLA j - I I + IgE] = histamine release induced by anti-rat IgE f rom sPLA j - I I 
pretreated cells as observed in the experiment. 
[sPLA2-II] + [IgE] = combined histamine release, calculated by adding the release 
induced by sPLAj -H alone to that induced by anti-rat IgE alone for each individual 
experiment. 
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Tab le 3 .11 Comparison between histamine release induced by anti-rat IgE f rom 
sPLA2-I I pretreated pur i f ied rat peritoneal mast cells w i th the calculated combined 
histamine release induced by sPLA2-II and anti-rat IgE. Anti-rat IgE induced 
histamine release was 31.37 士 2.30%. * * = p ^ 0.01 as compared w i th the 
calculated combined value. Values are means 士 SEM for n = 5-6. 
Histamine release (% o f total) 
sPLA2- I I [sPLA2-I I + I gE ] [sPLA2-n3 + PgE] 
10 Units ml-i 52.96 土 3 .68** 30.51 土 2.24 
7.5 Units ml-i 56.76 土 3 .80** 33.18 士 1.92 
5.0 Units ml_i 56.82 士 3 .26** 32.17 士 2.23 
2.5 Units ml-i 62.32 土 6 .09** 34.76 士 3.20 
1.0 Uni t ml-i 68.38 士 4 .03** 37.64 士 3.13 
0.5 Units ml-i 65.66 土 1.67** 35.80 土 2.59 
0.25 Units ml"^ 61.47 土 2 .04** 34.94 士 2.78 
0.1 Units ml-i 58.30 士 1.80** 34.58 士 2.70 ； 
0.05 Units ml-i 56.53 士 2 .08** 34.31 士 2.64 
0.025 Units ml"' 54.48 士 2 .72** 34.23 士 2.56 
0.01 Units ml_i 52.18 士 2 .38** 32.50 士 2.30 
0.005 Units ml'^ 50.09 士 2 .73** 32.38 土 2.60 
[ sPLA j - I I + IgE] = histamine release induced by anti-rat IgE f rom sPLA j - I I 
pretreated cells as observed in the experiment. 
[sPLA2-ir | + [IgE] = combined histamine release, calculated by adding the release 
induced by sPLAj - I I alone to that induced by anti-rat IgE alone for each individual 
experiment. 
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Table 3.12 Comparison between histamine release induced by anti-rat IgE f rom 
sPLA2-II pretreated pur i f ied rat peritoneal mast cells w i th the calculated combined 
histamine release induced by sPLA2-II and anti-rat IgE. Anti-rat IgE induced 
histamine release was 5.17 土 0.54%. * * = p < 0.01 and * = p < 0.05 as compared 
w i t h the calculated combined value. Values are means 土 S E M for n = 4-7. 
Histamine release (% of total) 
sPLA2-II [sPLA2-II + IgE] [sPLA2-m + PgE] 
10 Units ml-i 16.54 士 3 .06** 5.30 土 0.52 
7.5 Units ml"^ 20.85 士 3 .80** 5.45 士 0.64 
5.0 Units ml-i 20.77 士 4 .02** 5.49 土 0.68 
2.5 Units ml_i 27.55 士 5 .14** 9.03 土 1.47 
1.0 Uni t ml-i 28.78 土 6.73* 13.02 土 1.97 
0.5 Units ml_i 29.70 士 4.62* 10.12 士 2.00 
0.25 Units ml ' ' 25.11 士 4 .84** 7.74 土 0.90 
j 
0.1 Units ml_i 25.56 土 5 .04** 9.06 土 0.84 
0.05 Units ml-i 25.20 士 4 .45** 8.69 士 0.76 
0.025 Units ml_i 23.61 士 4 .42** 8.38 土 1.01 
I 
0.01 Units ml-i 22.55 士 3 .91** 7.00 士 0.82 
0.005 Units ml'^ 19.79 士 3 .16** 7.00 士 0.68 
[sPLA2-II + IgE] = histamine release induced by anti-rat IgE f rom sPLA2_n 
pretreated cells as observed in the experiment. 
[sPLA2-II] + [IgE] = combined histamine release, calculated by adding the release 
induced by sPLA2-II alone to that induced by anti-rat IgE alone for each individual 
experiment. 
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Table 3.13 Comparison between histamine release induced by anti-rat IgE f rom 
sPLA2-II pretreated pur i f ied rat peritoneal mast cells w i th the calculated combined 
histamine release induced by sPLA2-II and anti-rat IgE in the presence 0f /7-BPB. 
sPLA2-II concentration tested was 1 U m l ' ^ * = p < 0.05 as compared w i th the 
calculated combined value. Values are means 士 SEM for n = 5. 
Histamine release (% of total) 
P-BPB [sPLA2-II + IgE] [sPLA2-iq + PgE] 
0.01 f j iM 32.46 土 1.89* 19.82 士 1.98 
0.1 jitM 23.50 士 3.31* 16.97 士 1.96 
1.0 AtM 9.23 土 1.27 6.59 士 1.35 
10 AtM 1.86 士 0.67 0.52 土 0.32 
[ sPLA j - I I + IgE] = histamine release induced by anti-rat IgE f rom sPLA j - I I 
pretreated cells in the presence of p-BFB as observed in the experiment. 
[sPLA2-II] + [IgE] = combined histamine release, calculated by adding the release 
induced in the presence of p-BPB by sPLA2-II alone to that induced anti-rat IgE alone 
for each individual experiment. 丨 
121 . 
Table 3.14 Comparison between histamine release induced by anti-rat IgE f rom 
sPLA2-I I pretreated pur i f ied rat peritoneal mast cells w i th the calculated combined 
histamine release induced by sPLA^-II and anti-rat IgE in the presence o f 12-epi-
scalaradial. sPLA2-II concentration tested was 1 U m T 、 * * = p ^ 0.01 as compared 
w i th the calculated combined value. Values are means 土 S E M for n = 6. 
Histamine release (% of total) 
12-epi-scalaradial [sPLA^-II + IgE] [sPLA2-iq + PgE] 
0 . 1 j [ xM 3 6 . 8 7 士 5 . 1 0 * * 1 9 . 2 7 士 4 . 2 3 
0 . 3 j[xM 22.65 土 4 . 6 6 * * 1 0 . 4 9 士 3 . 0 9 
0.6 ^ M 1.19 土 0.82 0.36 士 0.20 
1 . 0 |xM 1 . 7 1 士 0 . 8 0 0 . 0 0 士 0 . 0 0 
[sPLA2-II + IgE] = histamine release induced by anti-rat IgE f rom sPLA2-II 
pretreated cells in the presence of 12-epi-scalaradial as observed in the experiment. 
[sPLA2-II] + [IgE] = combined histamine release, calculated by adding the release 
induced in the presence of 12-epi-scalaradial by sPLA^-n alone to that induced by anti-
rat IgE alone for each individual experiment. 
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Tab le 3.15 (a + b) Comparison between ⑷ histamine release and (b) PGD: 
production, induced by anti-rat IgE f rom sPLA^-I I pretreated pur i f ied rat peritoneal 
mast cells w i th the calculated combined values f rom sPLA2-II and anti-rat IgE. Anti_ 
rat IgE induced histamine release was 27.33 士 1.29% and PGD2 production was 33.19 
土 6.73 ng/106 cells. * * = p < 0.01 and * = p ^ 0.05 as compared wi th the calculated 
combined value. Values are means + SEM for n = 4-5. 
Tab le 3.15 a Histamine release (% o f total) 
sPLA2- I I [sPLA2-I I + I gE ] [sPLA2- i r i + PgE] 
1 Un i tm l_ i 66.44 土 2 .13** 37.08 士 1.23 
0.1 Units ml_i 55.14 土 2 .47** 30.25 士 1.25 
0.01 Units ml-i 47.17 士 3 .01** 29.32 土 0.89 
0.001 Units ml-i 36.68 士 2 .34** 28.64 ± 1.59 
Tab le 3.15 b P G D j product ion (ng/10^ cells) 
I 
( 
sPLA^- I I [sPLA2-I I + IgE ] [sPLA2- iq + JJgE] 
1 Uni t ml-i 164.19 士 23.70* 74.50 士 15.76 
0.1 Units ml-i 146.49 士 34.82* 52.68 士 11.49 
0.01 Units ml-i 124.86 土 27.59 46.22 土 7.32 
0.001 Units ml_i 71.86 士 27.15 39.57 士 7.44 
[sPLAj - I I + IgE] = histamine release and PGD2 production induced by anti-rat IgE 
from sPLA2_II pretreated cells as observed in the experiment. 
r 
[ sPLAj - iq + [IgE] = combined histamine release and PGD〗 production, calculated 
by adding the release/production induced by sPLA2-n alone to that induced by anti-rat 
IgE alone for each individual experiment. 
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3.6 Discussion 
3.6.1 Effects of sPLA2 on immunologically induced histamine release from 
activated RPMC 
Pretreatment o f rat peritoneal mast cells w i th the sPLA^-I isolated f rom Naja naja 
venom fo l lowed by activation wi th anti-rat IgE led to a significant enhancement o f the 
immunological ly induced histamine release. These results are in agreement w i th Nagai 
et al. (1991) who observed that non-releasing concentrations ofNaja naja venom (0.01 
to 0.5 U ml ' i ) accelerated antigen induced histamine release f rom rat peritoneal mast 
cells. L ikewise, pretreatment of rat peritoneal mast cells w i th the sPLA2-II pur i f ied 
f r o m Crotalus altrox venom fol lowed by immunological activation also led to a 
i 
t 
significant enhancement of the induced histamine release. This is in contrast w i th the | 
i 
findings reported by Murakamai et al. (1991a). They found that histamine release was 
unaffected i n antigen stimulated rat peritoneal mast cells fo l lowing pretreatment w i th 
the sPLA2-n isolated f rom rat platelets (6 fxg!wX). L i the present study both sPLA 2 
enzymes (0.4 to 40 jug/ml) significantly enhanced the anti-IgE induced histamine 
release dose dependently. This synergistic effect was observed w i th both the mixed 
cell population and puri f ied cells. Concentrations of the sPLA2 enzymes that caused 
enhancement in the present study, were similar to the concentrations found associated 
w i th acute pancreatitis. The normal serum sPLA! concentrations are 5.1 ng/ml (range 
2.0 to 7.9 ng /ml) for healthy individuals and this was elevated in patients w i th acute 
pancreatitis (range 10 to 4,000 ng/ml) (Nishi j ima et al.，1983). I t was also observed 
that at low concentrations of the immunological stimulus, a significant enhancement 
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o f histamine release was observed w i th both sPLA: enzymes. This would suggest that 
the sPLA2 enzymes may have a role i n p r im ing the mast cell for degranulation. 
The enhancement was unaffected by the cytosolic PLA2 inhibi tor M A F P , but was 
reduced w i t h the PLA2 inhibitors p -BPB and 12-epi-scalaradial. The enhancement 
was reduced w i th inhibitor concentrations that reduced the histamine releasing act ivi ty 
o f these enzymes. The observations in the present study would suggest that the 
enzymatic site/activity o f the sPLA2 may be responsible for the effects observed here. 
However, a reduction in histamine release was also observed w i th the immunological 
stimulus anti-IgE and complicates these analyses. Murakamai et al. (1991b & 1992b) 
have also reported similar findings, where the PLA2 inhibi torsp-BPB, mepacrine, anti-
(rat 14 kDa group I I PLA! ) antibody, rat C3a and thielocin A l al l inhibited antigen 
I 
induced histamine release f rom rat peritoneal mast cells. The 14 kDa group I I PLA2 
inhibi tors, rat C3a and thielocin A l also inhibited histamine release induced by 
A23187 and compound 48/80 (Murakamai et al，1992b). They proposed that the type 
n sPLA2 enzyme may play a central role in the activation/degranulation o f mast cells. 
Hydrolysis o f the membrane phospholipids may generate a l ip id substance which may 
be responsible for the enhanced histamine release. Bevers et al. (1983) reported that 
i n activated platelets, PE and PS were translocated to the outer layer o f the plasma 
membrane. Cross l inking o f the IgE receptor molecules on the mast cell membrane 
may lead to a membrane rearrangement event. This could make the specific 
phospholipid substrates PE and PS available for hydrolysis by sPLAj - I I . 
125 
PS at l ow concentrations ( lO to 50 fxg m r ” has been reported to enhance histamine 
release f r o m rat peritoneal mast cells induced by dextran, concanavalin A (con A ) , 
antigen or ant i- IgE whi le i t was without effect by itself (Goth et al. ； 1971 ； Baxter & 
Adamik , 1977). This enhancement was specific for agents wh ich activate mast cells 
through the immunological pathway, as i t had no enhancing effect on other mast cell 
secretatogues such as compound 48/80 and A23187. The other phospholipids 
phosphatidyl inositol (PI), PE and PC had no enhancing effect. Hydrolysis o f PS by 
PLA2 yields lysoPS and this lyso derivative at low concentrations (less than 10 /xM) has 
also been shown to enhance histamine release f rom rat peritoneal mast cells activated 
w i t h con A (Mar t in & Lagunoff，1979; Smith et al.，1979; Boarato et al, 1984; 
Hor igome et al., 1986). LysoPS is about 50 to 1,000 times more potent than PS and 
was wi thout effect on resting rat peritoneal mast cells. Higher concentrations o f 
i 
lysophospholipids are known to induce cytotoxic histamine release f rom rat peritoneal 
mast cells (Mart in & Lagunoff, 1979). Hydrolysis o f PS by sPLA2-II could generate 
lysoPS. This lysoPS may in some way be responsible for the enhanced histamine 
release observed here. 
sPLA2-I does not display any substrate selectivity for PS. However, a significant 
enhancement was observed wi th non-releasing concentrations o f sPLA2-I. sPLA2-I 
may bind to a binding site which facilitates the release o f histamine from mast cells and 
release o f the sPLA2 found in mast cell granules. Rat peritoneal mast cells release a 
14kDa type n P L A ] when stimulated wi th antigen (Murakami et al,，1992a). More 
recently this 14kDa P L A j has been located in the secretory granules of rat peritoneal 
mast cells (Chock et al” 1994). This secreted type I I 14kDa sPLA j could hydrolyse 
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PS to y ie ld lysoPS or another fusogenic compound and in this way augment the 
induced histamine release. Release o f this 14kDa type I I sPLA! fo l lowing cell 
activation may explain the enhanced histamine release observed w i th sPLA2-I in this 
study. Significant enhancement was observed wi th the longer activation t ime w i th anti-
IgE，suggesting that time may be needed for secretion o f the 14kDa type H s P L A j f r o m 
the mast cel l granules. 
The ftmction o f the type I I sPLA2 secreted f rom mast cell granules fo l lowing cell 
activation is unclear. The observations in the present study suggest that i t augments 
immunological ly induced histamine release. It may mediate this effect by acting as 
a signalling molecule through binding a site on the mast cell plasma membrane. Cross 
l ink ing o f the IgE receptor molecules on the mast cell membrane may lead to a 
membrane alteration event which may expose a specific binding site for sPLA2-II. 
However, no such binding site has been isolated on mast cells to date. The type I I 
sPLA2 displays a high affmity for heparin (Chock et aL, 1991; Murakami et aL, 
1992a). This affmity for heparin may help anchor the enzyme on the cell surface in 
order to mediate its effect. Alternatively, sPLAj - I I may also bind w i th low aff ini ty to 
the type I sPLA j - I binding site and mediate its effect that way. Hydrolysis o f PS by 
sPLA2-II would generate lysoPS and this lysoPS may in some way be responsible for 
the enhanced histamine release observed here. More studies are required to establish 
the mechanisn of action of sPLA2-II involved in enhancing histamine release f rom rat 
peritoneal mast cells. 
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3.6.2 Effects of sPLA! on PGD: production from immunologicaUy activated 
RPMC 
PGD2 production was enhanced in anti-IgE stimulated mast cells preincubated wi th the 
type I I sPLA2 enzyme puri f ied f rom Crotalus altrox venom. These results are in 
aggreement w i th Murakami et al. (1991a). They observed that preincubation o f rat 
peritoneal mast cells w i th the the type I I 14kDa sPLA2 (6 fjLg ml"^) isolated f rom rat 
platelets, subsequently activated wi th antigen, led to an increase in PGD2 production. 
Hara et al. (1991) also observed that in A23187 activated HL-60 granulocytes PGEj 
product ion was increased in the presence o f exogenous rat and human type I I PLA2. 
Foneth et al. (1994) reported that the mouse mast cell l ine (BBMC) secrete a 14kDa 
sPLA2 fo l lowing antigen challenge. This sPLA2-II enzyme leads to the rapid 
mobilisation of extracellular A A which is subsequently used for eicosanoid generation. 
The enhanced PGD】 production observed here is probably due to the release o f more 
A A f rom the membrane phospholipid, fol lowing the enzymatic action of the secreted 
PLA2-II . 
L i contrast w i th sPLA2-II, there was no significant enhancement o f PGD2 production 
observed wi th sPLA2-I fol lowing activation wi th anti-rat IgE. sPLA j - I may bind to a 
binding site on the mast cell plasma membrane and activate histamine secretion. Jn 
addition, this would lead to the release of the 14kDa sPLA2 found in the mast cell 
granules. Time may be required for its secretion and action on liberating free A A for 
PGD2 production. The lack of enhancement observed here may be due to this time 
factor. 
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3.6.3 Effects of flurbiprofen and zileuton on sPLA2 induced and enhanced 
histamine release from RPMC 
Both the cyclo-oxygenase (flurbiprofen) and lipoxygenase (zileuton) inhibitors fai led 
to inhibi t the sPLA2 induced histamine release and the enhanced immunological ly 
induced histamine release. These results are in accord w i th Nagai et al (1991) who 
observed that indomethacin and AA-861, were without effect on the porcine pancreas 
and the s P L A j isolated f rom Naja naja venom enhanced antigen induced histamine 
release f rom rat peritoneal mast cells. This suggested that the A A metabolites 
generated through the cyclo-oxygenase and lipoxygenase pathway were not responsible 
for the effects o f the sPLA2 enzymes in the present study. These results further 
support the hypothesis that the sPLA2 enzymes were having a direct effect on the mast 
cell plasma membrane either through binding sites or a hydrolytic effect. 
The present study has shown that both sPLA2 enzymes enhanced immunologically 
induced histamine release and this was not do to the generation of A A metabolites, 
which suggested that the sPLA2 enzymes may participate in some step required for 
anti-IgE induced release. I f the sPLA2 enzyme was involved in a common step in the 
secretory process, an enhancement of histamine release induced by other mast cell 
secretagogues such as compound 48/80 or A23187 would also be expected. Although 
the mechanisms by which mast cell secretagogues cause exocytosis are not ful ly 
understood, they differ in their requirement for extracellular calcium (Pearce, 1987). 
The immunological activation of mast cells is highly dependent on the calcium 
concentration in the extracellular medium, the release induced by compound 48/80 is 
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much less sensitive (Pearce et al., 1981). The calcium ionophore A23187 is also 
dependent on the calcium concentration in the extracellular medium, but can bypass 
all membrane activation events thus raising the [Ca^^Jj wi th in the cell cytosol (Foreman 
et 认,1973). The effects of the sPLA: enzymes on non-immunologically induced 
histamine release were next examined and their effects on intracellular calcium 
measurements were also investigated (Part 3). 
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PART 3: Investigation of the mode of action(s) of sPLA^ on rat peritoneal mast 
cells 
3.7 Results 
3.7.1 Effects of sPLAj-I on non-immunologically activated RPMC 
Mast cells can also be activated w i th non-immunological st imuli . The calcium 
ionophore A23187 and the classical mast cell degranulating agent compound 48/80 
were used in this study. When sPLA2-I preincubated cells were subsequently 
challenged w i th compound 48/80，there was no significant enhancement o f compound 
48/80 induced histamine release observed (Fig 3.32 and table 3.16). Concentrations 
o f sPLA2-I greater than 1 U ml'^ caused significant histamine release alone. Simi lar ly 
there was no significant enhancement o f histamine release observed when s P L A j - I 
preincubated cells were activated w i th A23187 (Fig 3.33 and table 3.17). 
3.7.2 Effects of sPLAj-II on non-immunologically activated RPMC 
I t was also observed that sPLA2-II preincubated cells did not produce any significant 
enhancement of compound 48/80 induced histamine release (Fig 3.34 and table 3.18). 
A t the highest concentration tested of 10 U mT、there was a reduction in the histamine 
release induced by compound 48/80. The histamine release observed was 12.02 土 
2.47% compared wi th 26.02 土 3.65% (compound 48/80 alone). Similar observations 
were seen when sPLA2-II preincubated cells were challenged wi th A23187 (Fig 3.35). 
131 
I 
There was no enhanced histamine release observed (Table 3.19). Again an sPLA2-II 
concentration of 10 U ml'^ reduced the A23187 induced histamine release by one fold. 
3.7.3 Effects of sPLA2-I on [Ca^^]j in immunologically activated RPMC 
When pur i f ied rat peritoneal mast cells, loaded wi th ftira-2 were exposed to sPLA2-I 
(0.1 U m l ] ) an increase in the [Ca?+]〗 was observed (Fig 3.36a). This increase was 
slow and reached a plateau within 2 minutes. The net increase in the [Ca^^]j observed 
was 23.66 士 6.00 n M for n = 5. The corresponding % histamine release observed 
w a s 2 . 7 0 ± 1 . 3 0 % . 
When fura-2 loaded cells were exposed to anti-rat IgE (1/3,000) a biphasic calcium 
response was observed (Fig 3.36b). The init ial peak was fast w i th a transient rise in 
the [Ca2+]i, fol lowed by a sustained plateau phase. The net increase in the [Ca^^]j 
observed was 78.89 ± 3.83 n M for the peak and 53.30 士 9.63 n M for the plateau 
phase. The corresponding % histamine release observed was 6.61 士 0.33%. 
To determine whether sPLA2-I was having any effect on the anti-rat IgE induced 
calcium response, cells were exposed to sPLA2-I for 5 min before the addition of anti-
IgE. Fig 3.36c illustrates that exposure to sPLAj- I led to a slow increase in the [Ca^^]j 
as before. Upon addition of anti-IgE the rapid transient increase in the [Ca^^]； was 
again observed. This was fol lowed by the sustained phase. The net increase in the 
[Ca2+]i observed was 22.86 土 2.86 n M for sPLAj- I , 94.17 土 10.89 n M for the peak 
and 82.82 土 13.71 n M for the plateau phase. The corresponding % histamine release 
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observed was 13.00 士 1.20%. 
The increase in the [Ca:+]., by sPLA2-I complicates these analyses. However, 
subtraction o f this net increase in the [Ca'^]； by sPLA2-I from the experimental 
observations above showed that sPLA2-I did not have any significant effect on the anti-
rat IgE induced calcium response. The % histamine release observed for these traces 
was less than 15%. I t should also be noted that in these experiments there was no 
significant enhancement of the anti-IgE induced histamine release f rom sPLA2-I 
pretreated cells (13.00 土 1.20%) when compared wi th the calculated combined value 
(9.32 士 1.38%). 
3.7.4 Effect of sPLAj-II on [Ca^ j^j in immunologically activated R P M C 
When mast cells, loaded wi th fura -2 were exposed to s P L A 2 - I I (0 . 1 U mr^), an 
increase in the [Ca^^], was observed (Fig 3.37a). This increase was slow and reached 
a plateau within 2 minutes. The net increase in the [Ca^^]j observed was 11.20 土 2.57 
n M for n = 6 compared wi th 23.66 土 6.00 n M for sPLA2-I (0.1 U ml"^). The 
corresponding % histamine release observed was 3.92 士 1.14%. 
As before when fura-2 loaded cells were exposed to anti-rat IgE (1/3,000), the 
biphasic calcium response was observed (Fig 3.37b). The net increase in the [Ca^+]j 
observed was 87.11 土 10.30 n M for the peak and for the plateau phase 51.07 土 5.80 
n M . The corresponding % histamine release observed was 13.05 士 2.07%. 
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To determine whether sPLA2-II was having any effect on the anti-rat I gE calc ium 
response, cells were exposed to s P L A j - I I for 5 m i n before the addit ion o f ant i- IgE. 
F ig 3.37c illustrates that exposure to sPLA2-II led to a slow increase in the [Ca^+]j as 
before. Upon addit ion o f anti-rat IgE a rapid transient increase in the [Ca^^]j was 
again observed wh ich was fo l lowed by the sustained phase. The net increase i n the 
[Ca2+]i observed was 11.91 士2.35 n M f o r sPLA2-II, 102.12 土 1 0 . 8 9 n M f o r t h e 
peak and for the plateau phase 87.12 士 10.30 n M . The corresponding % histamine 
release observed was 2 7 . 6 1 土 2 . 2 1 % . 
The increase in the [Ca^^]j by sPLA2-II complicates these analyses. Subtraction o f this 
net increase in the [Ca^^]j by sPLA2-II f rom the experimental observations above 
showed that sPLA2-II d id have a significant effect on the anti- IgE induced calcium 
response. However i t was only w i th the plateau phase that there was a significant 
increase observed in the [Ca】+];. I t should also be noted that there was a significant 
enhancement o f the anti-rat IgE induced histamine release f rom s P L A j - I I pretreated 
cells (27.61 士 2 . 2 1 % ) when compared w i th the calculated combined value (16.98 士 
2.78%). This corresponds w i th the increased [Ca^^]j fo l lowing cell activation. 
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Figure 3.32 Effects of sPLA2-I on compound 48/80 induced histamine secretion f rom 
puri f ied rat peritoneal mast cells. Control cells were incubated wi th sPLA2-I (0.001 
to 10 U ml-i) for 20 min ( • ) . Compound 48/80 stimulated cells were pretreated wi th 
sPLA2-I for 10 min and stimulated for a further 10 min ( • ) . Compound 48/80 (0.075 
y 
/xg ml_i) induced histamine release was 33.56 士 3A7% (—). The spontaneous 
histamine release was 9.59 土 0.63%. Results are given as the means 士 SEM for n 
= 6 - 7 . 
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Figure 3.33 Effects of sPLA2-I on A23187 induced histamine secretion f rom puri f ied 
rat peritoneal mast cells. Control cells were incubated wi th sPLAj - I (0.001 to 10 U 
ml-i) for 20 min ( • ) . A23187 stimulated cells were pretreated wi th sPLAj - I for 10 
m in and stimulated for a further 10 min ( • ) . A23187 (0.5 ptM) induced histamine 
release was 48.21 士 5.73% (—). The spontaneous histamine release was 10.48 土 
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Figure 3.34 Effects of sPLA2-II on compound 48/80 induced histamine secretion from 
purif ied rat peritoneal mast cells. Control cells were incubated wi th sPLA2-II (0.001 
to 10 U ml'^) for 20 min ( • ) . Compound 48/80 stimulated cells were pretreated wi th 
sPLA2-n for 10 min and stimulated for a further 10 min ( • ) . Compound 48/80 (0.075 
Mg ml ' i ) induced histamine release was 26.02 土 3.65% (—). The spontaneous 
histamine release was 12.59 士 1.77%. Results are given as the means 士 SEM for n 
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Figure 3.35 Effects of sPLA2-II on A23187 induced histamine secretion from purif ied 
rat peritoneal mast cells. Control cells were incubated wi th sPLA2-n (0.001 to 10 U 
ml_i) for 20 m in ( • ) • A23187 stimulated cells were pretreated wi th sPLA j - I for 10 
m in and stimulated for a further 10 min ( • ) . A23187 (0.5 /^M) induced histamine 
release was 51.93 土 2.61% (—). The spontaneous histamine release was 12.49 土 
1.58%. Results are given as the means 士 SEM for n = 3. 
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Figure 3.36 Effects of (a) sPLA2-I (0.1 U m l '), (b) anti-rat IgE (1/3,000) and (c) sPLAj-I 
+ anti-rat IgE, on [Ca^^]i in fura-2 loaded purified rat peritoneal mast cells in Hepes buffer. 
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Figure 3.37 Effects of ⑷ sPLA2-II (0.1 U ml」)’ (b) anti-rat IgE (1/3,000) and (c) sPLA2-II 
+ anti-rat IgE, on [Ca:+]; in ftira-2 loaded purified rat peritoneal mast cells in Hepes buffer. 
Traces are shown for changes in [Ca^^]j representative for n = 6. 
140 
Table 3.16 Comparison between histamine release induced by compound 48/80 f rom 
sPLA2-I pretreated pur i f ied rat peritoneal mast cells w i th the calculated combined 
histamine release induced by sPLA2-I and compound 48/80. Compound 48/80 (0.075 
jLtg ml"^), induced histamine release was 33.56 土 3.47%. Values are means 士 S E M 
for n = 6-7. 
Histamine release (% of total) 
sPLA2-I [sPLA2-I + 48/80] [sPLA2-q + [48/80] 
10 Units ml_i 77.38 士 0.85 105.94 土 3.21 
3 Units ml_i 81.95 士 0.52 107.08 士 3.43 
1.0 U n i t m l - i 72.20 土 1.53 74.31 士 4.33 
0.3 Units ml-i 56.42 士 3.02 51.25 士 3.19 
0.1 Units ml-i 47.47 土 3.28 46.59 士 3.21 
0.03 Units ml_i 43.64 土 3.60 43.47 士 3.69 
0.01 Units ml-i 37.66 土 3.72 37.98 士 3.87 
0.003 Units ml_i 38.47 土 5.51 37.50 土 3.98 
0.001 Units ml_i 31.86 士 3.80 35.73 士 4.68 
[sPLAj - I + 48/80] = histamine release induced by compound 48/80 f rom sPLA2-I 
pretreated cells as observed in the experiment. 
[sPLA2-r| + [48/80] = combined histamine release, calculated by adding the release 
induced by sPLAj- I alone to that induced by compound 48/80 alone for each individual 
experiment. 
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Table 3.17 Comparison between histamine release induced by A23187 f rom sPLA2-I 
pretreated pur i f ied rat peritoneal mast cells w i th the calculated combined histamine 
release induced by sPLA2-I and A23187. A23187 (0.5 ^tM), induced histamine release 
was 48.21 士 5.73%. Values are means 土 SEM for n = 5. 
Histamine release (% of total) 
sPLA2-I [sPLA2-I + A23187] [sPLA2-q + [A23187] 
10 Units mTi 78.31 土 2.30 118.89 士 6.26 
3 Units ml-i 84.01 士 1.16 119.97 士 6.76 
1.0 Un i t ml-i 74.97 士 1.86 86.77 土 8.58 
0.3 Units ml ' i 66.55 士 3.39 63.77 士 6.40 
0.1 Units ml_i 59.40 士 3.89 60.02 士 5.52 
0.03 Units ml-i 55.30 士 5.34 56.98 士 5.50 
0.01 Units ml_i 52.81 士 5.60 52.88 士 5.44 
0.003 Units ml ' ' 50.28 土 5.97 52.22 士 4.88 
0.001 Units ml_i 48.39 土 7.11 51.57 士 4.90 
[sPLA2-I + A23187] = histamine release induced by A23187 from sPLA2-I pretreated 
cells as observed in the experiment. 
[sPLA2-r| + [A23187] = combined histamine release, calculated by adding the release 




Table 3.18 Comparison between histamine release induced by compound 48/80 f rom 
sPLA2-II pretreated purif ied rat peritoneal mast cells wi th the calculated combined 
histamine release induced by sPLA2-II and compound 48/80. Compound 48/80 (0.075 
昭甜-1)，induced histamine release was 26.02 士 3.65%. * * = p ^ 0.01 as compared 
w i th the calculated combined value. Values are means 士 SEM for n = 3-5. 
Histamine release (% of total) 
sPLA2-II [sPLA2-II + 48/80] [sPLA2-iq + [48/80] 
10 Units ml_i 12.02 土 2 .47** 26.87 士 3.94 
3 Units ml_i 25.49 士 2.71 27.69 士 3.79 
1.0 Uni t ml-i 42.31 士 3.23 39.35 士 4.90 
0.3 Units ml-i 38.32 士 4.44 33.52 士 4.96 
0.1 Units ml_i 34.74 土 4.10 33.25 土 5.20 
0.03 Units ml-i 33.49 士 3.14 30.94 士 4.62 
0.01 Units ml-i 31.80 士 3.11 30.18 土 4.70 
0.003 Units ml—i 28.48 士 2.95 30.04 土 6.17 
0.001 Units ml-i 28.13 士 3.20 31.40 士 7.58 
[sPLA2-II + 48/80] = histamine release induced by compound 48/80 f rom sPLA2-II 
pretreated cells as observed in the experiment. 
[sPLA2-n] + [48/80] = combined histamine release, calculated by adding the release 
induced by sPLA2-II alone to that induced by compound 48/80 alone for each 
individual experiment. 
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Table 3.19 Comparison between histamine release induced by A23187 from sPLAj -H 
pretreated pur i f ied rat peritoneal mast cells w i th the calculated combined histamine 
release induced by sPLA^-I I and A23187. A23187 (0.5 fxM), induced histamine 
release was 51.93 士 2.61%. * = p ^ 0.05 as compared wi th the calculated combined 
value. Values are means 士 SEM for n = 3. 
Histamine release (% of total) 
sPLA2-II [sPLA2-II + A23187] [sPLA2-iq + [A23187] 
10 Units ml-i 41.70 土 1.50* 52.40 士 2.16 
3 Units ml-i 46.73 士 2.82 52.41 士 2.14 
1.0 Uni t ml-i 57.41 士 2.49 61.96 土 1.47 
0.3 Units ml-i 50.36 士 1.99 54.29 士 2.13 
0.1 Units ml-i 52.26 士 1.47 55.78 土 2.47 
0.03 Units ml-i 52.82 士 2.40 55.17 士 2.63 
0.01 Units ml-i 52.01 士 1.99 54.75 士 1.71 
0.003 Units ml'^ 49.20 土 2.58 53.72 士 1.94 
0.001 Units ml-i 49.77 土 2.00 54.00 土 2.32 
[ sPLA j - I I + A23187] = histamine release induced by A23187 f rom sPLAj -U 
pretreated cells as observed in the experiment. 
[sPLA2-II] + [A23187] = combined histamine release, calculated by adding the 




The specificity o f the sPLA j enzymes to enhance immunologically induced histamine 
release, suggested that they may participate in some step specifically required for IgE 
induced release. Al though the exact mechanisms involved in mast cell secretion are 
not fu l ly understood, i t should be pointed out that they differ in their requirement for 
extracellular calcium (Pearce, 1987). Whi le the immunological activation ofmast cells 
is highly dependent on the calcium concentration in the extracellular medium, the 
release induced by compound 48/80 is much less sensitive (Pearce et aL, 1981). The 
calcium ionophore A23187 is also dependent on the calcium concentration i n the 
extracellular medium, but can bypass all membrane activation events thus raising the 
[Ca2+]i w i th in the cell cytosol (Foreman et al., 1973). 
The sequence of events fol lowing aggregation of the IgE receptor molecules on the 
mast cell plasma membrane have not yet been ful ly determined. It is known that this 
aggregation step leads to the intracellular production of IP3 and an increase in the 
[Ca^^]j. This increase in the [Ca^^]j is due to the release of Ca^^ f rom intracellular 
stores by IP3. The transient increase in the [Ca^^]j, is insufficient to initiate complete 
secretion, but leads to the opening of plasma membrane calcium channels. Entry o f 
Ca2+ from the extracellular medium maintains an elevated level o f the [Ca^^]j, which 
then facilitates the maximum level of mediator release (for review see Sagi-Eisenberg, 
1993). This biphasic calcium response was observed in this study, when cells were 
stimulated wi th anti-rat IgE. 
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W i t h compound 48/80 the f irst known intracellular event is thought to be the activation 
o f a pertussis-toxin-sensitive G protein. This leads to the activation o f P L C w i t h an 
increase in IP3. Al though the optimal level o f histamine release requires the presence 
o f extracellular calcium, compound 48/80 can produce a significant release o f 
histamine in the absence o f extracellular calcium (Pearce et al., 1981; for review see 
Sagi-Eisenberg, 1993). Hence the opening o f plasma membrane calcium channels, is 
, n o t a prerequisite for histamine release induced by compound 48/80. 
The specificity o f the sPLA2 enzymes to enhance immunological ly induced histamine 
release here, suggested that they may in some way facilitate in the opening, or 
maintenance o f the opening of the plasma membrane calcium channels. T w o calcium 
in f lux pathways have been described in mast cells: IcRAc (calcium release-activated 
calcium) and a non specific 50-pS cation channel. IcRAc has been characterised in rat 
peritoneal mast cells (Hoth & Penner，1992 & 199¾ and the RBL-2H3 cell l ine 
OFasolato etal., 1993b; Zhang & McCloskey’ 1995). The 50-pS channel has also been 
demonstrated in rat peritoneal mast cells and is activated via G-proteins (Penner et al.， 
1988; Matthews et al.’ 1989; Kudo & Kimura，1992; Fasolato et al” 1993a). Jn this 
study only sPLA2-II produced any significant increase in the inf lux o f extracellular 
Ca2+ fo l lowing stimulation w i th anti-IgE. This inf lux in Ca】+ corresponded w i th the 
observed enhanced histamine release. This suggested that sPLA2-II may facilitate in 
the opening o f plasma membrane calcium channels. The mechanism(s) o f action o f 
y 
how sPLA2-II might do this is not clear at present. 
As previously discussed, both PS and lysoPS can enhance immunologically induced 
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histamine release, but not that of compound 48/80 or A23187. I t has been reported 
that PS can enhance antigen induced ' ^ a uptake in rat peritoneal mast cells (Foreman 
et 仗，1977; Ishizaka et al, 1979). Lloret & Moreno (1995) also reported that LysoPS 
could induce a significant ^^Ca inf lux in mouse mast cells. The lysoPS-induced 
histamine release was blocked by apomorphine which inhibits cyclic nucleotide 
phosphodiesterase and E D T A , further supporting a role for Ca:+. These authors 
proposed that the histamine release induced by lysoPS was mediated by a GTP-binding 
protein and subsequent PLC activation. Pertussis toxin blocked the histamine releasing 
activity. Secondly lysoPS also stimulated inositol phosphate formation. These reports 
wou ld support our observations wi th the increased Ca!+ inf lux observed here wi th 
sPLA2-I I fo l lowing stimulation wi th anti-IgE. However, the mechanism of action is 
unclear and further experiments are needed. 
There was no enhancement of the Ca:+ signal observed when cells preincubated wi th 
sPLA2-I, were stimulated wi th anti-rat IgE. There was also no corresponding 
enhanced histamine release observed. This could be due to the time factor, since cells 
were preincubated wi th sPLA2-I for 5 min before activation wi th anti-rat IgE for a 
further 5 m in for calcium measurements. A significant enhancement o f histamine 
release was only observed with a 10 min preincubation time wi th sPLA2-I and a 10 min 
activation time wi th anti-rat IgE. The shorter incubation times were employed here 
to reduce the problem of dye leakage. L i addition, in this study wi th a 20 min reaction 
y 
t ime, cell clumping was observed. This may represent the death of some cells due to 
a poor oxygen supply since a high number of cells were present in the cuvette in a 
small volume of buffer. The spontaneous calcium measurement also increased wi th 
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the reaction t ime of 20 min. sPLA^-I may bind to a binding site on the mast cell 
plasma membrane and cause histamine release and release of the 14kDa type I I sPLA2 
located in the secretory granules of mast cells. Thus time may be needed for its 
secretion and action on increasing the inf lux of calcium. This may explain why there 
was no significant increase observed w i th the Ca]+ signal. 
Both sPLA2 enzymes led to a slow increase in the [Ca】+]” However, the net increase 
in the [Ca^^]； observed wi th sPLA2-I was 23.66 士 6.00 n M compared w i th 11.20 士 
2.57 n M for sPLA2-II (0.1 U ml"^). This inf lux of extracellular calcium could be 
mediated by the opening of a calcium channel on the plasma membrane for the type I I 
sPLA2. W i th the type I sPLA2the calcium influx observed maybe due to its enzymatic 
activity since no potentiation was observed fol lowing activation wi th anti-IgE. Binding 
o f the sPLA2 enzymes to a putative binding site could lead to an intracellular signalling 
event which could activate the opening of a calcium channel in the plasma membrane. 
Alternat ively, the sPLA2 enzymes may disrupt the plasma membrane through their 
enzymatic activity and this could lead to the observed calcium inf lux. 
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3.9 Summary of the possible mechanisms of action of the sPLAj enzymes 
The physiological ftinction of the sPLA】 enzymes originally isolated f rom the 
pancreatic juices were of a digestive nature. With in the past decade, the identif ication 
o f sPLA2 enzymes in tissues and in inflammatory conditions has questioned the 
ftmction o f these sPLA j enzymes. More recently, the identif ication o f specific 
receptors for these sPLA】 enzymes on cells and tissues has suggested that they may 
funct ion as signalling molecules. L i this study two main hypotheses: (a) catalytic 
action and Q)) signalling molecule, were proposed to explain the effects observed wi th 
the type I sPLA】 isolated f rom Naja naja venom and the type I I sPLA j isolated f rom 
Crotalus altrox venom on resting and activated rat peritoneal mast cells. 
Histamine release was observed with high concentrations of sPLAj- I (0.5 to 10 U m T ) 
on resting mast cells. This histamine release required a metabolically active cell, 
extracellular calcium and the native structure of sPLA2-I. sPLA2-I could mediate its 
effects on unstimulated mast cells by directly digesting the mast cell plasma membrane. 
Hydrolysis of the plasma membrane phospholipid could disrupt the plasma membrane 
structure. This altered membrane structure could then allow the influx of extracellular 
ions such as calcium into the cell cytosol. A slow increase in the [Ca^^]j was observed 
when fura-2 loaded cells were exposed to sPLA2-I. This inf lux o f calcium would be 
sufficient to cause histamine secretion since calcium plays a central role in mast cell 
degranulation (Pearce, 1985). 
Bevers et al. (1983) reported that the outer layer of the plasma membrane in resting 
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platelets is occupied w i th PC. The type I sPLA^ enzymes display a substrate 
specificity for PC or PE (Verhei j i et aL，1981). I f the mast cell plasma membrane has 
a s imi lar phosphol ipid composit ion l ike platelets, sPLA2-I could hydrolyse this PC. 
Hydrolysis o f PC could yield a l ip id substance which could augment fusion o f the mast 
cell plasma membrane w i th the secretory granules during histamine secretion. LysoPC 
was reported to have ftisogenic properties (Poole et al., 1970) but in mast cells lysoPC 
has a cytotoxic (Mart in & Lagunoff，1979) and inhibitory effect (Chemomordik et al， 
1993). 
Al ternat ively, s P L A j - I could bind to a putative binding site on the mast cell plasma 
membrane and act as a signalling molecule. Receptor sites for sPLA2-I have been 
identif ied in a variety of cells and tissues, such as Swiss 3T3 fibroblast cells (Ar i ta et 
aL, 1991), rabbit skeletal muscle (Lambeau et aL, 1990)，and rat vascular smooth 
muscle ^Ianasaki & Arita，1992). The type I sPLA2 receptors have also been cloned 
in rabbit (Lambeau et al.’ 1994)，bovine (Ishizaki et al., 1994) and human (Ancian et 
al., 1995) species. Binding of sPLAj - I to a binding site, could activate an intracellular 
signall ing pathway which may lead to the opening o f a plasma membrane calcium 
channel. This is possible since a slow calcium influx was observed when ftira-2 loaded 
cells were exposed to sPLA2-I. 
Unl ike histamine which is stored preformed in the mast cell secretory granules, PGD2 
is rapidly synthesised and released f rom mast cells fol lowing activation, t i this study, 
PGD2 production was only observed wi th an sPLA j I concentration of 1 U ml'^ (20 m in 
incubation). This PGD: could be produced by the free A A generated through sPLA2-I 
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hydrolysis o f the mast cell plasma membrane phospholipid (PC). This free A A could 
then be rapidly metabolised by the enzymes involved in A A metabolism inside the cell. 
Alternatively, PGD2 could be generated by activation o f the intracellular c P L A j i f 
sPLA2- l activated an intracellular signal transduction pathway through receptor 
binding. However, X ing et al. (1995) observed that short term exposure o f N f f l 3T3 
, 
cells to the porcine pancreatic sPLA2, did not generate a significant amount o f A A , 
whereas a 6 hour exposure did. Kishino et al. (1995) also reported that the porcine 
pancreatic sPLA2 augmented PGE! production in rat mesangial cells over a period o f 
24 hours. This effect was receptor mediated and did not require the enzymatic action 
o f sPLA2-I. This suggested that the PGD2 production observed here may not be 
receptor mediated. 
I n the present study, histamine release and PGD〗 production were observed w i th high 
concentrations of sPLA2-I and within a short time span of 20 minutes, t i addition, the 
histamine releasing activity of sPLA2-I was significantly reduced w i th the sPLA2 
inhibitors employed in this study (p-BPB and 12-epi-scalaradial). I f sPLA2-I was 
acting through a specific receptor site on the plasma membrane, in accordance wi th the 
reports by X ing et aL (1995) one would expect to see histamine release in the presence 
o f the sPLA2 inhibitors. However, this was not the case and led to the suggestion that 
the enzymatic activity of sPLAj- I on the plasma membrane may be responsible for the 
effects observed here. Of course, the identification of sPLAj - I receptor sites on the 
mast cell plasma membrane would help resolve whether or not the enzymatic action 
o f sPLA2-I is solely responsible for the present effects observed here. 
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b i contrast w i th sPLA2-I, the maximum % histamine release observed wi th sPLA2-II 
was generally not greater than 10% with resting cells. This release was reduced wi th 
the sPLA2 inhibitors j^-BPB and 12-epi-scalaradial, suggesting that the enzymatic site 
o f sPLA2-II was involved in mediating the effects observed here. The type I I sPLA2 
enzymes display a specificity for the phospholipid PE and PS. Jn resting platelets, 
these phospholipid are found in the inner layer o f the plasma membrane OBevers et al.， 
1983). I f this membrane phospholipid composition was applied to mast cells, i t may 
explain the low level ofhistamine observed in these studies as the specific substrate for 
sPLA2-II was unavailable. 
t i contrast wi th sPLA2-I, PGD2 was produced in a dose dependent manner. This PGDj 
could be produced by hydrolysis of the membrane phospholipid (PC or PE) to yield 
free A A . This free A A could then be rapidly metabolised by the enzymes involved in 
A A metabolism inside the cell. sPLA2-II could bind to a putative binding site on the 
mast cell plasma membrane and PGDj could be produced by the activation of the 
intracellular cPLA】，if sPLA2-II acted as a signalling molecule. One of the 
characteristics of these sPLAj receptors is their ability to intemalise upon receptor 
binding. This intemalisation could direct the action of sPLA2-II into the target cell, 
where the substrates PE and PS are readily available. However, based on the reports 
by X ing et al. (1995) where the receptor mediated effect of the pancreatic PLA2 
enzyme was observed over a long time span of 6 hours, and Kishino et al, (1995) who 
also reported that the porcine pancreatic sPLAj augmented PGEj production in rat 
mesangial cells over a period of 24 hours, the events observed here are unlikely to be 
receptor mediated. Of course, the identification of sPLAj- I I binding sites on the mast 
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cel l plasma membrane would help settle this. 
The specificity o f these sPLA2 enzymes to enhance immunologically induced histamine 
release，suggested that they may participate in some step specifically required for IgE 
induced release. This enhancement was unaffected by the c P L A j inhibitor M A F P , but 
was reduced in the presence of the PLA2 inhibitors p-BFB and 12-epi-scalaradial at 
concentrations that reduced the histamine releasing activity o f these enzymes. This 
suggested that the enzymatic activity o f the sPLA2 was responsible for the effects 
observed here. 
I t was also observed here that both P L A ! inhibitors, ;7-BPB and 12-epi-scalaradial 
inhibi ted the anti-IgE induced histamine release. A 14kDa type I I sPLA2 has been 
located in the secretory granules of rat peritoneal mast cells (Chock et al., 1994)，and 
is released when cells are stimulated w i th antigen (Murakami et al, 1992a). This 
secreted type H 14kDa sPLA2 could hydrolyse PS to yield lysoPS or another fusogenic 
compound and in this way augment histamine release. 
Bevers et al (1983) reported that in activated platelets, PE and PS were translocated 
to the outer layer o f the plasma membrane. Cross l inking o f the IgE receptor 
molecules on the mast cell plasma membrane may lead to a membrane rearrangement 
event. This could make the specific phospholipid substrates PE and PS available to 
sPLA2-n, for l ip id hydrolysis. Hydrolysis of PS by sPLA j - I I would generate lysoPS. 
Both PS (10-50 fjLg m T ) and lysoPS (less than 10 /xM), have been reported to enhance 
con A induced histamine release f rom rat peritoneal mast cells wi th lysoPS being 50 
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to 1,000 times more potent than PS (Goth et al, 1971; Baxter & Adamik , 1977; 
Mar t i n & Lagunoff，1979; Smith et al.’ 1979; Boarato et al., 1984; Hor igome et al., 
198¾. PS can enhance antigen induced ^ ^ a uptake in rat peritoneal mast cells 
(Foreman et al., 1977; Ishizaka et al., 1979) and lysoPS could induce ^ ^ a in f lux in 
mouse mast cells (Lloret & Moreno, 1995). These reports would support our 
observations w i th the increased Ca:+ inf lux observed here wi th sPLAj -H fo l lowing cell 
activation w i th anti-IgE. Thus the specificity o f sPLA2-II to enhance immunologically 
induced histamine release here, suggested that i t may in some way facilitate i n the 
opening, or maintain the opening o f a plasma membrane calcium channel. The 
mechanism(s) o f action needs to be determined. 
PGD2 production was also enhanced in anti-IgE stimulated cells preincubated w i th the 
type n sPLA2 enzyme purif ied f rom Crotalus altrox venom. Foneth et al (1994) 
reported that the mouse mast cell l ine (BBMC) secrete a 14kDa type I I sPLA j 
fo l lowing antigen challenge. This sPLA2-n enzyme leads to the rapid mobil isation of 
extracellular A A which is subsequently used for eicosanoid generation. The enhanced 
PGD2 production observed here is probably due to the release of more A A f rom the 
membrane phospholipid fol lowing the enzymatic action of the secreted PLA2-n. 
> 
A significant enhancement of immunologically induced histamine release was observed 
w i th non-releasing concentrations of sPLA2-I. Release of the 14kDa type I I sPLA2, 
located in the mast cell secretory granules fol lowing cell activation, may explain the 
enhanced histamine release observed wi th sPLAj - I in this study. Significant 
enhancement was only observed with the longer activation time with anti-IgE (10 min), 
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suggesting that time may be needed for secretion o f the 14kDa type I I sPLA2 f rom the 
mast cell granules in order to mediate its effects i.e. opening o f calcium channel. 
However , there was no enhancement observed wi th the Ca:+ signal again suggesting 
that t ime may be required for secretion o f the 14kDa type I I sPLA2 and action on 
increasing the inf lux of calcium. There was also no significant enhancement o f PGD2 
production observed w i th sPLA2-I fo l lowing activation w i th anti-rat IgE. The lack o f 
enhancement observed here again maybe due to this time factor. Alternatively binding 





To conclude, the results o f these studies have indicated that the type I sPLA】 pur i f ied 
f r o m Naja naja venom, caused histamine release and PGDj production at h igh 
concentrations (0.5 to 10 U m l ] ) . The mode of action proposed for this effect 
involved the enzymatic site 0fsPLA2-I . The type I I sPLA2 pur i f ied f rom Crotalus 
altrox venom caused low levels o f histamine release. However, PGD2 was produced 
in a dose dependent manner (0.001 to 1 U mi'^). The mode o f action o f s P L A j could 
involve the digestive nature of the enzyme to generate free A A or be receptor mediated 
and activate cPLA】. 
t i addition to the effects observed on unstimulated mast cells, these sPLA2 specifically 
enhanced immunological ly induced histamine release. This suggested their 
participation in some step specifically required for anti-IgE induced release. Therefore 
these sPLA2 enzymes may have a pro-inflammatory role in inflammation. The inf lux 
o f calcium f rom the extracellular environment through plasma membrane calcium 
channels is required for immunologically induced histamine release. A n increase in 
the [Ca2+]i，during the second phase of the biphasic Ca】+ response, fol lowing cell 
activation wi th anti-IgE was observed wi th sPLAj- I I . This was not observed w i th the 
type I sPLA2. It was proposed that sPLA2-II may facilitate the opening, or maintain 
the opening of the plasma membrane calcium channels. This could be mediated by the 
enzymatic nature of sPLA2-II, as enhancement was reduced fol lowing p-BPB and 12-
epi-scalaradial treatment. sPLA2-II may participate in the opening of the plasma 
membrane calcium channels through the generation of a l ip id metabolite such as 
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lysoPS. 
Histamine release induced by anti-IgE was inhibited by the sPLA! inhibitors p-BPB and 
12-epi-scalaradial. A role for sPLA2 was proposed to be involved in anti-rat l gE 
induced histamine release f rom rat peritoneal mast cells. 
3.11 Future studies 
The mechanism(s) of action of the sPLA】 enzymes on the mast cell plasma membrane 
requires further studies. The development o f more specific sPLA j inhibitors both for 
the enzymatic site and receptor binding site would help establish what nature o f these 
enzymes is involved in the effects observed in this study. Membrane studies would 
help establish the phospholipid composition of the mast cell plasma membrane. 
Studies to identify the l ip id metabolites fol lowing phospholipid hydrolysis are also 
required. The present study did not provide direct evidence for the existence of 
selective binding sites for the sPLA2 enzymes on the mast cell plasma membrane. 
Therefore further studies such as radioligand binding studies would help in the 
identification of binding sites for the sPLA2 enzymes investigated here. The analysis 
o f the biochemical signal transduction pathway(s) activated in response to sPLA2 
binding is another area that requires further investigation. 
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CHAPTER 4 





Most o f the knowledge on the physiology and pharmacology o f mast cells was init ial ly 
derived f rom studies on the rat peritoneal mast cell. These cells can easily be obtained 
by direct lavage of the peritoneal cavity and can be readily puri f ied. W i t h the 
development o f methods for the enzymatic dissociation of mast cells f rom tissues o f 
experimental animals and man it was shown that these histaminocytes are different. 
M e e d these cells are known to exhibit heterogeneity in their morphological, 
histochemical and functional properties (for reviews see Barrett & Metcalfe, 1987; 
Barrett & Pearce，1993; Irani & Schwartz，1994). Today the idea o f mast cell 
heterogeneity is wel l established and i t is inappropriate to rely solely on the rat as an 
animal model for investigations. 
The or iginal description of mast cell heterogeneity was based on differential staining 
properties, between two distinct populations of mast cells identified in the rat intestine 
(for review see Enerback, 1981). Mast cells located in the lower layer of the intestinal 
wa l l resemble those found in other connective tissues and the serosal cavity. The mast 
cells located in the mucosa exhibit different properties. These mucosal mast cells 
require different f ixation and staining conditions when compared wi th cells f rom 
connective tissues. These differential staining properties are due to the proteoglycan 
content found in their secretory granules wi th in the cytoplasm. Rat peritoneal mast 
cells contain heparin (Yurt et al., 1977) and are stained wi th both alcian blue and 
safaranin. Litestinal mucosa mast cells contain chondroitin sulphate di-B but do not 
contain heparin (Stevens et al” 1986) and stain only w i th alcian blue. Based on this 
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fmd ing mast cells were divided into two classes, the connective tissue mast cel l 
( C T M C ) and the mucosal mast cell ( M M C ) . This classical classification was not so 
clear i n other species such as in human (Strobel et al,，1981; Befus et aL, 1985)，so 
other cr i ter ia were required. 
Mast cells can also be distinguished by their granular enzyme content. T w o 
antigenically different serine proteases, (rat mast cell protease (RMCP) type I and 11), 
w i t h chymotryptic activity are differential ly expressed in rat mast cells (Woodbury et 
a/ . , 1987). Rat peritoneal mast cells, together w i th cells f rom the skin and lung 
contain R M C P type I，while mast cells o f the intestinal mucosa contain R M C P type I I 
(Gibson & Mil ler，1986). 
Human mast cells are also distinguished by their granular protease content (for review 
see I rani & Schwartz, 1994). Two types o f proteases have been isolated, a tryptase 
( t rypt ic specificity) and a chymase (Schwartz et al” 1987a). Mast cells containing 
tryptase plus chymase (MCrc) are predominately located in the skin and the intestinal 
mucosa w i th a minori ty population present in the lung (10%). Most o f the mast cells 
i n the lung (90%) and cells in the intestinal mucosa only contain tryptase ( M C j ) (Irani 
etal., 1986; Schwartz^f aL, 1987b). 
b i addit ion to protease content, human mast cells are also heterogenous w i th respect 
to their cytokine content. H-4 is distributed among both mast cell phenotypes, w i th a 
higher distribution in the MCpc subset (85%) compared wi th 15% in the M Q subset. 
11-5 and IL -6 are found exclusively in the MC^ subset (Bradding et al., 1995). 
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Morpho log ica l studies o f human mast cells revealed that the secretory granules have 
patterns such as scrolls, crystals, particles or a mixture o f al l three. L i p i d bodies are 
also present in human mast cells. Guinea p ig mast cells contain basket shaped granules 
and may be homogeneous, granular, strandlike or crystall ine i n f o rm (Dvorak et aL, 
1983; Gal l i et al” 1984). Rat C T M C have homogeneous granules that are un i fo rmly 
electron dense (Behrendt et al.，1978). 
Mast cells also dif fer i n their responsiveness to various histamine liberators. The 
existence o f functional heterogeneity was init ial ly observed by Enerback in the rat w i th 
the basic secretagogue compound 48/80. This secretagogue could degranulate 
connective tissue mast cells in situ whereas the cells in the gastrointestinal mucosa 
were unresponsive (Enerback, 1966). Peritoneal mast cells o f the rat and hamster are 
responsive to this agent (Leung & Pearce，1984), whereas peritoneal cells f r om the 
mouse are less sensitive ^ a r r e t t & Pearce’ 1983). Tissue mast cells f rom the guinea 
pig lung and mesentery are refractory to this compound. Human lung mast cells were 
also unresponsive to compound 48/80. This unresponsiveness was also seen w i th 
peptide 401 and dextran in guinea pig and human lung mast cells (Pearce et aL, 1985). 
This functional heterogeneity is also seen w i th antiallergic drugs. Many potential 
antiallergic compounds tend to show a high degree o f mast cell selectivity in their 
action. Disodium cromoglycate is a very potent inhibitor o f IgE induced histamine 
r 
release from rat peritoneal mast cells (Pearce et al., 1989). L i contrast, i t is less active 
against mucosal mast cells f rom the rat, tissue mast cells o f the guinea pig and human 
as wel l as human basophils. The phosphodiesterase inhibitor, theophylline is active 
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against rat peritoneal mast cells (Pearce et aL, 1982), human cells (Barrett et al.， 
1986) but inactive w i th rat intestinal mucosal mast cells (Pearce et al.，1982). The p2_ 
adrenoceptor agonists salbutamol, formoterol and salmeterol are without effect on 
immunological ly induced histamine release f rom rat peritoneal mast cells. I n contrast 
histamine release was strongly inhibited in guinea pig and human lung mast cells (Lau 
etal., 1994). 
The heterogeneity o f mast cells was investigated here by comparing the effects o f the 
sPLA2 enzymes on rat peritoneal mast cells, human lung and guinea p ig lung mast 
cells. Rat peritoneal mast cells were employed in this study as they have been 
extensively characterised, are abundant and are easily isolated and puri f ied. Guinea 
p ig lung mast cells were also used in this study since the availabil ity o f human tissue 
was l imited. 
4.2 Methodology 




4.3.1 Effects of sPLA: on the spontaneous histamine release from HLMC 
Human lung mast cells were incubated w i th the sPLA2 enzymes for 10 and 20 min. 
W i t h sPLA2-I there was no significant release of histamine observed w i th 
concentrations less than 10 U m l 、 A p p r o x i m a t e l y 10% histamine release was 
observed at 10 U ml"^ (Fig 4.1). Similar results were obtained wi th sPLA2-II where 
no significant release of histamine was observed even at the highest enzyme 
concentration (Fig 4.2). 
4.3.2 Effects of sPLA2 on immunologically induced histamine release from 
HLMC 
Anti-human IgE was used as the immunological stimulus and a f inal concentration of 
1/100 dilution of the supplied stock was used to induce approximately 30% histamine 
release. Human lung mast cells were preincubated wi th the sPLAj enzymes for 10 
min . Anti-human IgE was subsequently added and histamine release allowed to 
proceed for a further 10 min. A t concentrations between 0.01 and 10 U m l ' \ sPLA j - I 
significantly inhibited the anti-human IgE induced histamine release in a dose 
dependent manner (Fig 4.3 and table 4.1). As illustrated in table 4.1 the 
experimentally observed histamine release induced by anti-human IgE f rom sPLA2-I 
pretreated cells was less than the sum of the individual effects. Differences between 
the observed and additive effects were compared using paired Student's t tests. No 
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significant inhibit ion was observed at lower concentrations of sPLA2-I (0.001 to 0.005 
U ml- i) . 
The type I I sPLA2 enzyme also produced a dose dependent inhibit ion o f the anti-human 
IgE induced histamine release. However, significant inhibit ion was observed at 
concentrations between 0.025 and 10 U m l ] (Fig 4.4 and table 4.2). 
Dose inhibi t ion curves were constructed to illustrate the inhibitory potency o f these 
enzymes (Fig 4.5). sPLAj - I was more effective than sPLA2-II in inhibit ing histamine 
release, w i th a maximum inhibit ion of 72.70 土 4.12% at 10 U ml_i, whereas 
max imum inhibi t ion was only 54.54 土 4.81 % wi th the type I I sPLA2. 
4.3.3 Effects of sPLA2 on A23187 induced histamine release from HLMC 
The effects of these sPLA】 enzymes on histamine release induced by the calcium 
ionophore A23187 were also investigated. Following preincubation wi th either sPLA! 
enzyme, the A23187 (1 ixM) induced histamine release was inhibited dose dependently 
(Fig 4.6 and 4.7). However this inhibition was only observed at sPLAj concentrations 
between 1 and 10 U ml"^ (Fig 4.8 and table 4.3 a + b). Jn this study the maximum 
percentage inhibit ion was lower than that observed wi th anti-human IgE, 59.64 土 




4.3.4 Effects of p-BPB on the inhibitory activity of sPLA^-I 
b i order to characterise the inhibitory activity o f the sPLA2-I enzyme, the enzyme was 
pretreated w i t h the P L A : inhibitor p -BPB before incubation w i th cells, h i a l imi ted 
series o f experiments (n = 3)，sPLA2-I was pretreated w i th 10，1 and 0.1 /xM o f p-
BPB. The effects o f the pretreated enzyme on anti-human IgE (1/100) induced 
histamine release were investigated. I t was observed that 10 /xM o f p - B P B alone 
signif icantly reduced the anti-human IgE induced histamine release (Table 4.4). 
Concentrations o f 0.1 and 1 / i M o f p - B P B did not effect the anti-human IgE induced 
release. I t was also noted that at these concentrations, /7-BPB did not abolish the 
inh ib i tory action o f sPLA2-I on immunological ly stimulated human lung mast cells. 
4.3.5 Effects of sPLA2 on partially purified HLMC 
The inhibitory activities of these sPLA2 enzymes on human lung mast cells could also 
be influenced by the presence of other functional cells in the mixed cell population. 
l n order to investigate this, attempts were made to partially puri fy the human lung mast 
cells population. However the relative population of mast cells was only enriched to 
11.13 土 2.06% (range 6.22 to 17.48%, n = 5)，from 5.09 土 0.75% (range 3.57 to 
7 .52%, n = 5) o f the total nucleated cells in the dispersed lung cell suspension. 
Al though many attempts at purif ication were made only f ive provided sufficient cells 
for further experiments. When cells were incubated w i th the sPLA2 enzymes for 20 
m in there was no significant release of histamine observed w i th both cell populations 
(Table 4.5 a + b). However the spontaneous histamine release was elevated in the 
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part ial ly pur i f ied lung mast cell population. 
The effects o f the sPLA2 enzymes on anti-human IgE induced histamine release were 
also investigated. The anti-human IgE (1/100) induced histamine release was itself 
reduced i n the partially puri f ied cells, 9.20 土 0.59% compared to 41.23 土 3.31% 
w i t h the mixed cell suspension (n = 3). Al though the anti-human IgE induced 
histamine release was reduced, the inhibitory effect of these sPLA j enzymes was sti l l 
observed between 1 and 10 U ml"^ (Table 4.6 a + b). 
4.3.6 Effects of sPLA2 on the spontaneous histamine release from G P L M C 
Guinea pig lung mast cells were incubated wi th the sPLA2 enzymes for 20 and 30 min. 
W i th sPLA2-I concentrations between 0.1 and 10 U m l ^ cells released histamine in a 
dose dependent manner at both time incubations (Fig 4.9). Significantly more 
histamine was released at the 30 min incubation than at the 20 min incubation between 
5-10 U ml'^ (p < 0.05). The maximum histamine release was 32.82 ± 4.30% (30 min) 
compared to 16.93 士 2.43% (20 min) at 10 U ml ' ^ However, lower concentrations 
o f sPLA2-I (0.001 to 0.10 U ml-i) did not seem to have any significant effect on the 
spontaneous histamine release, h i contrast the type I I sPLAj enzyme had no direct 
effect on the cells at any concentrations tested (0.001 to 10.0 U ml"^) (Fig 4.10). 
‘， 
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4.3.7 Effects of sPLA】 on immunologically induced histamine release from 
GPLMC 
Ovalbumin was used as the immunological stimulus at a f inal concentration o f 0 . 1 > g 
mTi. Cells were pretreated wi th the sPLA2 enzymes for 10 min before the addit ion o f 
ovalbumin. Histamine release was then allowed to proceed for a ftirther 20 min. The 
spontaneous release of histamine induced by sPLA2-I itself complicates these analyses. 
However, no enhancement of the ovalbumin induced histamine release was observed. 
Concentrations o f sPLA2-I between 0.05 and 10 U m \ ' \ significantly inhibited the 
ovalbumin induced histamine release (Fig 4.11 and table 4.7). This inhibitory effect 
is best illustrated in the dose inhibit ion curve (Fig 4.13). Between 0.5 and 10 U ml"^ 
the % inhibi t ion ranged between 84.83 士 3.12% and 94.63 土 3.97%. The type I I 
sPLA2 enzyme between 1 and 10 U ml'^ significantly inhibited the ovalbumin induced 
histamine release dose dependently (Fig 4.12 and table 4.8). This inhibitory effect was 
not observed at concentrations less than 0.5 U m l ' 、 T h e maximum inhibit ion was 
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Figure 4 .1 Effects of sPLA2-I on the spontaneous histamine release from human lung 
mast cells. Cells were incubated wi th sPLAj - I (0.05 to 10 U ml"^) for 10 ( • ) and 
(0.001 to 10 U ml"^) for 20 min ( • ) . The spontaneous histamine release was 5.64 士 
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F igure 4.2 Effects o f sPLA2-n on the spontaneous histamine release from human lung 
mast cells. Cells were incubated w i th sPLA2-n (0.05 to 10 U ml"^) for 10 ( • ) and 
(0.001 to 10 U ml'^) for 20 m in ( • ) • The spontaneous histamine release was 6.24 士 
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F igure 4.3 Effects of sPLA2-I on anti-human IgE induced histamine secretion f rom 
human lung mast cells. Control cells were incubated wi th sPLA2-I for 20 min ( • ) . 
Ant i-human IgE stimulated cells were pretreated wi th sPLA2-I for 10 m in and 
stimulated for a further 10 min wi th anti-human IgE ( • ) • Anti-human IgE (1/100) 
induced histamine release was 32.27 士 0.99% (—). The spontaneous histamine 
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Figure 4.4 Effects of sPLA2-II on anti-human IgE induced histamine secretion f rom 
human lung mast cells. Control cells were incubated wi th sPLAj - I I for 20 m in ( • ) . 
Ant i-human IgE stimulated cells were pretreated wi th sPLA2-II for 10 m in and 
stimulated for a further 10 min wi th anti-human IgE ( • ) . Anti-human IgE (1/100) ‘ 
induced histamine release was 31.40 土 1.81% (—). The spontaneous histamine 
release was 7.00 士 0.41%. Results are given as the means 士 SEM for n = 5-12. 
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Figure 4.5 hihibit ion of anti-human IgE induced histamine release f rom human lung 
mast cells by sPLAj - I (〇）and sPLAj - I I ( • ) . Results are given as the means 土 S E M 
for n = 5-14. 
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Figure 4.6 Effects of sPLA2-I on A23187 induced histamine secretion f rom human 
lung mast cells. Control cells were incubated wi th sPLA2-I (0.001 to 10 U m l . ) for 
20 m in ( • ) . A23187 stimulated cells were pretreated wi th sPLA2-I for 10 m in and 
stimulated for a further 10 min with A23187 ( • ) . A23187 (1 /xM) induced histknine 
release was 55.33 士 2.32% (—). The spontaneous histamine release was 5.61 士 
0.97%. Results are given as the means 土 SEM for n = 5-8. 
173 
60 ~| 
! 5 。十 r 1 \ ^ " ~ ^ 
i 40 - i \ ” 
？ > 




I 2 0 -^ 
c« 
“ 1 0 -
o J n — — ^ ^ - ^ 
I 1 1 1 1 
0.001 0.01 0.1 1 10 
sPLA2-II (Units ml i) 
Figure 4.7 Effects of sPLA2-II on A23187 induced histamine secretion from human 
lung mast cells. Control cells were incubated wi th sPLAj - I I (0.001 to 10 U ml"^) for 
20 m in ( • ) • A23187 stimulated cells were pretreated wi th sPLA2-II for 10 min and 
stimulated for a further 10 min wi th A23187 ( • ) . A23187 (1 f j M ) induced histamine 
release was 50.33 士 1.78% (—). The spontaneous histamine release was 6.62 士 
0.95%. Results are given as the means 士 SEM for n = 6-9. 
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F igu re 4.8 M u b i t i o n of A23187 induced histamine release f rom human lung mast 
cells by sPLA j - I (〇）and sPLAj - I I ( • ) . Results are given as the means 士 S E M for 
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Figure 4.9 Effects of sPLA2-I on the spontaneous histamine release f rom guinea pig 
lung mast cells. Cells were incubated wi th sPLA2-I (0.001 to 10 U mTi) for 20 ( • ) 
and 30 min ( • ) • The spontaneous histamine release was 3.30 土 0.68%. Results are 
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Figure 4.10 Effects of sPLAj-H on the spontaneous histamine release f rom guinea pig 
lung mast cells. Cells were incubated wi th sPLA2-II (0.001 to 10 U mr^) for 20 ( • ) 
and 30 min ( • ) . The spontaneous histamine release was 3.52 士 0.70%. Results are 
given as the means 土 SEM for n = 6-12. 
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Figure 4.11 Effects of sPLA2-I on ovalbumin induced histamine secretion f rom guinea 
pig lung mast cells. Control cells were incubated wi th sPLA2-I (0.001 to 10 U ml'^) 
for 30 min ( • ) . Ovalbumin stimulated cells were pretreated wi th sPLAj - I for 10 min 
and stimulated for a further 20 min wi th ovalbumin ( • ) . Ovalbumin (0.1 /xg ml"^) 
induced histamine release was 37.70 士 1.67% (—). The spontaneous histamine 
release was 4.20 土 0.83%. Results are given as the means 士 SEM for n = 4-8. 178 
5 0 "] 
, , o l t - - \ ^ 工 
I r = i 
f3。- \ 
S Y ““ 
1 20- ^^TT 1 1 K 10 - • 
_ ^ _ ^ W ° 
0」c> -^^"^"~0"^> o^^ 
I — I 1 1 1 
0.001 0.01 0.1 1 10 
sPLA2-II (Units ml i) 
y 
Figure 4.12 Effects of sPLAj-II on ovalbumin induced histamine secretion f rom 
guinea pig lung mast cells. Control cells were incubated with sPLAj- I I (0.001 to 10 
U mTi) for 30 min ( • ) . Ovalbumin stimulated cells were pretreated with sPLA2-II for 
r 
10 min and stimulated for a further 20 min wi th ovalbumin ( • ) . Ovalbumin (0.1 fjLg 
ml"^) induced histamine release was 37.70 土 1.67% (—). The spontaneous histamine 
release was 4.73 士 0.86%. Results are given as the means 士 SEM for n = 4-8. 
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Figure 4.13 feihibition o f ovalbumin induced histamine release f rom guinea p ig lung 
mast cells by sPLA2-I (〇）and sPLAj - I I ( • ) • Results are given as the means 士 S E M 
for n = 4-8. 
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Table 4.1 Comparison between histamine release induced by anti-human IgE from 
sPLA2-I pretreated human lung mast cells wi th the calculated combined histamine 
release induced by sPLA2-I and anti-human IgE. Anti-human IgE (1/100), induced 
histamine release was 32.27 士 1.00%. * * = p ^ 0.01 as compared wi th the 
calculated combined value. Values are means 士 SEM for n = 6 - l 4 . 
Histamine release (% of total) 
sPLA2-I [sPLA2-I + IgE] [sPLA2-q + PgE] 
10 Units mTi 17.59 士 1.99** 41.00 士 1.55 
7.5 Units mTi 19.43 士 3.32** 42.39 士 2.50 
5.0 Units ml-i 16.80 士 3.50** 45.41 士 4.62 
2.5 Units ml_i 17.14 士 3.08** 37.58 士 1.26 
1.0 Uni t mTi 18.60 士 1.33** 35.50 士 0.92 
0.5 Units ml-i 18.58 士 3.33** 35.70 土 1.14 
0.1 Units ml-i 23.28 土 1.94** 33.56 士 1.01 
0.05 Units mr^ 23.77 士 2.78** 33.81 土 1.14 
0.025 Units ml"^ 25.41 士 1.83** 33.49 土 1.11 
0.01 Units ml-i 29.55 士 1.46** 32.66 土 1.03 
0.005 Units ml_i 29.30 土 1.56 33.63 士 1.08 
0.001 Units ml-i 30.74 土 1.51 32.74 土 1.04 
[sPLA2-I + IgE] = histamine release induced by anti-human IgE f rom sPLA2-I 
pretreated cells as observed in the experiment. 
[sPLA2-I] + [IgE] = combined histamine release, calculated by adding the release 
induced by sPLA2-I alone to that induced by anti-human IgE alone for each individual 
experiment. 
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Table 4.2 Comparison between histamine release induced by anti-human IgE f rom 
sPLA2-II pretreated human lung mast cells w i th the calculated combined histamine 
release induced by sPLA2-n and anti-human IgE. Anti-human IgE induced histamine 
release was 31.40 土 1.81%. * * = p ^ 0.01 and * = p ^ 0.05 as compared w i th the 
calculated combined value. Values are means 士 SEM for n = 5-12. 
Histamine release (% of total) 
sPLA2-II [sPLA2-II + IgE] [sPLA^-iq + PgE] 
10 Units ml-i 17.61 土 1.83** 34.99 士 2.11 
7.5 Units m r i 18.19 士 1.94** 33.20 士 3.06 
5.0 Units ml_i 20.49 士 2 .28** 35.20 士 2.73 
2.5 Units ml-i 22.51 士 3 .02** 32.47 士 2.86 
1.0 Uni t ml_i 23.01 士 2 .13** 33.00 士 2.24 
0.5 Units ml-i 24.04 士 2 .21** 31.79 士 2.66 
0.1 Units ml-i 30.22 士 2.18* 32.30 士 2.00 
0.05 Units ml_i 29.57 士 2 .74** 31.62 士 2.57 
0.025 Units ml_i 30.40 土 3 .49** 32.85 土 3.50 
0.01 Units ml-i 31.57 士 2.27 31.83 土 2.20 
0.005 Units m l ^ 29.56 士 3.25* 31.22 士 3.00 
y 
0.001 Units ml-i 30.56 士 2.42 31.76 士 2.62 
[sPLA2-II + IgE] = histamine release induced by anti-human IgE f rom sPLAj - I I 
pretreated cells as observed in the experiment. 
[sPLA2-II] + [IgE] = combined histamine release, calculated by adding the release 
induced by sPLAj -n alone to that induced by anti-human IgE alone for each individual 
experiment. 
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Tab le 4.3 (a + b) Comparison between histamine release induced by A23187 f r o m 
(a) sPLA2-I and (b) s P L ^ - I I pretreated human lung mast cells w i th the calculated 
combined histamine release induced by sPLA! and A23187. A23187 (1 /xM) induced 
histamine release was 55.33 士 2.32% and 50.33 士 1.78%， respect ively. * * = p < 
0.01 and * = p < 0.05 as compared w i th the calculated combined value. Values are 
means 士 S E M for n = 5-9. 
Tab le 4.3 (a) H is tamine release (% o f total ) 
sPLA2- I [sPLA2-I + A23187] [sPLA2-q + [A23187] 
10 Units mTi 37.93 士 5 .60** 63.08 士 2.19 
5.0 Units ml_i 29.41 士 7 .19** 61.36 士 4.24 
1.0 Un i t ml- i 42.11 士 5 .91** 57.81 士 2.23 
0 .1 Units ml_i 53.33 士 4.46 56.64 士 2.48 
0.01 Units ml-i 55.78 土 3.28 56.03 士 2.38 
0.001 Units m " 51.60 士 4.02 55.68 土 2.38 
Tab le 4.3 (Jb) Histamine release (% o f total) 
sPLA2- I [sPLA2-I I + A23187] [ sPLA2- iq + [A23187] 
10 Units ml_i 34.87 士 5 .75** 53.80 士 2.44 
5.0 Units ml-i 32.13 士 5 .58** 50.66 士 2.38 
^ 1.0 Un i t ml_i 43.59 士 4.89* 52.33 士 2.20 
0.1 Units ml_i 50.52 士 3.51 50.90 土 1.68 
0.01 Units ml_i 51.16 士 2.79 50.56 士 1.77 
0.001 Units ml-i 49.58 士 3.90 51.32 士 2.00 
[sPLAj + A23187] = histamine release induced by A23187 f rom sPLA2 pretreated 
cells as observed in the experiment. 
[ sPLAJ + [A23187] = combined histamine release, calculated by adding the release 
induced by the enzyme alone to that induced by A23187 alone for each individual 
experiment. 
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T a b l e 4 .4 Effect o f p -BPB pretreatment on the inhibi tory activity o f s P L A j - I on 
histamine release induced by anti-human IgE f rom human lung mast cells. s P L A j - I 
was incubated w i th p-B?B for 30 m i n at 37。C. The pretreated sPLA2-I was then 
incubated w i th the cells for 10 min before stimulation w i th anti-human IgE for 10 min. 
Values are means 士 S E M for n = 3. * = p < 0.05 as compared wi th the appropriate 
control . 
H is tamine release (% of total) 
p-BPB 
sPLA2- I Con t ro l 0.10 ^ M 1.0 / i M 10 f M 
10 Units ml-i 16.0 士 1.5 17.6 士 2.4 15.7 士 2.4 5.0 土 0 .7* 
1.0 Un i t ml-i 18.1 士 2.6 19.2 士 4.0 17.7 士 2.7 5.2 土 1.1* 
0 .1 Units ml_i 23.1 士 1.8 24.4 土 1.7 22.5 士 1.1 4.8 士 1.4* 
0.01 Units ml_i 29.1 士 0.3 29.4 土 1.0 28.3 士 1.2 5.9 士 2 .1* 
0.001 Units ml-i 32.3 士 1.0 31.0 士 1.6 29.5 士 1.6 6.3 士 2 .6* 
IgE (1/100) 3 3 . 0 ± 1.0 32.3 士 0.2 29.7 ± 2 . 7 4 . 8 士 2 . 1 * 
J 
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Table 4.5 (a + b) Comparison between the histamine release induced by (a) PLA2-I 
and (b) sPLAj - I I , w i th mixed and partially purif ied human lung mast cells. Cells were 
incubated w i th either sPLA】 enzyme for 20 min. Values are means 士 SEM for n=3>4. 
Tab le 4.5 a Histamine release (% of total) 
sPLA2- I M i xed Par t ia l ly pu r i f i ed 
10 Units ml-i 9.01 士 2.62 9.70 士 2.68 
l . O U n i t mr^ 2.76 士 0.12 7.14 士 1.06 
0.1 Units ml-i 0.45 士 0.45 1.81 士 1.05 
0.01 Units ml-i 0.16 士 0.16 1.21 土 1.21 
0.001 Units ml-i 0.0 士 0.0 0.86 土 0.44 
Spontaneous 4.26 士 1.17 9.12 士 1.44 
Tab le 4.5 b Histamine release (% o f total) 
sPLA2- I I M ixed Part ia l ly pur i f i ed 
10 Units ml-i 3.19 士 1.16 1.77 士 1.18 
1.0 Uni t ml-i 2.79 士 1.82 1.31 士 0.68 
0.1 Units ml-i 0.67 士 0.28 0.38 士 0.23 
0.01 Units ml-i 0.49 士 0.40 0.19 士 0.14 
0.001 Units mTi 1.41 士 1.01 0.11 士 0.10 





Table 4.6 (a + b) Effect of (a) sPLA^-I and (b) sPLA2-II on anti-human IgE induced 
histamine release f rom partially purif ied human lung mast cells. Control cells were 
incubated wi th either sPLA2 enzyme for 20 min (sPLA2). Anti-human IgE stimulated 
cells were pretreated with sPLA2 for 10 min and stimulated for a ftirther 10 m in wi th 
anti-human IgE (sPLA2 + IgE). Data are expressed for two individual experiments 
w i th the corresponding sPLAj enzymes. 
Table 4.6 a Histamine release (% of total) 
sPLA2-I sPLA2-I sPLA2-I sPLA2-I sPLA2-I 
+ IgE + IgE 
l O U n i t s m l - i 15.03 18.48 6.35 11.32 
l . O U n i t m r i 6.98 12.27 5.39 9.09 
O . l U n i t s m l - i 3.79 13.74 0.23 7.64 
0.01 Units ml-i 2.62 13.26 0.00 7.70 
0.001 Uni tsml- i 1.42 11.26 1.16 8.24 
IgE release = 10.37 IgE release = 8.69 
Table 4.6 b Histamine release (% of total) 
sPLA2-II sPLA2-II sPLA2-II sPLA2-II sPLA2-II 
+ IgE + IgE 
) l O U n i t s m T i 5.24 8.84 0.86 7.01 
1.0 Units ml'^ 2.23 10.66 0.31 6.98 
0.1 Units ml-^ 0.00 10.47 0.61 6.37 
0.01 Units ml_i 0.61 8.70 0.00 8.03 
0.001 Units ml_i 0.01 S ^ ^ 6 ^ 
IgE release = 8.53 IgE release = 8.69 
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Table 4.7 Comparison between histamine release induced by ovalbumin f rom sPLA j - I 
pretreated guinea pig lung mast cells w i th the calculated combined histamine release 
induced by sPLA2-I and ovalbumin. Ovalbumin induced histamine release was 37.70 
士 1.67%. * * = p < 0.01 and * = p < 0.05 as compared wi th the calculated 
combined value. Values are means 士 SEM for n = 4-8. 
Histamine release (% o f total) 
sPLA2- I [sPLA2-I + Ova] [ sPLA2-q+ [Ova] 
10 Units ml-i 37.07 士 3 .78** 68.77 土 3.88 
7.5 Units ml_i 22.33 士 2 .09** 59.51 土 3.80 
5.0 Units ml-' 20.51 士 2 .77** 58.75 士 4.08 
2.5 Units ml-i 13.31 土 2 .16** 52.70 士 2.36 
1.0 U n i t m l - i 9.11 士 1.43** 42.53 士 2.67 
0.5 Units ml_i 9.05 士 2 .75** 45.34 士 1.20 ‘ 
0.1 Units ml-i 20.39 士 2 .68** 40.80 士 1.81 
0.05 Units ml-i 20.71 土 4.83* 41.72 士 0.51 
0.01 Units ml_i 33.34 土 2.28 38.09 士 1.62 
0.005 Units mT^ 36.37 士 3.78 41.08 土 0.79 
0.001 Units ml_i 38.95 士 2.39 39.53 士 1.51 
/ . 
[sPLAj - I +Ova] = histamine release induced by ovalbumin f rom sPLA2-I pretreated 
cells as observed in the experiment. 
[sPLA2-I] + [Ova] = combined histamine release, calculated by adding the release 
induced by sPLAj - I alone to that induced by ovalbumin alone for each individual 
‘ e x p e r i m e n t . 
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Table 4.8 Comparison between histamine release induced by ovalbumin from sPLAj -
n pretreated guinea pig lung mast cells wi th the calculated combined histamine release 
induced by sPLA2-II and ovalbumin. Ovalbumin induced histamine release was 37.70 
土 1.67%. * = p ^ 0,05 as compared wi th the calculated combined value. Values are 
means 士 S E M for n = 4-8. 
Histamine release (% of total) 
sPLA2-II [sPLA2-II + Ova] [sPLA2-iq + [Ova] 
10 Units ml-i 9.77 士 1.81* 44.29 士 2.37 
7.5 Units mTi 14.67 士 5.69* 46.86 土 3.06 
5.0 Units ml_i 15.41 土 5.36* 45.32 士 2.00 
2.5 Units mTi 19.63 土 4.92* 44.60 土 1.88 
1.0 U n i t m r i 21.40 士 3.74* 40.01 土 1.81 
0.5 Units mTi 35.16 土 3.46 41.71 士 1.06 
0.1 Units m r i 35.59 土 2.84 38.14 士 1.67 
0.05 Units ml_i 42.29 士 2.58 41.17 士 0.70 
0.01 Units mTi 39.44 士 2.62 38.78 士 1.96 
0.005 Units ml'^ 44.56 土 3.15 42.37 士 1.27 
0.001 Units ml-i 40.52 士 2.54 38.32 土 1.82 
[sPLA2-II +Ova] = histamine release induced by ovalbumin from sPLA2-II pretreated 
cells as observed in the experiment. 
[sPLA2-II] + [Ova] = combined histamine release, calculated by adding the release 




Mast cells isolated f rom the rat peritoneum, human and guinea pig lung tissues were 
generally unresponsive to the type I I sPLA2 isolated f rom the Crotalus altrox venom. 
The maximum % histamine release was generally not greater than 10%. This may be 
due to the phospholipid composition of the outer layer of the mast cell plasma 
membrane. As mentioned previously, Bevers et al. (1983) reported that in resting 
platelets, PC and sphingomyelin occupy the outer layer of the plasma membrane, while 
PE and PS are found in the inner layer. I t is possible that this asymmetric l ip id 
distribution may exist in the mast cell plasma membrane. The type I I sPLA2 enzymes 
display a substrate specificity for PE and PS (Kudo et al., 1993). The location o f these 
phospholipids in the inner layer of the plasma membrane, may explain the low level 
o f histamine release observed here i f sPLA2 was mediating its effects by digesting 
membrane phospholipids. 
The type I sPLA! isolated f rom the Naja naja venom caused the release o f histamine 
\ -
from rat peritoneal mast cells but it had no significant effect on human lung mast cells. 
The maximum % histamine release f rom human lung mast cells was generally not 
greater that 10% when compared wi th rat peritoneal mast cells (78%). Histamine 
release was also observed wi th guinea pig lung mast cells although the maximum 
release was only 33%. The type I sPLA2 enzymes display a substrate specificity for 
PC and PE. PC is located mainly in the outer la:yer of the plasma membrane of resting 
platelets (Bevers et al., 1983) and this l ip id distribution may apply to the mast cell 
plasma membrane. The histamine release observed here may be due to the enzymatic 
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activity of sPLAj - I on the mast cell plasma membrane. The digestive nature o f sPLA j 
I (1 and 10 U ml"^) was illustrated wi th the human and guinea pig lung mixed cell 
suspensions as red blood cell lysis was observed. Human lung mast cells were 
unresponsive to sPLA2-I and this may be due to a difference in the plasma membrane. 
As already discussed in chapter 3, sPLA2-I may mediate its effects by binding to 
specific receptor sites on the mast cell plasma membrane. sPLA2-I receptor sites have 
been characterised in guinea pig lung parenchyma (Kanemasa et al., 1992). I t was 
reported that the porcine pancreatic sPLA2-I exerted a potent contractile effect on 
guinea pig lung parenchyma and pleural strips (Kanemasa et al., 1992; Sommers et al.’ 
1992). This sPLA2-I response in guinea pig pleural strips was reduced by the cyclo-
oxygenase inhibitor, indomethacin and two 5-lipoxygenase inhibitors, B W A4C and 
REV 6866. However, Kanemasa et al. (1992) observed that the contractile response 
in guinea pig lung parenchyma was attenuated by indomethacin and two T x A j receptor 
antagonists (+)-S-145Na and ON03708. They proposed that some A A metabolites 
were involved in the response. However, mast cells were not thought to be involved, 
since histamine and PGDj levels were not significantly increased fol lowing exposure 
o f chopped guinea pig lung tissue to this sPLA2-I. Alveolar macrophages were also 
ruled out, since sPLA2-I receptor sites were not found on these cells and TXA2Was not 
released, fol lowing treatment with the porcine pancreatic sPLAj-I . They proposed that 
some other pulmonary cells such as fibroblasts, endothelial or smooth muscle cells 
were mediating the observed response. 
When cells were activated wi th the immunological stimulus anti-IgE, in the presence 
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of either sPLA2 enzyme, a significant enhancement o f the anti-IgE induced histamine 
release was observed w i th rat peritoneal mast cells. However, this enhancement was 
not observed w i th either human or guinea pig lung mast cell suspensions. The 
immunological ly induced histamine release was dose dependently inhibited by both 
sPLA2 enzymes, w i th sPLA2-I being the more potent of the two. This inhib i t ion was 
not restricted to immunological ly activated mast cells. When sPLA2-I pretreated 
human lung mast cells were activated w i th the calcium ionophore A23187, histamine 
release was again reduced. However, the % inhibi t ion was much lower than that 
observed w i th anti-IgE. 
As discussed in chapter 3，the specificity of the sPLA2 enzymes to enhance 
immunologically induced histamine release in rat peritoneal mast cells, suggested that 
they may participate in a step specifically required for IgE induced histamine release. 
I t was proposed that the sPLA2 enzymes were involved in the opening or in 
maintaining the opening of a plasma membrane calcium channel since the opening o f 
plasma membrane calcium channels is a prerequisite for immunological ly induced 
histamine release (Sagi-Eisenberg, 1993). The inhibit ion observed here w i th the 
human and guinea pig lung mast cells was not specific for the immunological activation 
o f these cells. Mdb i t i on was also observed wi th ionophore induced histamine release 
w i th human lung mast cells. This would suggest that the sPLA! enzymes were not 
mediating their effects by blocking the inf lux of calcium through plasma membrane 
calcium channels. Instead, the sPLA2 enzymes may exert their effects at some steps 
distal to the influx of calcium. Hydrolysis of the membrane phospholipids of activated 
cells may generate a l ip id substance. This l ip id substance may prevent fusion o f the 
191 
mast cel l plasma membrane w i th the secretory granules during exocytosis. LysoPC 
has been reported to inhibit mouse mast cell degranulation (Chemomordik et al.， 
1993). The inhibi tory effects observed here may also be due to the activation o f a 
signal transduction pathway fo l lowing binding to specific sPLA】 receptor sites on the 
plasma membrane. As already discussed in chapter 3, sPLA2-I receptors have been 
identif ied and cloned f rom a variety of tissues and cells (Lambeau et al.，1994; Ishizaki 
et aL, 1994; Ancian et al., 1995). I t is possible that there are receptor sites on the 
plasma membranes of human and guinea pig lung mast cells. 
Preliminary results w i th the PLA2 inhibitor p-BPB did not remove the inhibitory action 
o f sPLA2-I on immunologically induced histamine release. However, /7-BPB (10 |jM) 
alone significantly reduced the anti-human IgE induced histamine release. j^-BPB 
inactivates PLA2 by alkylation of the histidine residue found in the catalytic site 
(Roberts et al., 1977). The inability of p -BPB to reduce the inhibitory action o f 
sPLA2-I suggested that the catalytic site or the digestive nature of the enzyme were not 
involved in mediating this effect. 
The different effects mediated by these sPLA2 enzymes, could be due to the presence 
o f other functional pulmonary cells. Attempts were made to partially puri fy the human 
lung mast cell population to eliminate contaminating cells. The results were 
unsatisfactory, as the mast cell population was only enriched to 12%. However, the 
observations obtained wi th this enriched population of mast cells were similar to the 、 
mixed cell population. 
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Alveolar macrophages predominate cell suspensions obtained by the enzymatic 
dissociation o f lung tissue, but lymphocytes, neutrophils and eosinophils are also 
present (Schulman et aL, 1982; Dvorak et al., 1985). These cells are capable o f 
producing a whole spectrum of eicosanoids (Schulman et al.，1981) which may be 
indirect ly generated by mediators released f rom the activated mast cells. PGEj has 
been reported to have an inhibitory effect on mediator release (histamine) f r om 
dispersed human lung mast cells (Schulman et al.，1982; Peters et al.，1982b; PeacheU 
et a/.,1988). PGE2 leads to an elevation of the intracellular c A M P level and is thought 
to inhibi t mediator release through an antagonism of the intracellular Ca^^ 
concentration. This may explain the inhibit ion observed here wi th both the human and 
guinea pig lung mast cells. However, an enhancement o f immunological ly induced 
histamine release was observed wi th both a mixed and purif ied rat peritoneal mast cell 
population. This would suggest that the effects observed w i th both the human and 
guinea pig lung mast cells, maybe mediated through a direct action on the mast cells. 
The effects o f these sPLA2 enzymes on histamine secretion f rom human and guinea 
pig lung mast cells, has shown an inhibitory action on immunologically activated cells. 
However, the effect may be influenced by the presence of other pulmonary cells. Jn 
order to further investigate the biochemical events involved, there is a requirement for 
highly pur i f ied preparations of human and guinea pig lung mast cells. 
The differences observed here may be due to the known heterogeneity among mast 
f . 
cells from different species (for review see Barrett & Pearce, 1993) and are not ‘\ 
influenced by the different methods employed to obtain the mast cells (Pearce & Ennis, 
1980; Barrett et al., 1983; A l i & Pearce，1985). The differences observed here 
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highl ights the importance of studying different mast cell populations and it is 
inappropriate to rely solely on the rat as an animal model for investigations. 
4.5 Conclusions 
To conclude, these studies have indicated that the sPLA】 enzymes have a pro-
inflanunatory role in immunologically activated rat peritoneal mast cells. This pro-
inf lammatory effect was specific for the rat and was not observed w i th human or 
guinea pig lung mast cells. On the contrary, an inhibitory effect was observed when 
mast cells f rom human and guinea pig lung tissue were immunologically activated in 
the presence of both sPLA2 enzymes. This would suggest that the sPLA2 enzymes 
wou ld have a protective role. This role must be further investigated, in order to 
resolve the question of the influence of other pulmonary functional cells and establish 
i f A A metabolites are involved. This w i l l help establish i f the anti-inflammatory role 
observed here is mediated through a specific action on mast cells. The functional 
heterogeneity observed here also emphasizes the importance of studying the precise 
mast cell population as the development of specific sPLA2 inhibitors would abolish the 
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